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SUMMARY 
 
The continuing demographic shift towards a greater proportion of elderly individuals in the populations of 
developing nations and associated increased morbidity is fuelling the drive for increased research into healthy 
lifespan.  
Excessive circulating glucocorticoid (GC) levels (e.g. Cushing’s Syndrome) often cause hypertension, 
osteoporosis, central obesity, muscle weakness, skin thinning and poor wound healing - conditions also 
commonly associated with the ageing process. Studies in our group investigating the enzyme 11-beta 
hydroxysteroid dehydrogenase type 1 (11β-HSD1), that generates active GC and regulates their local tissue-
specific concentrations, have previously demonstrated increased levels in bone cells derived from older 
compared to younger donors. 
This thesis provides exciting new research that reproduces this observation in the organ most noticeably affected 
by ageing - skin. 11β-HSD oxoreductase activity (i.e. GC-activating) was found to be elevated in skin from older 
compared to younger donors - with increased enzyme levels in dermal fibroblasts (cells crucial to collagen 
production and skin remodelling). Activity also was inducible by GC exclusively in cells from older individuals, 
further increasing dermal cortisol generation potential with advancing age. Evidence is presented for 11β-HSD1-
specific regulation of GC target genes in dermal fibroblasts that may be dysregulated during ageing and for novel 
GC targets in skin that also correlate with enzyme activity. Finally, initial studies characterizing the phenotype of 
the ageing 11β-HSD1-null mouse reveal exciting morphological alterations in skin structure that are more 
similar to those of young animals than aged controls.  
GC are often used to treat a wide range of common skin disorders in the elderly including xerosis (dry skin), 
bullous pemphigoid (blistering) and psoriasis. However, elderly patients also have an increased risk of 
developing treatment side-effects including skin thinning, susceptibility to bruising and tearing and increased 
infection risk.  
In addition to gaining knowledge of a potential contributor to the skin ageing process, the findings presented in 
this thesis provide support for development of a novel therapeutic target that may minimize side-effects 
associated with GC therapy in the elderly and may reduce the ageing process in skin and its associated adverse 
pathologies. 
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CHAPTER 1  GENERAL INTRODUCTION 
1.1 Skin 
1.1.1 Overview 
Skin is the largest organ of the human body, weighing on average 5kg and covering a surface 
area of 2m
2
. It acts as a mechanical barrier, protecting the underlying tissues from the external 
environment (such as destructive solar radiation), whilst preventing water loss from within 
through secretion of sebum. It is a protective envelope, producing defensins and cathelicidins 
(endogenous antibiotics) which provide resistance against bacteria, viruses and fungi, and 
containing sentinel immune cells which patrol the epidermis and guard against invading 
pathogens. 
Skin aids in the maintenance of temperature homeostasis through vasoconstriction or 
vasodilation of its extensive vasculature and by producing approximately one litre of sweat 
each hour during moderate exercise. Pheromones released from apocrine sweat glands play a 
role in sociosexual communication and attraction. 
Subcutaneous fat (around 80% of total body fat in non-obese individuals) acts as a calorific 
reserve in addition to providing thermal insulation and cushioning against physical trauma. 
Dermal adipose tissue is also thought to contribute to endocrine regulation of hunger and 
energy metabolism by releasing the hormone leptin. Skin further contributes to metabolism by 
synthesizing vitamin D. 
Collectively these roles define skin as a vital, highly versatile organ, structurally engineered to 
meet a diverse range of physiological requirements. 
Chapter 1  General introduction 
2 
1.2 Skin structure 
1.2.1 Key features 
The structure of human skin is generally subdivided into three categories; the uppermost, 
stratified, highly cellular, epidermis (0.05-1mm) which undergoes a continual process of 
proliferation and differentiation, the underlying dermis (0.5-5mm) composed primarily of 
connective tissue and the subcutaneous - panniculus adiposus - layer which functions as an 
adipose depot (Burns et al., 2010, Figure 1-1). This is separated from the subdermal structures 
by a thin layer of striated muscle, the vestigial panniculus carnosus. The dermal-epidermal 
junction (DEJ) is normally undulating, with the epidermis projecting into the dermis forming 
“rete ridges” which provide mechanical support. 
Epidermis
Dermis
Hypodermis
Touch receptor Hair
Sebaceous 
gland
Apocrine
sweat gland
Pressure receptor
Eccrine
sweat gland
Capillaries
Subcutaneous 
fat
Subcutaneous artery and veinHair follicle  
Figure 1-1 The skin and associated appendages 
Cells line the basement membrane at the DEJ, anchoring the epidermis to the superficial 
dermis below through protein and glycoprotein projections, and giving rise to keratinocytes 
above, which differentiate into the spinous layer, granular layer and stratum corneum before 
culminating in the process of desquamation. Originating from the Latin term desquamare, 
meaning “to scrape the scales of a fish”, desquamation describes the shedding of dead, 
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anuclear keratinocytes (corneocytes) following approximately 30 days of differentiation. 
Additionally to keratinocytes, the epidermis contains pigmentory melanocytes, 
immunological Langerhans' cells and somatosensory Merkel cells. 
Hair follicles are dermal appendages present in all but glabrous skin (palms and soles), 
varying with body site from the large follicles of the scalp to the vellus-producing follicles of 
the forehead. The epithelium surrounding follicles is continuous with the epidermis and 
follicles undergo periodic cycling, enveloping a small papilla of dermis during the active 
phase. Hair follicle motion is regulated by arrector pili smooth muscle bundles which anchor 
between the epidermis and follicle wall. Sebaceous glands located at the apex of the pilary 
canal secrete sebum which functions to moisturize the skin and hair and are associated with 
apocrine glands in some body parts (e.g. axilla). Epidermally-derived eccrine sweat glands are 
also present in varying degrees of density (100-600/cm
2
) throughout the body. 
The dermis mainly consists of a densely packed protein and polysaccharide matrix providing 
the skin with a high affinity for water retention (around 60% of the total weight). The vast 
proportion of the protein component is collagen (80-85%), conferring a high tensile strength, 
with elastin and elastin-associated microfibrils making up the remainder. Embedded within 
this matrix are dermal fibroblasts, which comprise the majority of the dermal cell population, 
and a variety of surveillance immune cells including mast cells, monocytes and macrophages. 
The dermis is also highly vascularised and benefits from a rich blood supply. 
1.2.2 Epidermal compartment 
1.2.2.1 Keratinocyte differentiation 
The majority of the epidermis is composed of non-proliferating terminally differentiating 
keratinocytes of basement membrane basal cell origin. During their transit, keratinocytes form 
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four well-defined layers (Figure 1-2) characterized by a range of layer-specific 
microstructures, proteins and signalling molecules; the stratum basale (basal layer), stratum 
spinosum, (spinous layer), stratum granulosum (granular layer) and stratum corneum 
(cornified layer). Additionally, palmoplantar skin contains a further layer between the 
granulosum and corneum - the stratum lucidum. 
The basal layer is the only actively proliferating keratinocyte epidermal layer composed 
primarily of basement membrane-bound multipotent progenitor stem cells (further discussed 
in section 1.4) and is generally one-cell thick. The 10-14nm cuboidal cells can be 
characterized by a K5/K14-keratin filament-containing cytoskeleton and a high prevalence of 
adherens intercellular junctions. The stratum basale is succeeded by the spinous layer - its 
name attributable to the high density of desmosomes, molecular complexes of cell-to-cell 
adhesion proteins that link to cytoskeletal K1/K10-keratin filaments anchoring neighbouring 
keratinocytes to each other. Additionally, transglutaminases produced in the spinous layer 
catalyse the cross-linking of proteins rendering them insoluble - such as involucrin, a 
constituent of the cornified envelope of corneocytes (Candi et al., 2005). The subsequent 
granular layer contains intracellular keratohyalin granules, lipid-filled lamellar granules which 
discharge their contents into the extracellular space conferring corneocyte barrier function 
though lipid membrane formation (Feingold, 2007) and L granules containing loricrin - a 
major component of cornified envelope. 
The uppermost stratum corneum is formed by keratin filament alignment and disulphide 
cross-link formation - a process assisted by fillagrin (keratohyalin granule protein) which 
causes keratin filament aggregation. Increasing intracellular calcium concentrations induce 
formation of the cornified envelope through desmosomal protein remodelling to form an 
internal scaffold onto which involucrin, loricrin and other small proline-rich proteins are 
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incorporated and transglutaminase cross-linked (Figure 1-8). Finally, during desquamation, 
lamellated intercellular lipids and desmosomal interconnections are degraded and the 
resulting flattened corneocytes, lacking nuclei and cytoplasmic organelles are removed 
through friction (Milstone, 2004). 
 
Figure 1-2 The process of epidermal differentiation. Human palmoplantar epidermis depicting basal layer (1), 
spinous layer (2), granular layer (3), lucidar layer (4) and cornified layer (5) http://histol.narod.ru/atlas-en/skin-
en.htm. Illustration annotations describe layer-specific structures, macromolecules, transcription factors and 
signalling molecules (Fuchs, 2008) 
Keratinocyte differentiation is positively regulated by peroxisome proliferator-activated 
receptor (PPAR) and liver X receptor (LXR) pathways which stimulate lipid synthesis, 
lamellar body formation and secretion (Schmuth et al., 2008). Concomitantly, these pathways 
are also anti-inflammatory, suppressing proliferation whilst inducing growth arrest, apoptosis 
and terminal differentiation thus maintaining normal epidermal turnover in a non-inflamed 
state. 
1.2.2.2 Melanocytes 
Epidermal melanocytes produce melanin pigment and transfer it to neighbouring 
keratinocytes and hair follicles via melanosomes. Two types of melanin are produced, 
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brown/black eumelanin and yellow/red phaeomelanin, with varying proportion and 
distribution resulting in a global mosaic of colour diversity. 
Melanin functions to absorb ultraviolet (UV) light, protecting DNA, cellular components and 
subdermal structures from sun-induced damage. UV exposure is associated with an increase 
in functional melanocyte number, melanosome synthesis and transfer of melanin to 
neighbouring keratinocytes, resulting in a post-exposure browning of the skin known as 
delayed tanning (Ortonne, 1990). 
Melanin pigment production is regulated, in part, by melanocortin-1 receptor activation which 
promotes eumelanin formation at the expense of phaeomelanin. Regulation of such receptors 
has been shown to influence photo-protection in addition to skin colour (Carlson et al., 2007). 
Changes in melanocyte signalling pathways can induce dramatic phenotypic alterations. For 
example, downregulation of Notch signalling is associated with precocious hair greying 
attributable to reduced melanocyte precursor cells (melanoblasts), implicating Notch 
signalling as an integral regulator of melanocyte regeneration during hair follicle cycling 
(Schouwey and Beermann, 2008). 
1.2.2.3 Langerhans' cells 
Dendritic Langerhans' cells play a crucial role in epidermal immune surveillance and are a 
first line of defence against invading pathogens. Through lengthening and recoiling of 
dendritic processes between keratinocytes (dendrite surveillance extension and retraction 
cycling habitude - dSEARCH) they patrol the epidermal environment for foreign antigens 
(Mohr and Takashima, 2007). Upon contact, Langerhans' cells engulf foreign bodies, process 
them for antigen presentation and interact with lymphocytes by secretion of cytokines such as 
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interleukin (IL)-1 to initiate an immune response, as well as upregulating dSEARCH for 
increased antigen sampling. 
Interestingly, Langerhans' cells are more likely to induce an anti-inflammatory type 2 helper 
T- cell (Th2)-mediated response rather than the pro-inflammatory type 1 helper T-cell (Th1)-
mediated response typically associated with pathogen recognition. This is further supported 
by Langerhans' cell-deficient mice which appear to have enhanced contact hypersensitivity. 
Furthermore, keratinocytes have been implemented as potentiators of both innate and adaptive 
immune responses through antimicrobial peptide (AMP), cytokine and chemokine production 
(Nestle et al., 2009). Collectively, recent findings are redefining the roles of Langerhans' cells 
to include induction of tolerance and regulatory properties that counteract the emerging pro-
inflammatory actions of keratinocytes (Asahina and Tamaki, 2006). 
1.2.2.4 Merkel cells 
Merkel cells are located throughout the epidermis, amongst basal keratinocytes particularly in 
hairy skin and tactile areas of glabrous skin, forming close connections (touch spots) with 
unmyelinated sensory nerve endings at the base of rete ridges. Interestingly, photo-exposed 
(PE) skin contains around twice as many Merkel cells compared to photo-protected (PP) skin. 
Rich in neurosecretory granules, Merkel cells are involved in somatosensory signalling by 
acting as mechanoreceptors for the sensation of touch, although there is no clear evidence for 
direct synaptic transmission at Merkel cell-neurite complexes (Lucarz and Brand, 2007). 
1.2.3 Pilosebaceous unit 
Pilosebaceous units (hair) are subcategorised into four classes: terminal (scalp and beard), 
apopilosebaceous (axilla and groin), sebaceous (face, back and chest) and vellus (the 
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remaining majority of skin). The dermal papilla locates to the follicular base and is 
encompassed by a rich germinative cell matrix which generates the hair fibre innermost 
medulla, cortex and surrounding cuticle. Lining the cuticle is the inner root sheath (IRS) 
composed of three layers of cells that undergo keratinisation (IRS cuticle, Huxley layer and 
Henle layer) and provide support for the hair fibre, terminating at the sebaceous gland. The 
IRS is separated from the outer root sheath (ORS), which is continuous with the epidermis, by 
a companion cell layer (Schlake, 2007, Figure 1-3). 
 
Figure 1-3 Pilosebaceous unit structure. Mouse hair follicle (dorsal skin) stained with haematoxylin/eosin in 
late catagen/telogen and schematic representation of the hair follicle. AP, arrector pili; CCL, companion cell 
layer; DP, dermal papilla; HF, hair follicle; HS, hair shaft; IFE, interfollicular epidermis; Inf, infundibulum; Ist, 
Isthmus; SC, stem cells; SG, sebaceous gland; TAC, transient amplifying cell (Margadant et al., 2010) 
A dense hair coat is essential in most mammals, assisting in temperature homeostasis and 
protection from the external environment. Hair requires continuous renewal throughout life, 
achieved through cycling of the lower section of the pilosebaceous unit through phases of 
growth (anagen), regression (catagen) and rest (telogen), whilst the infundibulum, isthmus, 
bulge and sebaceous gland remain stable. 
Chapter 1  General introduction 
9 
Following hair loss, a new follicle is formed and grows during anagen through the upward 
proliferation and differentiation of bulb matrix cells which also form the IRS downwards, 
adding stability to the elongating hair. During catagen, the hair shaft stops growing and both 
differentiation and proliferation processes are halted. Matrix cells undergo apoptosis 
accompanied by follicle degeneration and regression, moving the bulb upwards until it 
reaches the bulge. At this stage of telogen, the follicles are quiescent awaiting anagen re-
initiation when the old hair is lost, and new matrix cells are re-formed following interaction 
between dermal papilla cells and bulge stem cells (Fuchs et al., 2006, Figure 1-4). 
1.2.4 Eccrine and apocrine glands 
There are two types of sweat gland in humans: eccrine and apocrine. The former are 
responsible for the majority of thermoregulatory sweating and are located over nearly the 
entire body, with highest density in the soles, palms and forehead. Sweat glands consist of a 
bulbous coil in the lower dermis and a secretory duct which transverses the epidermis and 
opens at the skin’s surface. Perspiration is insensible, originating from water in the blood and 
evaporating passively at a rate determinable by the ambient temperature and humidity, or 
active where intense heat, mental/emotional stimulation, exercise and carbon dioxide levels 
induce active sweating. The neurological pathways involved in regulating perspiration are not 
fully understood but thought to involve cholinergic stimulation of sympathetic nerve fibres 
(Shibasaki et al., 2006). This leads to secretion of an isotonic precursor fluid lacking proteins 
but containing sodium and chloride ions which are generally reabsorbed but during periods of 
intense perspiration can lead to ion loss as the reabsorption mechanisms become 
overwhelmed. 
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Figure 1-4 The hair cycle. Hair follicles cycle through alternating phases of anagen, catagen, and telogen. 
Reproduced from Paus and Cotsarelis, 1999 
Conversely, apocrine glands are localised exclusively to axillary, genital and mammary skin 
in association with hair follicles. They have minimal rates of lipid-rich secretions that do not 
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contribute to temperature homeostasis, and are decantered directly into the hair shaft by 
excretory ducts which fuse with the epithelium of hair follicles. The role of apocrine glands in 
humans is unknown. 
1.2.5 Dermal compartment 
1.2.5.1 Extracellular matrix 
The dermal compartment comprises the greatest proportion of skin and, in contrast to the 
epidermis, is largely acellular, consisting of an extracellular matrix (ECM) composed of a 
complex network of connective tissues. ECM connective tissue includes collagen fibres 
providing tensile strength, elastic fibres allowing flexibility and resilience, glycoproteins 
serving as structural organizers and proteoglycans/glycosaminoglycan (GAG) units which 
maintain hydration. 
The majority of the dermis is composed of several types of collagen with a common triple-
helical structure of three varying α-chain (α1-α6) polypeptide monomer subunits with a 
glycine-X-Y amino acid sequence (Figure 1-5). To date, 29 distinct vertebrate collagen types 
have been identified (I-XXIX) with 12 of particular relevance to skin. Collagen types I, III 
and V form large fibrils and together comprise ~95% of dermal collagen (80%, 10% and 5% 
respectively). These are assembled into an organized structure supported by anchoring 
collagen type VI microfibrils, network forming collagen type VIII and other fibril-associated 
collagens with interrupted triple helices such as collagen type XIV. Important membrane-
associated collagens include type IV: a component of the basement membrane and dermal 
vasculature, type VII: the major constituent of anchoring fibrils that interact with other DEJ 
proteins to form U-shaped loops that ensnare and stabilize larger fibres of the underlying 
dermis, type XVII: a component of hemidesmosomes that assist in anchoring the epidermal 
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basal cell layer to the basement membrane and types XIII and XV which are ubiquitously 
expressed including in epidermis and basement membrane respectively. Most recently, 
mutations in the gene for a novel putative epidermal collagen type XXIX (COL29A1) have 
been linked to atopic dermatitis (Soderhall et al., 2007). 
 
Figure 1-5 Collagen microstructure. Schematic representation of a typical collagen monomer subunit 
composed of a repeating Glycine-X-Y amino acid sequence and its assembly into a triple-helix 
The different collagen types are characterized by considerable complexity and diversity in 
their structure, their splice variants, the presence of additional, non-helical domains, their 
assembly and their function (Gelse et al., 2003). For example, collagen II is composed of 
three identical α1 (II)-chains (homotrimer) contributing to the torsional stability and tensile 
strength of articular cartilage, while the microfibrillar collagen VI is composed of three 
distinct α1(VI)-, α2(VI)- and α3(VI)-chains (heterotrimer) is also highly disulfide cross-linked 
and contributes to a network of beaded filaments interwoven with other collagen fibrils. 
Additionally to the collagen network, elastin fibres are an integral component of the dermal 
ECM, although contributing only 2-4% of the total dry weight (Figure 1-6). The elastin 
system forms a horizontally aligned complex of elastin fibres from which a relatively finer 
vertical structure of microfibrils (oxytalan fibres) and cross-linked elastin (elaunin fibres) 
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extend (Midwood and Schwarzbauer, 2002). Other elastin-associated proteins include 
fibrillins, latent transforming growth factor-β proteins which bind the pro-fibrotic cytokine 
transforming growth factor (TGF)-β, fibulins (calcium-binding glycoproteins), microfibril-
associated glycoproteins/proteins, interface proteins (emilins) and lysyl oxidases which are 
critical for the cross-linking of elastic fibres. 
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Figure 1-6 Elastin network in human skin. The elastic fibre system in skin is confined to the dermis where 
composite elastic fibres in the reticular dermis give way to arrays of fibrillin microfibril bundles at the DEJ. The 
fibrillin microfibrils of the elastic fibre system are synthesised by both keratinocytes and dermal fibroblasts 
Proteoglycan macromolecules contribute the remainder of dermal non-cellular structures. 
Formed by the linkage of unbranched disaccharide GAG to a central protein core, 
proteoglycan subfamilies are highly variable existing in multiple combinations of core 
proteins, number of associated GAG units and GAG molecular mass. GAGs are formed by 
alternating pairs of different monosaccharides (e.g. glucose or galactose) joined by 1-3 or 1-4 
serine O-linkage and include heparin, heparan sulphate, hyaluronic acid, keratan sulphate, 
chondroitin sulphate and dermatan sulphate. Core proteins can be intracellular, membrane 
bound or extracellular. In the dermis, key proteoglycans include versican (260-370kDa), 
linked to 10-30 chondroitin/dermatan sulphate GAGs. Versican also contains a hyaluronic 
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acid binding domain enabling the formation of large aggregates (Figure 1-7). Smaller ECM 
proteoglycans include type I collagen-associating decorin (36kDa), with a single dermatan 
sulphate GAG that is also able to bind to tenascin-X, another ECM component with collagen 
affinity. Therefore, proteoglycan interactions with surrounding structures provide stability and 
assist the organization of connective tissues architecture. 
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Figure 1-7 Dermal proteoglycans. Versican core protein size is variable due to alternative splicing of the 
versican mRNA, limiting the number of associated GAG units. All isoforms are capable of binding hyaluronan 
(Wight, 2002). Decorin is a much smaller proteoglycan that associates with collagen through its protein domain 
Proteoglycans have also been found to bind growth factors, cytokines, cell adhesion 
molecules, growth factor binding proteins and can also function as antiproteases. 
Additionally, GAGs can also bind directly to other ECM molecules chondroitin and dermatan 
sulphate, for example, bind to fibronectin and laminin. 
Another vital function of proteoglycan/GAG structures is their high affinity for binding water, 
providing hydration to the skin and facilitating the movement of molecules though the 
protein-rich matrix. 
1.2.5.2 Dermal fibroblasts 
Dermal fibroblasts are the principal cells responsible for the production and regulation of 
ECM macromolecules including collagen, elastin and proteoglycan/GAG with niche-specific 
product synthesis variations such as greater collagen type III production in papillary (upper) 
compared to reticular dermis (Sorrel et al., 2007). Fibroblasts express a specific genetic 
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profile depending on the developmental stage of the donor, anatomical site and signals in the 
local environment e.g. in wound healing (Chang et al., 2002, Rinn et al., 2006). 
Positional memory is inferred, in part, by the retention of site-specific HOX gene expression 
patterns established during embyogenesis, suggesting fibroblasts have positional memory that 
enables their function to be tailored exclusively according to environmental requirements. 
Hence, fibroblasts originating from different skin sites can even be considered as distinct, 
differentiated cell types. Remarkably, recent findings have demonstrated that fibroblasts can 
also be induced to become pluripotent stem cells by treatment with certain transcription 
factors (Takahasi et al., 2007). 
Fibroblast dysfunction has been implicated in a range of dermal conditions, including 
connective tissue tumours (keloids) characterized by excessive collagen deposition and a 
myofibroblast-like cellular phenotype. 
1.3 Dermal vasculature, lymphatics and subcutaneous fat 
The vasculature of the skin is structured as a subpapillary plexus with capillary/venule loops 
that reach between rete ridges of the DEJ, originating from vessels in the underlying 
subcutaneous adipose tissue. Arterioles are distinguishable from venules by the presence of 
subendothelial elastic tissue. Dermal vasculature provides the skin with nutrients and oxygen, 
in addition to regulating body temperature through vasodilation (allowing the dissipation of 
excess heat in a hot climate) or vasoconstriction (reducing dermal blood flow to maintain core 
temperature in a cold environment). 
Lymphatic bulbs terminate in the papillary dermis and form an interconnecting system that 
drains particulate liquid materials (e.g. proteins) into local lymph nodes. The lymphatic 
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system is crucial for regular skin function, with abnormalities leading to diseases such as 
lymphoedemas (Jurisic and Detmar, 2009). 
The subcutaneous adipose layer provides mechanical protection, insulation and energy 
storage. Adipocytes are also involved in endocrine signalling by secreting the appetite-
regulating hormone leptin (Farooqi and O’Rahilly, 2008), as well as roles in osteogenesis, 
angiogenesis and phagocytosis. 
1.4 Stem cells 
The maintenance of dermal integrity is achieved through distinct resident stem cell (SC) pools 
occupying the hair follicle bulge, basal epidermal layer and base of sebaceous glands (Braun 
and Prowse, 2006, Watt and Hogan, 2000). Expression of discrete signalling pathways 
(Fuchs, 2008) direct the fate of SC towards either self-renewal through proliferation (e.g. c-
Myc, integrin β-1, p63, TGF-α, TGF-β (-)) or specialization through differentiation (e.g. 
Notch, PPAR-α, CCAAT-enhancer-binding protein α/β, activating protein (AP)-2 α/γ). 
The exact models for dermal SC propagation are still undergoing clarification. In the case of 
epidermal SC, evidence exists for both (i) symmetrical proliferation where transient-
amplifying cells (derived from a single SC) undergo differentiation following several rounds 
of lateral division and (ii) asymmetrical proliferation where SC can shift their spindle 
orientation to perpendicular thus giving rise to either more SC or directly to differentiated 
spinous layer cells (Lechler and Fuchs, 2005). 
In addition to niche-specific dermal SC, skin-derived precursors have been isolated from 
human skin with multipotent capabilities for differentiation into neurons, glia, and smooth 
muscle cells (Toma et al., 2005). Furthermore, certain dermal fibroblast subsets have been 
identified with adipogenic, osteogenic, chondrogenic, neurogenic and hepatogenic potential 
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when cultured with certain inducers (Chen et al., 2007), or the ability to be reprogrammed 
into pluripotent embryonic SC-like precursors (Park et al., 2008), increasing the feasibility of 
donor-specific cell therapies. 
1.5 Skin function 
Skin provides organisms with a variety of vital functions including physical, chemical and 
UV radiation barrier function, temperature homeostasis, mechanical protection, 
immunomodulation, sensory response and sociosexual communication (further detailed 
below). Severe loss of function has been defined by Irvine as ‘skin failure’, occurring in 
several dermatological diseases (Irvine, 1991). 
1.5.1 Barrier function 
1.5.1.1 Physical 
Arguably the most immunologically active organ in the body, the skin’s primary role is to 
form a two-way physical barrier to the exterior environment, preventing both the inward and 
outward passage of water and electrolytes. This vital function is granted exclusively by 
differentiated epidermal keratinocytes with the underlying dermis being almost completely 
permeable. Specifically, the terminally differentiated, cornified stratum corneum 
keratinocytes (corneocytes) are embedded in a lipid-rich intercellular matrix. The corneocyte 
envelope develops during keratinocyte differentiation forms an insoluble exoskeleton (Rice 
and Green, 1977) which is also durable and flexible (Figure 1-8). 
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Figure 1-8 Generation of the epidermal cornified cell envelope. Calcium gradient-mediated desmosomal 
proteins are reorganised to form a scaffold along the plasma membrane used for the external attachment of lipid-
rich molecules (cholesterol and ceramide) and internal attachment of loricrin, small proline-rich protein (SPR) 
cross-linked by transglutaminases (Candi et al., 2005) 
Additionally, lamellar bodies (membrane coating granules) excrete lipid-rich molecules such 
as free fatty acids (Schurer and Elias, 1991), cholesterol (Feingold et al., 1990) and ceramides 
(Elias and Brown, 1978) into the extracellular milieu, coating the cornified envelope exterior. 
This highly lipophilic environment is perfectly adapted as an impermeable barrier to polarised 
molecules, preventing excessive water loss from the body. 
1.5.1.2 Chemical 
The stratum corneum also prevents undesirable invasion by resident skin flora or pathogenic 
microorganisms. The physical barrier, assisted by continuous desquamation, is also re-
enforced by antimicrobial chemical barrier properties. Sebum lipids and 
glycophospholipids/free fatty acids of the stratum corneum are naturally antibacterial and 
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bacteriostatic respectively, while AMPs coating the skin and associated appendages provides 
the first line of defence against bacteria, fungi and some viruses (Niyonsaba et al., 2006). 
Antibiotic α-defensins are expressed in skin by neutrophils with direct antibacterial properties 
and the ability to stimulate the immune system through increased tumour necrosis factor 
(TNF)-α/IL-1 expression in bacteria-activated monocytes. Conversely, β-defensins act solely 
by indirect means, being chemotactic for immature dendritic and memory T-cells, facilitating 
histamine release and prostaglandin production in mast cells. Mammal-specific cathelicidin 
also possesses bactericidal abilities following proteolytic activation from its precursor by 
neutrophil elastase and proteinase. Cathelicidin also functions as a chemoattractant for a host 
of inflammatory cells. 
Cathelicidins and defensins are reported in a variety of dermal environments including sweat 
gland fluids, duct epithelia and hair follicles (Schittek et al., 2001, Fulton et al., 1997), 
providing additional protection in areas where the physical barrier is absent or limited. 
Furthermore, impaired AMP production has been linked to atopic dermatitis (Ong et al., 
2002). Importantly, AMP production is upregulated in response to cutaneous injury, both by 
increased keratinocyte production and from neutrophils that respond during acute 
inflammation (Gallo et al., 2002). 
1.5.1.3 UV radiation 
The skin also functions as a barrier against damaging solar UV radiation. UVB rays penetrate 
the superficial epidermis causing acute sunburn which, over the course of chronic lifetime 
exposure, contributes to photo-ageing and skin cancer while UVA is able to penetrate deeper 
and is thought to be the primary cause of skin ageing. 
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Protection against UV is granted by the epidermal melanin barrier and lipid barrier of the 
stratum corneum. A large proportion of UV is absorbed in these structures, reducing the 
exposure of DNA and minimising the impact on genomic instability. 
1.5.2 Temperature homeostasis 
The skin is able to detect and respond to extreme changes in ambient temperature in order to 
maintain a constant core temperature. Warm- and cold-sensitive thermoreceptors are 
distributed evenly over the skin signalling through the hypothalamus to regulate sweating and 
shivering. The rich dermal vasculature is also integral to thermoregulation. 
However, these processes play only a minor, physiological role in the modulation of core 
temperature, which is influenced to a much larger degree by behavioural responses such as 
adding/removing layers of clothing. 
1.5.3 Mechanical function 
Mechanical protection against blunt physical trauma is granted primarily by the structural 
properties of the dermis. Elastic fibres allow a reversible initial stretching capacity of 10-50%. 
Secondary ‘viscous extension’ stretching occurs if remaining taut for longer periods of time 
and is irreversible, which causes collagen fibrils to slip relative to each other in contrast to a 
stationary reorientation toward the load axis during reversible stretching. Moreover, dermal 
collagens are aligned to form a dense, highly organized structure conferring skin with tensile 
strength. 
Skin can also be reversibly compressed around a pressure point, exerting the force, reducing 
the pressure on any particular point and leaving a temporary imprint (such as from a pinch) 
thought to occur as a result of a flow of inter-collagen ground substance flow. 
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Due to its protein and lipid constituents, the epidermis is also relatively strong, capable of 
stretching to maintain blister fluid. This contrasts to the relatively weak DEJ with underlying 
collagen of the papillary dermis particularly susceptible to blistering agents. 
1.5.4 Skin as an immune system 
Skin plays a crucial role in immunological host defence. Following breach of the physical and 
chemical barrier, an orchestra of permanently-resident epidermal cells e.g. keratinocytes, 
Langerhans' cells and dermal cells e.g. natural killer T (NKT)-cells, fibroblasts, dendritic 
cells, macrophages, mast cells and T-cells are activated to initiate an immune response (Nestle 
et al., 2009, Figure 1-9). Remarkably, the skin contains 2x10
10
 T-cells - twice the normal 
number in circulation. If required, additional transiently-resident cells are recruited from the 
extensive dermal vasculature. 
Traditionally, keratinocytes have been regarded as a passive “brick” contributing primarily a 
structural role to the integrity of the epidermis. However, research conducted over the past 
decade has revealed that keratinocyte function also includes the ability to secrete a plethora of 
inflammatory and immunomodulatory mediators including cytokines, chemokines, peptides 
and growth factors and associated receptors following injurious stimuli. IL-1 and TNF-α 
cytokines directly promote endothelial adhesion molecule expression (e.g. E-selectin, 
intercellular adhesion molecule-1, vascular cell adhesion protein) facilitating leukocyte 
recruitment from the circulation and indirectly induce Langerhans' cell activation, 
differentiation and migration by stimulating expression of secondary cytokines e.g. 
granulocyte-macrophage colony-stimulating factor (GM-CSF). Keratinocyte-derived 
cytokines are involved in the modulation of T-cells and dendritic cells. Furthermore, secreted 
chemokines (e.g. monocyte chemotactic protein, cutaneous T-cell-attracting chemokine, 
eotaxin) regulate lymphocyte, neutrophil, eosinophil, monocyte, macrophage, mast cell and 
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dendritic cell trafficking. Studies have also implicated keratinocytes in antigen-specific 
responses through inflammatory stimuli-induced expression of CD80, a molecule typically 
associated with antigen-presenting cells (APCs), suggesting a further role for keratinocytes in 
antigen presentation (Wakem et al., 2000).  
 
Figure 1-9 Immune cells of the skin. Following stimulation by UV, trauma, irritants or infection, a host of 
permanently-resident cells become immunologically active including pre-dendritic cells (pDC), fibroblasts, 
NKT-cells, dendritic cells (DC). Cytokine/chemokine-activated APCs (e.g. DC) then contribute to adaptive 
immunity by initiating clonal expansion of memory T-cells which also secrete pro-inflammatory mediators 
further amplifying the immune response (further discussed in text, Nestle et al., 2009) 
Dermal-resident NKT-cells are a lymphocytic subset (representing 10% of circulating 
lymphocytes) capable of inducing apoptosis of tumour and infected cell targets. In contrast to 
T- and B-cells, NKT-cells are immediate initiators of the innate immune response, lacking the 
requirement for a proliferative amplification phase. Following target recognition, NKT-cells 
generate cytokines (e.g. TNF-α, interferon (IFN)-γ, GM-CSF) and chemokines, enhance 
cytotoxicity and migrate. Virus-induced IFNs (α/β) and IL-12 are also potent activators of 
NKT-cell cytotoxicity and IFN-γ respectively, highlighting the importance of NKT-cells 
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during innate defence against viral infections (Biron, 1997). Furthermore, NKT-cells are 
activated during infection by a host of other cytokines (e.g. TNF-α, IL-15) and chemokines, 
although the exact mechanisms underlying activation remain elusive (Scott and Trinchieri, 
1995). Dysfunction of NKT-cells has been linked to a variety of skin disorders including 
atopic dermatitis (De Benedetto et al, 2009), sarcoidosis (Noor and Knox, 2007) and infection 
(Smith and Kotwal, 2002). 
Similar to keratinocytes, fibroblasts are also capable of playing a dual role by producing 
structural ECM proteins under physiological conditions and by regulating immunological 
processes during inflammation and wound healing. Fibroblast-derived GAGs form 
proteoglycans which can bind cytokines, chemokines and growth factors, increasing their 
availability to immune modulators whilst collagens, laminins and fibronectin regulate 
interactions between fibroblasts and inflammatory cells. The functional profile of fibroblasts 
is dictated by their immediate microenvironment, including structural interactions (e.g. 
collagen contraction status) and extracellular cytokine, chemokine, protease and growth factor 
milieu (Nagakawa et al., 1989, Kovacs, 1991, Xu and Clark, 1996). Furthermore, fibroblasts 
isolated from hypertrophic scars display an altered response to epidermal growth factor (EGF) 
and increased collagen production (Garner et al., 1993). During wound healing, activated 
fibroblasts (myofibroblasts) migrate toward the damaged tissue, using ECM proteins as a 
scaffold, increasing proliferation and production of new ECM components. As the newly 
synthesized collagens mature and the wound contract, proliferation is gradually inhibited and 
the myofibroblasts return to a resting state (Grinnell, 1996). In addition to the exclusive role 
of matrix remodelling during wound repair, dermal fibroblasts secrete pro-inflammatory 
mediators (e.g. TNF, IL-6) which assist in sustaining the immune response until resolution of 
the initial trigger. 
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Immunologically-activated keratinocytes, NKT-cells and fibroblasts secrete a variety of 
factors that propagate the immune response through the regulation of APCs including 
macrophages and dendritic cells (differentiated from bone marrow-derived monocytes) which 
function in both innate immunity whilst processing and presenting foreign- or host-derived 
antigens to T- and B-cells during acquired immunity. Briefly, macrophages function primarily 
as professional phagocytic cells, recognizing, engulfing and destroying pathogens through the 
production of destructive mediators including acidic phagosomes, proteolytic enzymes, matrix 
metalloproteinases (MMPs) and reactive oxygen species (ROS, Gordon, 2003). Furthermore, 
microbial stimulation (for example through lipopolysaccharides – LPS), coupled with IFN-γ 
priming, triggers cytokine release which further stimulate (e.g. IL-1/6, TNF) or inhibit (e.g. 
IFN-α/β) macrophage function in an autocrine manner, whilst contributing to paracrine 
regulation of surrounding immune cells, resulting in a highly co-ordinated immune response. 
Alternatively, macrophages can be activated in a non-microbial manner through antibody and 
complement receptors, or subsequent to IL-4/13 cytokine stimulation as part of phagocytic 
humoral immunity. Macrophages are also regulated in an endocrine fashion for example, 
through GC receptor (GR) signalling, which leads to downregulation of APC function, 
induction of anti-inflammatory cytokine secretion and production of auto-inhibitory 
prostaglandins. Macrophage immunosuppression can also be induced by certain pathogens 
(e.g. human immunodeficiency virus), contributing to sustained infection. Whilst 
macrophages are initially recruited to sites of inflammation as undifferentiated monocytes, 
they are poor proliferators, instead remaining quiescent in the skin for months, guarding 
against future insults. 
Dermal dendritic cells are classed according to function, varying in their abilities as APCs, 
Langerhans' cell precursors, pro-inflammatory mediators and phagocytic cells (Savina and 
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Amigorena, 2007). Recently, a novel class of pre-dendritic cell producing IFN type 1 has been 
identified in inflamed skin (Magyarics et al., 2008). 
Antigen-activated T-cells support the immune response by amplifying T-cell subtype specific 
cytokine secretion. ‘Helper’ T-cells secrete either IL-2/IFN-γ (Th1) assisting cytotoxic and 
cell-mediated responses, or IL-4/5/9/10/13 (Th2) aiding antibody-mediated responses. Th1 and 
Th2 T-cells primarily support APCs and B-cells respectively, whilst activated cytotoxic T-
cells (IFN-γ-producing Tc1 or IL-4/5-producing Tc2 subtypes) induce apoptosis through 
mechanisms similar to those implemented by NKT-cells. Selection of appropriate T-cell 
response (i.e. preferential subset expression) is tailored to meet the specific requirements of 
the inflammatory trigger (UV, bacterial, viral etc.) by inter-subset cross-regulation such as 
Th1 cytokines inhibiting Th2 cells and vice versa. 
The inflammatory responses in skin are further regulated by numerous other cellular 
components including transiently-resident phagocytic neutrophils, circulatory basophils and 
eosinophils and permanently-resident granulated mast cells which facilitate innate immunity 
by increasing vascular permeability, inducing neutrophil recruitment and promoting a Th2 T-
cell phenotype. Further dissection of the multitude of cellular components and associated 
mediators involved in the complex process of cutaneous inflammation and immunity is 
beyond the scope of this thesis and will not be further discussed here. 
1.6 Ageing 
1.6.1 Overview 
Ageing can be defined simply as the accumulation of changes in an organism or object over 
time. However, in humans, ageing refers to a complex multidimensional process of physical, 
psychological, and social change. It involves a progressive loss of biological function 
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accompanied by decreasing fertility and increasing mortality with advancing age (Bowen and 
Atwood, 2004). 
Ageing affects every tissue in everybody, although the rate of ageing is highly variable both 
between organs in the same individual and between the same organs in different individuals 
based on differing environmental and genetic modifying factors. The most obvious symptoms 
of ageing manifest as changes in our external physical appearance in tissues such as skin (e.g. 
wrinkling, dryness, age spots), hair (greying, thinning, balding), fat (e.g. omental distribution, 
increased storage) and muscle (e.g. decreased strength and mass). Internal changes affect 
tissues including bone (e.g. decreased mass, increased porosity, osteoporosis), heart (e.g. 
blood pressure, cardiovascular disease), reproductive organs - particularly females (e.g. 
menopause) and brain (e.g. decreased reaction time and memory, Alzheimer’s disease). These 
physical changes are attributable to alterations in the homeostatic control of processes such as 
metabolism and immunity (Figure 1-10) - largely influenced by a modified hormonal 
regulation repertoire (Bowen and Atwood, 2004).  
 
Figure 1-10 Age-related diseases. Schematic representation of the relationship between ageing and associated 
diseases which result in consequences associated with frailty. Reproduced from Fulop et al., 2010 
 
Chapter 1  General introduction 
27 
Age-related dysregulation of homeostasis culminates in associated pathologies such as 
increased susceptibility to infection, neurodegenerative disease, type 2 diabetes (T2D), 
atherosclerosis and chronic heart failure (Fulop et al., 2010). It should be stressed, however, 
that although all organisms are subjected to ageing, similarly to the variation in physical 
changes occurring at a tissue level, individuals differ in their tolerance to ageing with regards 
to exhibiting disease. This variation is based on the ability of individuals to cope with the 
traditionally non-modifiable internal changes associated with chronological ageing and the 
superimposing contribution of modifiable external factors termed intrinsic and extrinsic 
ageing respectively. 
With the ever-increasing proportion of elderly individuals within the populations of 
developed countries resulting from increased life-expectancy, closely followed by the ongoing 
transition of developing countries, research into the causes of ageing and age-related diseases 
will be an absolute necessity in the forthcoming years. 
1.6.2 Chronological (intrinsic) ageing 
Chronological ageing encompasses the ageing of all organs including skin, independently of 
external influences and its causes are far less clear than those of extrinsic ageing. 
1.6.2.1 Oxidative metabolism 
A plausible contributor to intrinsic ageing is the generation of ROS during oxidative 
metabolism (Sohal and Weindruch, 1996), primarily mitochondrial in origin, with effects 
similar to those of extrinsic ageing such as DNA oxidation resulting in mutation, protein 
oxidation with loss of function and oxidation of membrane lipids leading to reduced transport 
and/or membrane signalling. A major consequence of these effects is a reduction in cellular 
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antioxidant capacity causing further oxidative damage, an exacerbation of the ageing 
phenotype (Harman, 2001) and ultimately, organismal death. 
Molecular oxygen is a primary source of cellular stress but equally indispensable for aerobic 
life. In addition to the cellular damage inflicted by metabolism- and photochemically-derived 
ROS, it has been proposed that ROS act as subcellular signals that may regulate a “molecular 
clock” that determines the pace of ageing (Sohal and Allen, 1990). Hyperoxia (O2 above 5%) 
has been shown to cause toxicity in a variety of organisms and decreased proliferation of cells 
(Davies, 2000) including vascular smooth muscle cells (VSMCs, Absher et al., 1994), and 
unlike hydrogen peroxide, at no point is hyperoxia stimulatory to cell growth. The underlying 
causes of this toxicity are not fully known but studies have demonstrated an impact on 
specific points of the cell cycle (Balin et al., 1978) and a stimulation of telomere shortening 
(Von Zglinicki et al., 1995) as well as regulation of gene expression and signal transduction 
pathways (Monteiro and Stern, 1996, Gillespie et al., 2010, Hsieh et al., 2010, Circu and Aw, 
2010). 
1.6.2.2 Replicative senescence 
The process of cellular replicative senescence is also postulated to contribute to endogenous 
ageing (Cristofalo et al., 2004), and may also be involved in extrinsic ageing. In contrast to 
cancer cell lines, somatic cells in culture are capable of only a limited number of divisions 
(Hayflick, 1965), morphologically enlarged and flattened, sensitized to contact inhibition, 
unresponsive to mitogenic treatment and express beta-galactosidase upon senescence (Dimri 
et al., 1995). Senescent fibroblasts express increased MMPs and decreased tissue inhibitor of 
MMPs (TIMPs, Millis et al., 1992, West et al., 1989) alongside decreased expression of ECM 
components such as elastin, laminin and several forms of collagen (Linskens et al., 1995) 
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shifting their function from matrix-synthesizing to matrix-degrading. The mechanisms 
underlying replicative senescence are highly complex and involve the dysregulation of 
multiple systems including signal transduction, cellular stress, apoptosis and telomere 
shortening. Alterations in lipid-mediated signalling involve increased release of growth-
inhibitory prostaglandins and ceramide (Venable et al., 1995) whilst stimulatory second 
messengers such as diglyceride are decreased (Venable et al., 1994). This leads to defects in 
signal transduction including the downregulation of phosphatidylinositol 3-kinase /protein 
kinase B and Raf/MEK/ERK pathways - essential for normal proliferative response to 
mitogenic stimulation. 
Regarding the former, the protein kinase p70
s6k
1, phosphorylated in its active form, is 
involved in regulating translation of mRNAs containing polypyrimidine tracks through 
ribosomal protein S6 phosphorylation. Activation of this kinase is reduced in senescent 
fibroblasts (Zhang et al., 2000) leading to decreased translation of mRNAs such as 
components of translational machinery (Brown and Schreiber, 1996). Additionally, treatment 
with phosphatidylinositol 3-kinase inhibitor in early passage fibroblasts induces growth arrest 
and senescence (Tresini et al., 1998). 
Activation of the Raf/MEK/ERK pathway is also compromised during senescence with a 
dramatic reduction in phosphorylated (activated) ERK in the nucleus of late-passage 
fibroblasts (Park et al., 2000, Tresini et al., 2001). Concomitantly, there is reduced expression 
of, and failure to induce upon mitogenic stimulation, the ERK target early response gene c-fos 
(Seshadri and Campisi, 1990, Irving et al., 1992, Riabowol et al., 1992) which is essential for 
cell-cycle progression. The downregulation of ERK signalling may occur through the 
increased activity of MAP kinase phosphatases (MKP) which dephosphorylate and deactivate 
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MAP kinases (Torres at al., 2003). The signalling pathways affected by replicative 
senescence are illustrated in Figure 1-11. 
 
Figure 1-11 Signal transduction pathways activated by receptors with tyrosine kinase activity. The EGF 
receptor is shown as an example. Events following receptor ligation and autophosphorylation include formation 
of multi-protein complexes, phospholipid turnover, calcium mobilization and activation of protein kinases, 
phosphatases and transcription factors. Some of these events are illustrated above with an emphasis on pathways 
known to be affected by replicative senescence. Bold arrows indicate signalling molecules with altered 
expression and/or activity in senescent cultures (Cristofalo et al., 2004) 
As cellular senescence is believed to contribute to the ageing process, it seems implausible 
that senescence is associated with a downregulation of c-fos-mediated AP-1 signalling in vitro 
while in vivo evidence suggests AP-1 signalling increases with ageing (Fisher et al., 1998, 
Walter and Sierra, 1998, Xiao and Majumdar, 2000, Jung et al., 2009). This disparity is 
explained by the formation of functional Jun/Jun AP-1 homodimers (additionally to Fos/Jun 
heterodimers) as c-jun expression increases with ageing in vivo (Chung et al., 2000) but is not 
altered during replicative senescence (Irving et al., 1992), while c-fos decreases with 
replicative senescence (described above) but remains unchanged with in vivo ageing (Fisher et 
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al., 1998). Furthermore, c-fos, c-jun and AP-1 were found to be  fully responsive to 
mitogenic stimuli in same-passage fibroblasts from centenarians compared to young donors 
(Grassilli et al., 1996), suggesting the mitogenic response deficit postulated to occur with 
replicative senescence does not translate to in vivo ageing. The inconsistent “loss of function 
in vitro” but “gain of function in vivo”, regarding AP-1 and ageing (the cause of which 
remains unclear), highlights the need to exercise caution when attempting to interpret data 
generated using replicative senescence as a model of ageing. 
1.6.2.3 Proteolysis 
The proteasome is a multicatalytic protease composed of a catalytic core and a regulatory 
subunit that confers ubiquitin specificity and adenosine triphosphate dependence. It functions 
primarily to degrade abnormal, misfolded, biologically inactive proteins produced during 
processes such as oxidative damage.  
Several studies report a decrease in proteasomal function with age in epidermis (Bulteau et 
al., 2000), T lymphocyte subsets (Ponnappan, 2002), muscle (Husom et al., 2004), retina 
(Louie et al., 2002) and in heart, lung, kidney, liver and spinal cord (Keller et al., 2000). This 
results in an accumulation of ubiquitin-conjugated protein aggregates that impede a variety of 
cellular processes (Lindner and Demarez, 2009). The mechanisms underlying reduced 
proteasomal activity with age remain to be fully elucidated but are thought to involve 
alterations in the quantity/composition of proteasomal subunits, modification causing loss of 
function (e.g. oxidation) and inhibition by damaged proteins that accumulate with age 
(Carrard et al., 2002).  
The proteasome is not only responsible for the removal of undesirable proteins but also 
functions to regulate the normal turn-over of proteins involved in cell cycle progression (King 
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et al., 1996), gene expression (Muratani and Tansey, 2003), apoptosis (Naujokat and 
Hoffmann, 2002), antigen presentation (Lehner and Cresswell, 1996) and signal transduction 
(Coulombe et al., 2003). This suggests the age-related decrease in proteasomal activity is a 
plausible contributor to the ageing phenotype. 
1.6.2.4 Apoptosis 
Apoptosis is a highly conserved process of programmed cell death that prevents the sporadic 
lysis and release of cellular content into the extra-cellular environment as occurs in necrosis. 
This prevents release of degenerative enzymes and the onset of inflammation reactions. 
Specific proteases (caspases) and nucleases are activated by a wide range of stimuli including 
excessive DNA damage, serum withdrawal and steroid hormone treatment, resulting in the 
degradation of cellular structures. 
 While apoptosis is essential for the normal proliferation and amelioration of dysfunctional or 
damaged (including cancerous) cells, it is also implicated to be defective and a causative 
agent in ageing (Campisi, 2003). Evidence to support this includes mice with transgenic 
defects in apoptotic pathways that die prematurely of cancer (Wu and Pandolfi, 2001) and, 
conversely, aged rats that have reduced hepatocyte apoptosis compared to young rats 
following induced DNA damage (Suh et al., 2002). Equally, no clear consensus exists 
regarding apoptosis rates during cellular senescence with studies reporting both increased 
(Wang et al., 1995, Seluanov et al., 2001) and decreased (DeJesus et al., 2002, Zhang et al., 
2002) resistance to apoptosis. It is therefore likely that age-related alterations in apoptosis are 
regulated by a variety of tissue and cell-type specific responses to complex signalling 
pathways. 
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1.6.2.5 Telomeres 
In humans, telomeres are nucleoprotein complexes composed of several kilo-bases of double-
stranded sequence repeats (or up to 400 bases of single-stranded repeats at the 3'-end 
overhang) of the sequence TTAGGG that cap the ends of chromosomes. Forty years ago, 
Olovnikov proposed the Theory of Marginotomy - which suggests the 5'-end progeny strand 
of linear chromosomes would shorten upon each round of replication and may contribute to 
the finite number of replications of cells in culture (Olovnikov, 1973). The process of 
telomere erosion is controlled by telomerase, a nuclear protein with reverse transcriptase 
activity which replaces lost TTAGGG units following replication. Telomerase activity is 
associated with cellular longevity in normal physiology (Klapper et al., 1998) alongside 
immortal cells and cancer (Kim et al., 1994).  
Although initially hypothesized that promoting telomerase expression would defer cellular 
senescence and increase organismal longevity, studies have revealed a propensity towards 
malignancy in cultures with induced telomerase activity, albeit possessing unlimited 
proliferative capacity (Wang et al., 2000). This suggests that replicative senescence, through 
mechanisms such as telomere shortening, has evolved to prevent cancer. Many ongoing 
studies are investigating the signalling process between telomere shortening and the induction 
of senescence with emerging evidence suggesting that “uncapped” telomeres (lacking 
telomerase activity) are recognized as double stranded DNA breaks (di Fagagna et al., 2003). 
As telomere length and telomerase regulation is known to have such a profound effect on the 
longevity of cells in culture, it may appear surprising that studies comparing telomere length 
in proliferating and non-proliferating human tissues have only demonstrated a modest 
decrease with age (Aikata et al., 2000, Kveiborg et al., 1999). Furthermore, Rudolph et al 
reported that telomerase-deficient transgenic mice did not display attenuated survival rates 
Chapter 1  General introduction 
34 
compared to WT controls until after several generations (Rudolph et al., 1999), although this 
could be due to the telomere length being over four-fold longer than in humans.  
In addition to conflicting data regarding cell signalling pathways (e.g. AP-1), the discordance 
between in vitro modulation of telomere length and limited in vivo evidence casts further 
doubt on the occurrence of replicative senescence during ageing, and its relevance as a model 
to study age-related processes in situ (Rubin, 2002). Finally, the fact that the senescent 
phenotype has not been confirmed in healthy tissues in vivo is consistent with this view 
(Severino et al., 2000). 
1.6.2.6 Genomic instability 
Genomic instability increases with organismal age and contributes to the ageing phenotype 
through several mechanisms including somatic mutations in extranuclear mitochondrial DNA 
(mtDNA, Lee et al., 2010), decreased cellular DNA repair capacity (Gorbunova et al., 2007) 
and chromosomal abnormalities. The age-related changes associated with these mechanisms 
are described in more detail below. 
1.6.2.7 mtDNA mutations 
Mitochondria are particularly susceptible to age-induced genomic instability as mtDNA has a 
greater mutation rate than nuclear DNA due to a lack of protecting histones, limited repair 
mechanisms and proximity to the high rate of ROS generation through oxidative 
phosphorylation. Progressive damage to the human fibroblast mtDNA replication control 
region in the form of somatic mutations is reported in normal old, but not young, donors 
(Michikawa et al., 1999). Additionally, a correlation between specific mtDNA mutations and 
donor age has been described for a range of human tissues including liver (Yen et al., 1991), 
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brain (Corraldebrinski et al., 1992) and diaphragm (Torii et al., 1992) alongside other species 
such as rhesus monkey muscle (Schwarze et al., 1995) and mouse muscle and brain (Chung et 
al., 1994 and Brossas et al., 1994 respectively).  
Lee et al. demonstrated that not only does the mutation detection rate increase with human 
age (beginning around the mid-thirties), but also varies by tissue, with mutations arising 
earlier and in greater proportions in highly energy-demanding tissues such as muscle 
compared to testis (Lee et al., 1994), further highlighting the role of oxidative metabolism 
(and ROS) on the acceleration of ageing. Moreover, the proportion of mutant mtDNA 
correlates with oxidative modification levels (Lezza et al., 1999) in human brain while a 
common age-related mtDNA deletion can be directly induced with a sub-lethal dose of 
oxidative stress in human dermal fibroblasts (Dumont et al., 2000). 
The causal role of mtDNA mutations to the ageing phenotype has been extensively studied in 
animal models where their induction resulted in a reduced lifespan and signs of premature 
ageing such as weight loss, reduced subcutaneous fat, alopecia, kyphosis (curvature of the 
spine), sarcopenia, osteoporosis, anaemia, thymic involution, testicular atrophy associated 
with depletion spermatogonia, reduced fertility, loss of intestinal crypts, heart enlargement, 
and hearing loss (Trifunovic et al., 2004, Kujoth et al., 2005). The mutant mice did not show 
any increased sensitivity to or signs of oxidative stress compared to wild-type (WT) controls, 
suggesting that oxidative stress is causative of age-related mtDNA mutations rather than a 
consequence. Further analysis revealed that cellular proliferation and senescence rates were 
not accountable for the premature ageing phenotype, but rather the extent of apoptosis which 
increased more rapidly during ageing of the mutant mice (Kujoth et al., 2005). Recently, there 
is an ongoing debate regarding whether point mutations or deletions are the main contributing 
factor to the phenotype of these mice (Vermulst et al., 2007, Edgar et al., 2010). Although 
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these studies provide strong evidence for a causal role of mtDNA mutations in the ageing 
process, there is arguable uncertainty around the applicability of transgenic mouse as models 
of natural ageing and the mechanisms involved remain unclear.  
One possibility is that mitochondrial dysfunction may result in an age-related defect in 
retrograde (mitochondria-to-nucleus) signalling (Finley and Haigis 2009), striking at the heart 
of cellular systems and causing dysregulation in energy production, oxidative stress and cell 
survival. Transcriptional pathways implicated in this process include peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PPARGC1A, master transcriptional regulator 
of mitochondrial function and biogenesis), sirtuin (SIRT)-1 (protein deacetylase regulator of 
energy metabolism and oxidative capacity), AMPK (protein kinase sensor of cellular energy 
status) and mTOR (mitochondrial energy production). In addition to evidence suggesting 
these pathways are integral to correct mitochondrial function, emerging studies are reporting a 
link to lifespan in model organisms such as yeast, worms and flies and dysregulation in 
mammalian ageing (Figure 1-12). Currently, alterations in retrograde signalling pathways and 
increases in mitochondrial ROS production with age (further exacerbating mtDNA, protein 
and lipid damage, Short et al., 2005) are fundamental areas of research focus for the 
elucidation of molecular mechanisms involved in ageing. 
 
Figure 1-12 The role of major mitochondrial regulators on lifespan and ageing. All four proteins are capable of 
increasing measures of mitochondrial function, including mitochondrial number, oxidative phosphorylation 
capacity and fatty acid oxidation. Expression of the SIRT1 ortholog, Sir2, increases lifespan in yeast, worms and 
flies; AMPK increases lifespan in worms but decreases yeast lifespan, and inhibition of mTOR increases lifespan 
in all three model organisms. For mammalian ageing, arrows indicate how a given protein’s expression or 
activity changes (reproduced from Finley and Haigis, 2009) 
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1.6.2.8 Decreased DNA repair mechanisms 
As with mtDNA, nuclear DNA damage accumulates with age, occurs at an increased rate in 
older organisms and characteristically includes genomic rearrangements (Stuart and 
Glickman, 2000, Vijg and Dolle, 2002). Normally, mispaired bases are corrected by the 
mismatch repair (MMR) system (Figure 1-13), which would otherwise result in the 
introduction of point mutations. Defects in MMR have been associated with cellular 
senescence of T-cell clones in vitro (Annett et al., 2005) and mutations in MMR genes have 
been implicated in microsatellite destabilization, the incidence of which increases during 
human ageing (Karran, 1996, Neri et al., 2005). 
Similarly, age-related alterations have been documented for base excision repair (BER) 
mechanisms (Figure 1-13) which function to remove lesions affecting one DNA strand and 
utilising the complementary strand to “fill the gap”, particularly during repair of oxidised 
bases produced through ROS damage. Senescent human fibroblasts and leukocytes from older 
donors contain greater numbers of abasic sites (Atamna et al., 2000) - produced following 
glycosylase cleavage of the damaged base - suggesting a failure in the subsequent repair 
process; abasic endonuclease excision to leave a single-stranded gap, DNA polymerase-β base 
re-incorporation and ligation by DNA ligase. Indeed, reduced abundance of DNA 
polymerase-β in aged rodent tissues (Cabelof et al., 2002) and of abasic endonuclease in aged 
mouse germ cell extracts (Intano et al., 2002) has been reported. Furthermore, upon treatment 
with oxidizing hydrogen peroxide or a methylating agent, the number of abasic sites rose 
faster in young cells (early passage fibroblasts or young donor-derived leukocytes) suggesting 
a further defect in the initial mutation detection or excision by DNA glycosylases (Atamna et 
al., 2000).  
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Moreover, following γ-radiation, tissues from older mice contain higher levels of oxidized 
guanine than younger animals (Hamilton et al., 2001). As a key repair mechanism for 
oxidative damage, BER was analyzed in tissue extracts from young and old animals by 
incubating protein extracts with radiolabelled oligonucleotides containing single base lesions. 
A reduction in cleavage products indicated reduced glycosylase incision activity in the brains 
of older mice and interestingly, this defect was much greater in mtDNA compared to nuclear 
DNA (Imam et al., 2006). These results have also been corroborated using in vitro senescence 
culture of human fibroblasts (Shen et al., 2003). Alongside enzymatic dysfunction, age-
related BER insufficiency may be caused by a lack of recognition of or response to DNA 
damage. For example, in old mice and senescent human fibroblasts, the translocation of 
glycosylase and abasic endonuclease into the nucleus and mitochondria is impaired (Szczesny 
et al., 2003, 2004). Moreover, impaired enzymatic recognition of single strand breaks by 
poly-(ADP ribose) polymerase (PARP) to initiate the repair process has been implicated in 
age-related genomic instability (Burkle et al., 2004) and defects in proteasome function 
(Bakondi et al., 2011). Conversely, PARP activation is associated with diabetic neuropathy 
(Stevens et al., 2011) suggesting enzyme levels must be tightly controlled to prevent disease. 
Nucleotide excision repair (NER) removes short oligonucleotide sequences containing a 
damaged base (Figure 1-13), typically bulky lesions caused by carcinogens and UV exposure. 
NER is further classified into global genome repair or transcription coupled repair where 
corrections can be made in the transcribed strand of active genes and both systems require 
intricate multi-protein complexes. Studies exploring links between NER and cellular 
senescence have shown conflicting results in vitro. Following UV-induced cyclobutane 
pyrimidine dimers (CPD) in human fibroblast and trabecular osteoblast DNA no difference in 
the rate of NER was observed between early and late passage cells (Christiansen et al., 2000), 
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while another group demonstrated reduced UV-induced CPD removal in senescent fibroblasts 
(Boyle et al., 2005). 
 
Figure 1-13 Excision repair pathways for DNA damage. The three main excision repair pathways in human 
cells - BER, NER and MMR - proceed through similar steps to restore the normal DNA sequence. Following 
recognition of altered DNA bases, incision of DNA is achieved by endonuclease activation. Subsequent 
displacement or degradation of single-stranded DNA sections containing the damage occurs via enzymes with 
helicase and exonuclease activity. Repair replication of the resulting DNA gap and strand ligation restores the 
double-stranded DNA molecule. The many repair enzymes that are involved in each specific step are tightly 
coupled and may be regulated or inducible by DNA damage response pathways (Cline and Hanawalt, 2003) 
Conversely, studies comparing NER according to donor age have consistently demonstrated 
an age-related decrease in NER efficacy. UV-irradiated plasmids containing a damaged, 
inactive chloramphenicol acetyltransferase, transfected into human peripheral blood 
lymphocytes from donors of varying age displayed higher rates of reactivation following 
successful DNA repair in young donor-derived cells (Wei et al., 1993). 
A similar study design in human dermal fibroblasts also reported increased introduction of 
new mutation in plasmids transfected into older donor cells in addition to reduced plasmid 
reactivation (Moriwaki et al., 1995), suggesting that not only is NER more ineffective with 
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age, but also more inefficient. Interestingly, repair efficiency of telomeric DNA is also 
reduced in fibroblasts from older human donors (Kruk et al., 1995). Furthermore, animal 
studies report CPD removal by NER is lower in aged rat hepatocytes (Guo et al., 1998). CPD 
and pyrimidine photoproduct removal rates are also decreased in dermal fibroblasts from 
older human donors (Goukassian et al., 2000), with removal also reduced in aged mouse 
round spermatids in a cell-type specific manner (Xu et al., 2005). Increased CPD removal 
rates have also been documented in younger skin epidermis in situ following upper arm UVB 
radiation (Yamada et al., 2006). Moreover, photoproducts in UV-irradiated skin are induced 
at a higher frequency in older human donors (Xu et al., 2000). Recently, studies inducing 
mutations in NER genes have reported accelerated ageing in mice (Niedernhofer et al., 2006).  
1.6.2.9 Chromosome abnormalities 
Chromosome abnormalities are the most severe form of genomic instability and if unrepaired, 
threaten the survival of the cell. Double stranded breaks (DSBs) are the most lethal type of 
DNA lesion and cause chromosomal loss, however, if incorrectly repaired they lead to 
genomic rearrangements - the incidence of which increases with age (Dolle et al., 1997, Vijg 
and Dolle, 2002, Ramsey et al., 1995, Tucker et al., 1999). 
DSBs are repaired either by homologous recombination, where the sister chromatid serves as 
a template to complete the faulty locus, or by non-homologous end joining (NHEJ) which 
fuses two broken ends with little regard for sequence homology. The latter is highly error 
prone and often leads to deletions or insertions of filler DNA (Sargent et al., 1997). 
Additionally, DSBs situated between two direct repeats can be repaired by single strand 
annealing resulting in mutagenic deletion of the sequence between the repeats. These three 
mechanisms of DSB repair are illustrated in Figure 1-14. 
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Figure 1-14 Double-strand break repair. Breaks are efficiently repaired in mammalian cells by homologous 
recombination (HR), NHEJ or single strand annealing (SSA). HR initiates with end resection, producing a 3′ 
single-stranded end that invades the sister chromatid template to initiate repair. Alternative HR pathways can 
ensue from the displacement loop (D-loop) intermediate: synthesis-dependent strand annealing (SDSA) and DSB 
repair (DSBR). In SDSA, the newly synthesized strand displaces to anneal to the other DNA end, resulting in a 
non-crossover outcome with the template DNA unchanged. In DSBR, the second DNA end is 'captured' by the 
D-loop forming a double Holliday junction, which can result in a non-crossover (cleavage at black or grey 
arrowheads) or a crossover (cleavage at black arrowheads on one side and grey arrowheads) outcome. SSA takes 
place when end resection occurs at sequence repeats (arrowheads) to provide complementary single strands that 
anneal, giving rise to a product with a single copy of the repeat and a deletion of intervening sequences, often 
with mutagenic outcomes (Moynahan and Jasin, 2010) 
Studies investigating age-related changes in DSB repair are limited. Seluanov et al. recently 
reported that the efficiency of NHEJ is reduced by up to 4.5-fold in pre-senescent and 
senescent human fibroblasts, with higher precise ligation frequency in younger cells and 
extended deletions in older cells (Seluanov et al., 2004). Reduced NHEJ efficiency is also 
documented in ageing rat brain neurons (Vyjayanti and Rao, 2006) and interestingly in 
nuclear cortical extracts from brains of Alzheimer’s disease - a highly publicised age-related 
condition (Shackelford, 2006). 
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Age-related abnormalities in NHEJ DSB repair may, in part, be due to alterations in the 
availability and function of accessory proteins involved in the process. For example, levels of 
the protein Ku which recognizes and binds DSB are reduced in ageing rat testis (Um et al., 
2003), older donor-derived human lymphocytes (Ju et al., 2006) and senescent human 
fibroblasts (Seluanov et al., 2007). Furthermore, an age-related decline in nuclear targeting 
and DNA binding affinity of Ku has been demonstrated in human peripheral blood 
mononuclear cells (Frasca et al., 1999). 
Although there is strong evidence for reduced efficiency of NHEJ DSB repair with age, it 
may also be the case that this potentially mutagenic pathway is more heavily relied upon than 
the efficacious homologous recombination repair route. As the latter is restricted to the G2/M 
phase of the cell cycle when a sister chromatid is available, the major pathway for DSB repair 
in mammalian G1/G0 (senescent) cells may shift to favor NHEJ (Saleh-Gohari and Helleday, 
2004). It remains to be defined whether this occurs in ageing organisms where the presence of 
pre-senescent and senescent cells remains controversial. 
1.6.3 Endocrine Dysfunction 
Ageing is associated with a multitude of hormonal changes that constitute a decline in 
endocrine function involving the responsiveness of tissues as well as reduced hormone 
secretion from peripheral glands. These changes are highly complex with endocrine functions 
so intertwined that alterations in one system often affecting others. Changes in gonadal 
hormone secretion in healthy ageing are among those most well established and comprise the 
menopause in females and andropause in males. 
During the reproductive period, the hormones of the hypothalamic-pituitary-gonadal (HPG) 
axis are in balance, but the age-related decline in reproductive organ function triggers a 
decrease in gonadal inhibin secretion in both females (Welt et al., 1999) and males, causing 
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an increase in activin signalling (Baccarelli et al., 2001). This induces HPG axis drive with 
increased gonadotrophin releasing hormone and subsequent gonadotrophin secretion 
(Baccarelli et al., 2001). Additionally, the age-related decrease in gonadal oestrogen and 
testosterone sex steroid production (Couzinet and Schaiso, 1993, Baccarelli et al., 2001) 
causes a further loss of hypothalamic feedback inhibition and also stimulates gonadotrophin 
release from the pituitary (Figure 1-15). 
Hypothalamus
Pituitary
Gonads
LH/FSH
GnRH
Activin
Oestrogen/Testosterone Inhibin
 
Figure 1-15 The HPG axis. Activins in the periphery stimulate the hypothalamus to secrete gonadotrophin-
releasing hormone (GnRH). This stimulates the anterior pituitary to secrete the gonadotrophins LH and FSH 
which bind to gonadal receptors to stimulate oogenesis/spermatogenesis, sex steroid and inhibin production. 
Inhibin binds to activin receptors to downregulate the HPG axis. During menopause and andropause, inhibin and 
sex steroid production decrease as a result of reduced gonadal function, removing the HPG negative feedback 
control and causing an increase in LH/FSH secretion in a futile attempt to restore reproductive capabilities. 
Adapted from Bowen and Atwood, 2004 
In females, this manifests as a 3- to 4-fold and 4- to 18-fold increase in circulating luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH) respectively, greatest during the onset 
of menopause and remaining elevated for the next 4-5 years before declining but never 
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reaching levels seen during the reproductive years (Chakravarti et al., 1976). In males, the 
loss in reproductive function is more gradual, reflected in a more blunted increase in LH and 
FSH of 2- and 3-fold respectively (Neaves et al., 1984). 
The circulating levels of anabolic/lipolytic growth hormone (GH) and its downstream 
mediator insulin-like growth factor (IGF)-1 also decline during ageing - a process referred to 
as the somatopause (Corpas et al., 1993). Data suggests an age-dependent decrease in 
endogenous hypothalamic GH releasing hormone output (Russel-Aulet et al., 1999); reduced 
physical activity and increased adiposity contribute to this decline (Vahl et al., 1996). As 
young adults with GH deficiency exhibit physical attributes resembling the ageing phenotype 
which are improved by long-term recombinant human GH therapy (Carrol and Christ, 1998), 
it was suggested that the elderly have genuine GH deficiency and would therefore benefit 
from GH replacement. However, whist improvements in body composition have been 
reported (e.g. muscle mass), functionality (e.g. muscle strength) was unaffected (Blackman 
and Harman, 2002). Furthermore, concerns have been raised regarding adverse side effects 
associated with therapy including arthralgia, carpal tunnel syndrome, oedema, 
hyperglycaemia and cancer risk (Vance, 2003). 
Moreover, dwarf mice deficient in pituitary hormone secretion (including GH) are sterile but 
have an extended lifespan (Brown-Borg et al., 1996) - prompting the hypothesis that 
decreased GH signalling contributes to increasing longevity. Indeed, transgenic mice 
overexpressing GH and acromegalic individuals who secrete large amount of GH die 
prematurely (Wolf et al., 1993, Ohalloran and Shalet, 1995), whilst GH receptor-null mice 
display increased longevity (Coschigano et al., 2000) and individuals with Laron Syndrome 
(primary GH resistance or insensitivity) have a normal life expectancy (Laron, 2004). 
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These studies suggest that GH signalling is associated with decreased life expectancy and that 
the reduced secretion of this hormone during ageing may be affected by other factors 
prolonging lifespan. A recent theory proposes that LH/FSH may be involved in promoting the 
GH/IGF-1 signalling pathway at the expense of reduced life expectancy in favour of 
reproduction and growth (Bowen and Atwood, 2004). Thus the increased LH/FSH signalling 
in post-reproductive years, responding to decreased gonadal function in an attempt to 
maintain reproductive function, may also lead to increased activation of the IGF-1 signalling 
pathway causing increased negative feedback to suppress GH secretion and contributing 
indirectly to the age-associated decline of this hormone. Moreover, GH secretion is also 
inhibited by activins (Bertherat et al., 1995), which are known to drive the age-related 
increase in LH/FSH thus potentially also contributing directly to a decrease in GH production 
as the HPG axis becomes hyperactivated. A recent study that may assist in unifying these 
theories demonstrated that transplanting reproductively viable organs from young into 
senescent rats significantly extended their lifespan (Cargill et al., 2003), providing compelling 
evidence that increasing germ cell number increases longevity. 
In addition to the menopause, andropause and somatopause, levels of dehydroepiandrosterone 
(DHEA) and its predominantly circulating sulphate-bound form (DHEAS) markedly decrease 
after the age of 25 (Orentreich et al., 1984) - a process referred to as the adrenopause. 
Histomorphological analysis of adrenal specimens suggests that ageing results in alterations 
within the adrenal cortex, resulting in a reduction in the size of the zona reticularis, this being 
responsible for the diminished production of DHEA (Parker et al., 1997). As well as an 
abundant circulating adrenal androgen, DHEA(S) is also thought to act directly as a 
neurosteroid that may have cardioprotective, antidiabetic, anti-obesity and immunoenhancing 
properties (Yen and Laughlin, 1998), prompting much debate on the anti-ageing properties of 
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DHEA and its potential as a ‘hormone of youth’ (Baulieu, 1996). Although correlations 
between declining DHEA(S) levels and age-associated pathologies such as cardiovascular 
disease, breast cancer, low bone mineral density, depressed mood, T2D and Alzheimer’s 
disease have been reported, a causal relationship has not been established, casting doubt over 
the usefulness of DHEA replacement therapy in individuals with only a relative decline in 
circulating DHEA levels (including ageing), although benefits have been reported in 
conditions of adrenal insufficiency (Arlt, 2004). Indeed, studies assessing the effect of oral 
DHEA in otherwise healthy older subjects did not conclusively report any improvements in 
well-being, cognition or sexuality (Allolio and Arlt, 2002). 
Age-associated alterations in hypothalamo-pituitary-thyroid axis function have also been 
reported, although, as with DHEA, it has been challenging to disseminate these from indirect 
alterations caused by simultaneous thyroid or nonthyroidal illness, or other physiological or 
pathophysiological states whose incidence increases with age. Thyroid hormone clearance 
decreases with age, but thyroid hormone secretion is also reduced, leading to unchanged total 
and free serum thyroxine (pro-hormone) concentrations. In contrast, serum total and free 
triiodothyronine concentrations decrease with healthy ageing, although these changes do not 
occur until after the eighth decade of life. This reduction is believed to be mostly due to 
reduced peripheral conversion of thyroxine to triiodothyronine, due either to the direct effect 
of non-thyroidal illness or to ageing itself, although decreased thyroid stimulating hormone 
secretion has also been reported (Mariotti et al., 1993). 
Finally, whilst sex steroid, GH, DHEA and triiodothyronine concentrations are reported to 
decline, there is evidence for increased hypothalamic-pituitary-adrenal (HPA) axis (Figure 
1-16) drive with resultant increased circulating cortisol levels (Van-Cauter et al., 1996, 
Seeman et al., 1997), although this increase is modest and some studies have failed to detect it 
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(Waltman et al., 1991). There are also complex age-related changes in the HPA axis response 
to stress, with a prolonged response in older subjects (Bergendahl et al., 2000) and diminished 
sensitivity to GC-mediated negative feed-back through the HPA axis, although this more 
pronounced in females (Laughlin and Barrett-Connor, 2000). 
 
Figure 1-16 The HPA axis. In response to stress, corticotrophin-releasing hormone (CRH) is secreted from the 
hypothalamic paraventricular nucleus which stimulates the pituitary to release adrenocorticotrophic hormone 
(ACTH). This in turn stimulates the adrenal secretion of GC (cortisol in humans and corticosterone in rodents) 
which feed back to the level of the hippocampus, hypothalamus and pituitary to dampen excess activation of the 
HPA axis. Reproduced from Hyman, 2009 
1.6.4 Extrinsic ageing 
1.6.4.1 Photo-ageing 
Solar UV radiation is the primary contributor to the acceleration of the skin ageing process 
and also arguably the most aggressive form of extrinsic ageing. Through the photochemical 
Chapter 1  General introduction 
48 
generation of ROS, a host of cellular components are initiated by increasing pro-inflammatory 
cytokines e.g. IL-1/6, vascular endothelial growth factor (VEGF) and TNF-α (Rabe et al., 
2006) which activate protein kinase signal transduction pathways e.g. AP-1 (Angel et al., 
2001) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB, Abeyama et 
al., 2000), regulating enzymes which synthesize and degrade structural proteins in the dermis 
including MMP1, MMP3, and MMP9 (Fisher and Voorhees 1998), reducing the structural 
integrity and functional properties of the skin. 
These detrimental pathways can be activated following only a minimal, sub-erythemal dose of 
UV, with 5-15min exposure in midday sun on alternate days being sufficient to maintain 
elevated MMP levels. Furthermore, inflammation attracts neutrophils which burrow 
destructively through the ECM and produce free-radicals increasing the skin’s ROS load, 
whilst angiogenesis is promoted by increased VEGF levels and contributes to UV-associated 
telangiectases. In addition, ROS including superoxide anion, peroxide, and singlet oxygen 
directly modify DNA, proteins and lipids in a detrimental manner. 
UV radiation also induces hydrogen peroxide generation in skin by upregulating nicotinamide 
adenine dinucleotide phosphate (NADP) oxidase, which catalyzes the reduction of molecular 
oxygen to superoxide anion. This is then converted to hydrogen peroxide which has reduced 
cellular toxicity (Fisher et al., 2002). Hydrogen peroxide acts to induce multiple signalling 
pathways and leads to premature senescence in vitro (Frippiat et al., 2000), although low 
concentrations can stimulate growth (Irani et al., 1997). It is a cofactor for peroxidases and 
also has potential for conversion to the hydroxyl radical and singlet oxygen, the latter of 
which is able to upregulate collagenase (MMP1) expression in human dermal fibroblasts 
(Scharffetterkochanek et al., 1993). 
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In addition to the degradation of mature collagen by the upregulation of MMPs, UV radiation 
also directly impacts on de novo collagen synthesis by downregulating procollagen I and III 
expression in primary human dermal fibroblasts (Fisher et al., 2000). This occurs through 
several mechanisms, for example, (i) by upregulating the transcription factor AP-1 (Pfundt et 
al., 2001) which binds to and sequesters factors required for a procollagen transcription 
initiation complex (ii) by sequestering a signalling protein activated by TGF-β, a major pro-
fibrotic cytokine (Chung et al., 1996) and (iii) by downregulating the TGF-β receptor (Quan 
et al., 2001). 
Interestingly, c-jun expression was found to be elevated in PP buttock skin from >80 year old 
compared to that from 18-28 year olds (Chung et al., 2000), suggesting that upregulation of 
AP-1 signalling is a mediator common to both photo-ageing and chronological ageing, likely 
driven by similar mechanisms such as UV- or metabolism-induced generation of ROS 
respectively. Additionally, AP-1 is known to upregulate MMP1 (collagenase), MMP3 
(stromelysin-1) and MMP9 (92-kD gelatinase, Angel et al., 2001) and these matrix-degrading 
enzymes are also elevated in both PE and chronologically aged (Varani et al., 2000) skin 
further supporting a role for AP-1 signalling in skin ageing. 
UV radiation further accelerates the ageing process by inducing genomic instability in the 
form of mtDNA mutation (Berneburg et al., 1999) and causes the disruption of many other 
structural components of the skin besides collagen including the elastin fibre network, 
anchoring fibrils, proteoglycans and GAGs (Bernstein and Uitto, 1996). 
1.6.4.2 Diet 
The benefits of a balanced diet to maintaining optimal organismal health and nutrition are 
well documented (Finch, 2010) and as such play a key role in modifiable extrinsic longevity. 
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Furthermore, restriction of calorific intake was first described over eight decades ago to 
increase lifespan in rats (McCay et al., 1935) and has since been a focus for research into 
healthy ageing. Studies have demonstrated increased lifespan through caloric restriction (CR) 
in a diverse range of species including yeast, worms, flies and rodents (Fontana et al., 2010) 
but in humans, although shown to reduce risk factors for diabetes, cardiovascular disease, and 
cancer, its influence on lifespan is still not clearly established (Fontana and Klein, 2007). 
Much progress has been made in unveiling the molecular mechanisms underlying the 
contribution of CR to increasing longevity, centred on a shift from a state of growth and 
proliferation to maintenance and repair (Walford et al., 1987). Perhaps unsurprisingly, 
evidence is emerging for the suppression of common pathways (e.g. IGF-1) that are activated 
by reproductive hormones at the expense of extending lifespan. Indeed, the decrease in 
LH/FSH observed during CR (Veldhuis et al., 1993, Bergendhal et al., 1998) has been 
postulated to drive longevity in an attempt to increase the chance of reproductive success, 
acting as an evolutionary mechanism to preserve fertility until environmental conditions (e.g. 
food supply) become favourable again (Holliday, 1989, Bowen and Atwood, 2004). 
Additional mechanisms through which CR functions to increase longevity include 1) reduced 
metabolism and oxidative stress (Brand, 2000) with decreased mitochondrial superoxide 
radical and hydrogen peroxide generation, slower accumulation of oxidative damage, 
decreased alkane production and a delayed loss of membrane fluidity (Sohal and Weindruch, 
1996), 2) altered body composition with decreased fat mass and increased lipid oxidation to 
preserve carbohydrate (Heilbronn et al., 2006) and a reduction in age-related loss of beneficial 
brown adipose tissue function (Valle et al., 2008) leading to reduced mortality from obesity-
related diseases such as diabetes and heart disease (Poirier et al., 2006) and 3) reduced 
systemic inflammation (Spaulding et al., 1997), partly through reduced adiposity (Fontana, 
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2009). Recently, the importance of reduced body temperature as a mediator of these 
mechanisms has been described (Carrillo and Flouris, 2011). 
1.6.4.3 Other environmental influences 
Although research into extrinsic factors contributing to ageing (particularly of the skin) have 
traditionally focused on solar radiation, with the terms ‘extrinsic ageing’ and ‘photo-ageing’ 
used synonymously, there is growing evidence that other environmental factors (e.g. diet) are 
also involved. Such studies, however, remain challenging as individual influences are difficult 
to extrapolate from other factors and must contribute a large, independent effect in order to be 
identified. Furthermore, many environmental influences may require chronic, often lifelong 
exposure to contribute an effect (i.e. smoking one cigarette or drinking one glass of wine in a 
lifetime is unlikely to contribute to an alteration in lifespan or healthy ageing), and the very 
nature of these highly variable lifestyle choices between different individuals makes such 
assessments difficult to validate, power and quantify. 
However, in addition to solar radiation and diet, several other independent extrinsic factors 
have been reported to contribute to the ageing process. Smoking is strongly associated with a 
variety of cardiovascular and pulmonary diseases and cancers and is the single largest 
preventable cause of death and disability in developed countries. In addition to health 
complications, there is ample evidence for contribution to premature ageing in skin including 
poor wound healing, wrinkling, squamous cell carcinoma, psoriasis, hair loss and oral cancers 
(Freiman, 2004). Premature greying of hair is also accelerated by smoking (Stamp, 1995). 
Mechanisms involved in the manifestation of these changes include the induction of genomic 
instability by increasing the rate of mtDNA mutations (Lee et al., 1999) - a key factor 
underlying intrinsic ageing. In skin, tobacco smoke has been shown to induce premature skin 
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ageing by upregulating MMPs through the aryl hydrocarbon receptor pathway - also involved 
in mediating toxicity of UVB photoproducts (Morita et al., 2009). Similarly, airborne particle 
pollution also correlates with signs of extrinsic ageing such as pigment spots (Vierkotter et 
al., 2010) which may result through increased oxidative stress and mitochondrial damage (Li 
et al., 2003). 
Other extrinsic factors that may be involved in the ageing process include alcohol 
consumption, possibly through HPA axis activation (Spencer and Hutchison, 1999) and 
altered social interactions (Nilsson, 1996), although further detail on these and other 
environmental influences is beyond the scope of this thesis. 
1.6.5 Summary 
Ageing is a complex multi-factorial process, in its most simplified form, resulting from a 
systemic imbalance of damage and repair ultimately leading to an accumulation of 
unrepairable genomic damage. This causes dysregulation of normal gene transcription 
patterns (Bahar et al., 2006), further exacerbating the imbalance and culminating in a 
cascading decline of age-related physiology. Reduced genomic integrity and dysfunctional 
systems may trigger a compensatory increase in apoptotic pathways, potentially reducing the 
SC pool and diminishing the capability for cellular renewal (Gatza et al., 2007). 
1.7 Skin ageing 
1.7.1 Overview 
As organisms age, most organs and tissues undergo a chronological process of change 
resulting in a diminished capacity to function normally. In no other organ is this inevitable 
progression more obviously apparent than in the skin. Obvious signs include atrophy, laxity, 
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wrinkling, sagging, dryness, yellowness, various blemishes and sparse, greying hair. The 
mechanisms underlying skin ageing are highly complex and encompass a multitude of 
endogenous (e.g. genetic mutation, cellular metabolism, hormonal environment) and 
exogenous (e.g. UV exposure, ionizing radiation, chemicals, toxins, pollutants) factors. 
Changes resulting from exogenous ageing occur primarily in PE skin such as the face, neck, 
décolletage and hands while those resulting from endogenous ageing are typical of PP areas 
and are often also considered to be representative of internal organ ageing. Importantly, 
exogenous ageing superimposes on endogenous ageing causing an acceleration of ageing 
processes that is clearly visible when comparing PE and PP skin. 
1.7.2 The phenotype of ageing skin 
1.7.2.1 Structural alterations  
There are several morphological differences between chronological (intrinsic) and exogenous 
(extrinsic) skin ageing. Intrinsically aged skin undergoes a gradual thinning of the epidermis - 
up to 50% by 80 years of age (Lavker, 1979) and a flattening of DEJ rete ridges, although 
these observations are complicated by morphological epidermal variations depending on 
anatomical site. Dermal atrophy is moderate compared to PE skin, with decreased cellularity 
especially dermal fibroblasts (Varani et al., 2001). Intrinsically aged skin appears thin, finely 
wrinkled, smooth, dry, unblemished, sallow, and pale, with some loss of elasticity. 
Conversely, extrinsically aged epidermis undergoes thickening attributable to processes 
comparable to chronic wounding and repair. PE skin is characterized by deep wrinkles, laxity, 
roughness, sallowness, increased fragility, blister formation, pigmentary changes, 
teleangiectases, impaired wound healing, and benign and malignant growths. 
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1.7.2.2 Cellular alterations 
At a cellular level, dermal fibroblasts from aged skin adopt a stellate phenotype with a highly 
activated endoplasmic reticulum with increased biosynthetic activity (Ma et al., 2001) and 
there is a decrease in fibroblast number and size. Epidermal keratinocytes become less evenly 
aligned on the basement membrane with increased irregularities in size, shape, staining 
properties and a decrease in cellular turnover (Cerimele et al., 1990) consistent with a 
reduction in epidermal repair and wound healing (Ashcroft et al., 1995). Age-spots are caused 
by alterations in melanocyte distribution with increased localized proliferation at the DEJ.  
1.7.2.3 Molecular alterations 
The key morphological differences between intrinsically and extrinsically aged skin are 
attributable to a host of alterations at the molecular level. In the epidermis, keratinocytes of 
the stratum corneum undergo irreversible terminal differentiation resulting in an increase of 
the molecular marker involucrin which is found to be more highly expressed in PE skin in 
vivo compared to PP (Bosset et al. 2003). Additionally, basal keratinocytes displayed reduced 
expression of β1-integrins (transmembrane receptors that assist in anchoring neighbouring 
keratinocytes to each other and to the basal membrane) in PE than in PP skin (Bosset et al., 
2003). These data give examples of two epidermal processes; an increased level of 
keratinocytes terminal differentiation and reduced keratinocyte cell adhesion, which 
exacerbate the underlying morphological phenotype of intrinsically aged skin and contribute 
to the phenotype of PE skin. 
Structural proteins of the dermis are also affected by extrinsic ageing. Fibrillin is truncated 
and depleted in the upper dermis of PE skin (Watson et al., 2001) as is collagen VII, which 
forms anchoring fibrils at the DEJ (Contet-Audonneau et al., 1999). Additionally, aged PE 
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skin undergoes solar elastosis, where an increase is elastin promoter activity (Bernstein et al., 
1996), coupled with decreased fibrillin-1 expression, results in a heavy deposition of 
dysmorphic elastin fibres in the upper dermis that is not as apparent in PP aged skin (Figure 
1-17), although age-induced disintegration and increased abnormal fibres still occur. 
Furthermore, versican (an elastin-associating chondroitin-sulphate proteoglycan) expression is 
also increased in areas of solar elastosis. Elastic fibres altered though photo-ageing contain 
deposits of lysozyme which has been shown to correlate with their basophilic degeneration 
(Suwabe et al., 1999). Over time, the normal collagen composition of the dermal matrix in PE 
skin is replaced by dysfunctional elastic tissue and contributes to the phenotype of photo-
ageing. 
A B
 
Figure 1-17 PP and PE skin samples of two healthy female subjects. Following staining with elastica [E], PP 
(inner upper arm) skin from an 83-year old (A) displays reduced accumulation of abnormal elastic tissue (arrow) 
and increased rete ridge formation compared to PE skin from the face of a 75-year old (B). Reproduced from 
(Makrantonaki and Zouboulis, 2007) 
Expression of the most abundant structural protein of the ECM, collagen type I, diminishes 
with age in PE skin (Griffiths et al., 1993) leading to a loose, erratic arrangement with poor 
tensile properties instead of the densely packed, highly organized composition of PP tissue 
(Bernstein et al., 1996). Studies suggests that the reduction in collagen type I is the result of 
increased degradation rather than reduced production (Varani et al., 2001). 
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Intrinsically aged skin also contains reduced abundance of collagen (although more moderate 
than in PE skin) and also in elastic fibres, lacking the solar elastosis of PE cutis (Braverman 
and Fonferko, 1982). 
GAGs (e.g. hyaluronic acid) are involved in the maintenance of dermal hydration and are 
more highly expressed in PE skin (Bernstein et al., 1996). The paradox that PE skin is less 
hydrated while having greater GAG expression may be explained by a change in the 
distribution of these proteins. Typically located diffusely between collagen bundles in the 
dermis of PP skin, it is thought that during solar elastosis GAGs become dysfunctionally 
associated with abnormal elastotic material - a hypothesis supported by the presence of a 
hyaluronic acid binding domain in versican. Therefore, water content is increased in PE skin - 
a somewhat surprising concept as lax PE skin is often attributable to a lack of water. In 
keeping with a lack of solar elastosis, the water content of intrinsically aged skin is similar to 
non-aged skin (Waller and Maibach, 2006). 
1.7.2.4 Dermal appendage alterations 
Greying hair bulbs contain fewer melanocytes with abnormal cytoplasmic vacuoles and only 
lightly melanized melanosomes (Commo et al., 2004). The reduced melanin production is 
linked to a lack of tyrosinase enzyme - involved in the initial stages of melanin pigment 
synthesis. Hair also becomes sparser with increasing age, particularly scalp hair which 
undergoes a transformation of terminal to interterminate then vellus hairs with follicle 
miniaturization resulting in balding. Occurrence of balding is caused by alterations in local 
androgen levels (androgenic alopecia) and is much more common in males (Otberg et al., 
2007). 
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Sebaceous gland sebum production also declines after the seventh decade in males, and earlier 
in females with the onset of menopause (Zouboulis and Boschnakow, 2001). Eccrine gland 
numbers are also reduced and produce less sweat. 
1.7.2.5 Skin immunity alterations 
Age-related changes in skin immune components include reduced numbers of epidermal 
Langerhans' cells which are also less responsive to migratory stimuli (e.g. TNF-α, Bhushan et 
al., 2002). T- and B-cell mitogenic responses are also impaired, although cell numbers remain 
constant (Thivolet and Nicolas, 1990). 
1.7.3 Skin disease in old age 
Skin conditions in the elderly occur as a result of the interplay of several factors associated 
with the ageing process including changes in its structure and function, cumulative exposure 
to environmental insults especially UV radiation, indirect effects of ageing or age-related 
disease in other organs, increased frailty and reduced wound healing. These factors contribute 
to an increased incidence of skin complaints in older people. For example, over two thirds of 
over 50-year olds and 83% of over 80-year olds reporting with a skin condition of some kind 
(Beauregard and Gilchrest, 1987). 
Pruritus, or itching, is a common symptom in old age and can be so severe that, if untreated, 
may rapidly deteriorate a patient’s quality of life. In the majority of cases, a primary 
cutaneous disease (e.g. xerosis) or systemic disorder (e.g. renal disease) explains this 
symptom (Reich et al., 2011) with the remainder classified as displaying an intractable senile 
pruritus, accompanied by difficult and often unsatisfactory management regimes. 
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The texture of skin in the elderly is often described as “dry” and senile xerosis is often a 
primary cause for pruritus - particularly in winter and especially pronounced on the legs. The 
surface of the skin adopts a “cracked paving” appearance known as asteatotic eczema, which 
may be partly due to reduced epidermal water content in the elderly (Potts et al., 1984). 
Psoriasis onset often peaks in later life (Bonifati et al., 1998), typically around the late 50s, 
and is less well tolerated in older individuals than when presenting earlier in life - when the 
disease is also more clearly associated with a family history. The mechanisms underlying this 
increased prevalence are largely unknown and often complicated by associated co-morbidities 
and other primary pathologies. 
Leg ulcers are also a common skin complaint amongst older subjects (Nelzen et al., 1991) 
mostly associated with venous hypertension and complicated by poor wound healing 
(Tallman et al., 1997). Studies have reported an age-related decrease in the migratory 
response to hypoxia in keratinocytes isolated from older donors, with a concomitant lack of 
MMP1, MMP9 and TIMP1 induction hypothesized to contribute to reduced re-
epithelialisation (Xia et al., 2001). 
1.8 Glucocorticoids 
1.8.1 Overview 
Glucocorticoids (GC) form a class of adrenal steroid hormones that bind the ubiquitously 
expressed GR and regulate a multitude of biological processes. GC are used extensively in 
pharmacology due to their potent anti-inflammatory and immunosuppressant properties, 
although their indiscriminate actions affecting almost all tissue types are associated with a 
broad range of systemic side-effects, diminishing their therapeutic potential for long-term 
treatment. In humans, the most important GC is cortisol (hydrocortisone); although a range of 
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synthetic GC (e.g. dexamethasone, prednisolone) with increased potency are commonly used 
as therapies. The chemical structures of cortisol and dexamethasone are illustrated in Figure 
1-18. 
 
Cortisol Dexamethasone
 
Figure 1-18 The chemical structures of endogenous (cortisol) and synthetic (dexamethasone) GC 
1.8.2 GC synthesis 
Cortisol is synthesized from the common steroidal precursor cholesterol in the zona fasiculata 
of the adrenal cortex. Through the actions of highly related yet discrete steroidogenic 
enzymes, cholesterol undergoes minor modifications regarding number, location and type of 
active side groups or number of carbon atoms to yield several similarly structured moieties 
with individual functional properties. In addition to cortisol, these include the 21-carbon 
progestagens (e.g. progesterone) and the mineralocorticoid aldosterone both synthesized in 
the zona glomerulosa, and the sex steroids; 19-carbon androgens and 18-carbon oestrogens 
produced in the zona reticularis (Figure 1-19). Secreted cortisol then enters systemic 
circulation bound to corticosteroid binding globulin and serum albumin - the majority of 
cortisol is transported in this manner (>90%) with the concentration of the remaining free 
cortisol of approximately 1ug/dL - only the latter is functionally active and able to activate the 
GR.  
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Cortisol production is regulated by the HPA axis; adrenal secretion is stimulated by pituitary-
derived adrenocorticotrophic hormone (ACTH) which is positively regulated by hypothalamic 
corticotrophin releasing hormone (CRH). GC, in turn, decrease both CRH and ACTH 
secretion resulting in a classical negative feedback regulatory loop (Makino et al., 1995). 
 
Figure 1-19 Major pathways human steroidogenesis. The common precursor cholesterol is sequentially 
modified by the enzymes to synthesize the steroid hormones 
Adrenal cortisol secretion displays a circadian (diurnal) rhythm reflecting the light-dark 
cyclical metabolic requirements. This rhythm superimposes on the HPA axis through central 
nervous system control with various neurotransmitters e.g. noradrenaline and gamma-
aminobutyric acid negatively regulating hypothalamic CRH release. Furthermore, melatonin, 
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secreted at night from the pineal gland, also inhibits CRH production, while CRH functions to 
inhibit melatonin secretion during the day. Consequently, cortisol levels are low in late 
evening, continuing to decline into the first hours of sleep, then increasing in the third to fifth 
hour of sleep, reaching peak levels between 06.00 and 08.00h, after which the concentrations 
gradually decline during the day excluding transient bursts in response to eating and exercise 
(Krieger et al., 1971). 
1.8.3 GR action 
The GR belongs to a large superfamily of nuclear receptors (NRs) that mediate a 
transcriptional response in response to binding of a hormonal or alternative metabolic ligand 
(Evans, 1988). NRs share several structural elements including an n-terminal regulatory 
domain with ligand-independent activating function, a double zinc finger DNA-binding 
domain (DBD), a hinge region involved in nuclear localization and cellular distribution, a 
ligand-binding domain (LBD) with ligand-dependant activating function and a variable c-
terminal domain (Kumar and Thompson, 1999). 
NRs are classified according to their activating ligands and mechanism of action. Classical 
type I steroid receptors include those for progestins, oestrogens, androgens, 
mineralocorticoids and GC. Following ligand binding in the cytosol, type I receptors 
dissociate from anchoring heat shock proteins, homodimerise (involving the DBD and LBD) 
and translocate to the nucleus where they bind directly to DNA hormone response element 
(HREs) consisting of two inverted repeat half-sites separated by a variable length of DNA 
(Figure 1-20). 
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Figure 1-20 Mechanism of class I NR action. Ligand (e.g. cortisol) binds to the LBD of cytoplasmic NRs (e.g. 
GR) causing dissociation from anchoring heat shock proteins (HSP). NR/hormone complexes then dimerise and 
translocate to the nucleus where they bind to HREs via the DBD. Association with regulatory proteins results in 
regulation of target gene expression and altered downstream function 
Conversely, type II receptors (e.g. thyroid hormone, all-trans and 9-cis retinoic acid and 
vitamin D3 receptors) are permanently nuclear-resident, switching between 
corepressor/coactivator proteins in the absence/presence of ligand and bind DNA as 
heterodimers (typically with retinoid X receptors). Type III receptors consist of recently 
identified orphan receptors that act similarly to type I receptors by forming homodimers, but 
differ by binding to direct repeat HREs, while type IV receptors bind to a single half-site HRE 
(Mangelsdorf et al., 1995). Following GC ligand binding (Kd 20-40 nM), the GR regulates 
target gene expression through two principal mechanisms of action. During transactivation, 
expression of target genes (e.g. anti-inflammatory lipocortin-1) is upregulated through GR 
homodimer/ligand-complex binding to HREs following dissociation from cytoplasmic heat 
shock proteins (Jibard et al., 1999) and nuclear translocation. 
Alternatively, the ligand-bound GR complex can sequester other cytoplasmic transcription 
factors (e.g. pro-inflammatory NF-κB, AP-1), preventing their nuclear translocation and 
indirectly downregulating target genes - a process known as transrepression (Hayashi et al., 
2004). The ability of the GR to stimulate the expression of some genes in a tissue-specific 
manner whilst concomitantly repressing others creates a powerful mechanism for generating 
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diversity of transcriptional control, resulting many pleiotropic effects in development, 
homeostasis, metabolism and immune function. 
1.8.4 Mineralocorticoid receptor action 
The mineralocortocoid receptor (MR) has a high and approximately equal affinity (Kd 0.5-2 
nM) for the mineralocorticoid ligand, aldosterone, but also for cortisol and their shared 
precursor corticosterone. However, in contrast to the GR, it exhibits a much more restricted 
distribution of expression being localized mainly to cells/tissues involved in Na
+
/K
+
 balance 
such as the distal renal tubule, sweat glands, parotid glands and colon, but also found in 
specific brain regions (neurones within the limbic system, entorhinal cortex and, to a lesser 
extent, the hypothalamus). 
As a class I NR, MR ligand binding leads to activation of target genes in a similar manner to 
the GR (Figure 1-20), regulating sodium transport through the basolateral sodium-potassium 
adenosine triphosphatase pump and apical sodium channels, culminating in sodium retention, 
potassium excretion, water retention and raising extracellular fluid volume and hence blood 
pressure (Sheppard and Funder, 1987). 
The shared dual affinity of the MR for both cortisol and aldosterone, the latter being very 
tightly regulated by the renin-angiotensin system (Foster et al., 1979), contributes to the 
pathological conditions associated with GC excess (where circulating GC concentrations can 
exceed 300nM) including hypertension and cardiovascular disease, posing a key complication 
for patients on long-term GC therapy. However, for many years the mechanisms explaining 
the preference for tissues such as the kidney to be regulated in vivo by aldosterone despite 
their high affinity for GC (further complicated by the higher circulating concentration of GC 
compared to aldosterone, 1ug/dL compared to 0.006ug/dL respectively) remained 
frustratingly elusive. Answers to this conundrum were revealed following the discovery of 
Chapter 1  General introduction 
64 
tissue-specific mechanisms for the delivery of GC to their receptors, allowing the 
maintenance of discrete physiological functions of GC and mineralocorticoids. 
1.8.5 Pre-receptor metabolism of GC 
The availability of GC to activate either the GR or MR is controlled at a tissue-specific pre-
receptor level by isozymes of the enzyme 11 beta-hydroxysteroid dehydrogenase (11β-HSD), 
largely independent of circulating GC levels. 11β-HSDs interconvert cortisol and its inactive 
metabolite cortisone (or corticosterone and 11-dehydrocorticosterone – 11-DHC – in rodents), 
regulating the availability of GC to the GR in GC target tissues and preventing the 
inappropriate activation of the MR in aldosterone target tissues. Indeed, 11β-HSD(2) 
deficiency was first described in 1988 by Stewart et al, termed apparent mineralocorticoid 
excess (AME) and characterised by hypertension, hypokalaemia, suppression of the renin-
angiotensin system and impaired inactivation of cortisol to cortisone (Stewart et al., 1988). 
Since the cloning of two distinct 11β-HSD isoforms, 11β-HSD1 and 11β-HSD2 (Figure 
1-21), extensive studies have demonstrated their integral role in the regulation many 
biological processes (Edwards et al., 1996). 11β-HSD2 is a high-affinity, nicotinamide 
adenine dinucleotide (NAD
+
)-dependent, constitutive enzyme that functions exclusively as a 
dehydrogenase, inactivating cortisol to cortisone. It is this isoform that colocalizes with the 
MR and protects it from activation by circulating free cortisol (Quinkler and Stewart, 2003) 
and as such is expressed in mineralocorticoid target tissues such as the kidney, parotid gland, 
sweat glands, colon and VSMCs. Murine 11β-HSD2 knockout studies revealed high perinatal 
mortality with severe corticosterone-dependant hypertension and other features of AME in the 
survivors (Kotelevtsev et al., 1999), as do human patients with 11β-HSD2-inactivating 
mutations (Edwards et al., 1996) and animals or humans that have been treated with 
glycyrrhetinic acid (the active component of liquorice) or its derivative carbenoxolone. 11β-
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HSD2 is also expressed in a few non-MR-expressing tissues such as placenta and developing 
brain, again providing protection from potentially harmful exposure to excessive levels of 
cortisol/corticosterone (Brown et al., 1996). 
A
B
 
Figure 1-21 Pre-receptor metabolism of GC. The amplification of GC signalling in GR-expressing cells occurs 
through 11β-HSD1 oxoreductase activity (A), whilst prevention of inappropriate MR activation by GC is 
mediated through 11β-HSD2 dehydrogenase activity which inactivates cortisol (B). The reductase activity of 
11β-HSD1 is dependent on the local generation of NADPH by hexose-6-phosphate dehydrogenase (H6PD). In 
rodents, 11β-HSD1 and 11β-HSD2 catalyse the interconversion of corticosterone and 11-DHC respectively 
In contrast, 11β-HSD1 is ubiquitously expressed particularly in liver, adipose tissue 
(especially omental) and brain and is regulated by a wide variety of factors including GC, 
stress, sex steroids, cytokines and PPAR ligands. In intact cells it functions exclusively as an 
oxoreductase, activating cortisol from cortisone in an NADPH-cofactor-dependant manner. 
NADPH is supplied by the enzyme hexose-6-phosphate dehydrogenase (H6PD) which co-
localizes with 11β-HSD1 in the endoplasmic reticulum (Draper et al., 2003). In homogenized 
tissues, the cofactor concentration gradient provided by H6PD is disrupted and 11β-HSD1 
switches to dehydrogenase activity, with oxoreductase activity restored following exogenous 
restoration of NADPH concentrations. However, in vivo 11β-HSD1 functions as an 
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oxoreductase, amplifying the local concentration of active GC in steroidal target tissues such 
as the liver.  
Although phenotypic studies in the 11β-HSD1-null mouse revealed higher circulating 
corticosterone levels (due to impaired HPA axis negative feedback), the animals are resistant 
to diet- and stress-induced hyperglycaemia seen in WT littermates, supporting the hypothesis 
that 11β-HSD1 regulates target tissue function independently of circulating GC levels. 
Furthermore, knockout animals displayed improved circulating cholesterol profiles with 
raised high-density lipoproteins, reduced low-density lipoproteins and lowered triglycerides, 
driven by decreased hepatic gluconeogenesis and lipid β-oxidation and potentially also 
through attenuated GC-dependant functions in visceral adipose tissue (Seckl, 2004). 11β-
HSD1-null mice also display reduced weight gain when placed on a high-fat diet which, 
together with altered fat deposit distributions favouring subcutaneous rather than visceral 
deposition, is indicative of a mouse model protected against certain aspects of metabolic 
disease. Further evidence, including 11β-HSD1 inhibitor studies displaying improved insulin 
secretion rates, has contributed to a consensus that 11β-HSD1 may be involved in the 
development of insulin resistance, obesity and other aspects of metabolic dysfunction, 
highlighting its potential use as a therapeutic target in these common endocrine disorders. 
Recently, 11β-HSD1 blockade has demonstrated further exciting applications to conditions of 
impaired cognitive function, with elderly subjects displaying improved brain performance in 
the treated group, further corroborated by genetic studies indicating an association between 
certain 11β-HSD1 haplotypes and Alzheimer’s disease. Interestingly, these studies implicate 
11β-HSD1 inhibition as being pharmaceutically relevant in traditionally non-metabolic GC 
target tissues such as the brain, emphasizing its role as a key regulator in a variety of global 
processes and the requirement for site-specific therapeutic targeting. 
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1.8.6 GC function 
1.8.6.1 Normal physiology 
The ubiquitous nature of GR expression coupled with the ability to modulate the transcription 
of ~10% of all known genes through both agonism, and antagonism, translates to a regulatory 
system capable of affecting a wide variety of biological processes. Primarily, GC are involved 
in maintenance of homeostasis and in the preparation for, responding to and coping with 
physical and emotional stress (Sapolsky et al., 2000), promoting carbohydrate and protein 
degradation in muscle and exerting complex effects on lipid reorganisation. Stress responses 
originate in the central nervous system, increasing hypothalamic CRH secretion which 
stimulates pituitary ACTH release. ACTH stimulates the adrenals to release cortisol within 
minutes of the onset of stress, abolishing the circadian rhythm of cortisol secretion if the 
stressor persists. 
1.8.6.2 Metabolic functions 
One such ‘HPA-stressor’ is hypoglycaemia (blood glucose <2.2 mmol/l) which triggers 
ACTH release and cortisol secretion to raise circulating glucose levels and maintain them in a 
narrow and tightly regulated range. Glucose release and synthesis (gluconeogenesis) is 
stimulated in the liver through the upregulation of gluconeogenic enzymes 
phosphoenolpyruvate carboxykinase and glucose 6-phosphatase (Rooney et al., 1993), 
providing the organism with additional energy required to cope with the stressor. GC further 
facilitate this process by increasing permissiveness to other hepatic gluconeogenic hormones 
(e.g. glucagon and catecholamines) whilst inhibiting peripheral tissue glucose uptake and 
pancreatic insulin secretion (Delaunay et al., 1997). Furthermore, the metabolism of glucose 
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to fatty acids and neutral fats by adipose tissue is inhibited and gluconeogenic substrate (e.g. 
fatty acid, glycerol) release into the circulation is stimulated, for example, by the GC-induced 
upregulation of hormone-sensitive lipase activity. 
1.8.6.3 Immune system functions 
GC are also key regulators of immune and inflammatory processes and control many aspects 
of host defence, acting in a stress-protective manner to limit the pathophysiological 
consequences of tissue injury and inflammation, preventing them from exacerbating to a point 
where they threaten host survival (Munck and Narayfejestoth, 1992). GC decrease circulating 
lymphocytes, monocytes and eosinophils but increase neutrophils, platelets and erythrocytes 
and also reduce leukocyte migration to inflammatory sites. Pro-inflammatory cytokine 
secretion (e.g. IL-1, TNF-α) is inhibited by GC - largely through NF-κB and AP-1 
transrepression - and also drive the HPA axis to limit the inflammatory response (Beutler et 
al., 1986). GC anti-inflammatory and immunosuppressive properties also endow their use as 
therapeutics in a wide range of conditions. 
1.8.6.4 Other functions  
Further endogenous actions of GC include raising blood pressure, in part by altering 
sensitivity to catecholamines and modulating systemic water and electrolyte balance in an 
‘aldosterone-like’ manner. Additional tissue-specific functions include negatively regulating 
bone metabolism, promoting apoptosis and inhibiting proliferation of bone cells and 
promoting neurodegeneration of the central nervous system by targeting neurone and glial 
cells. Furthermore, GC affect mood and behaviour, food intake, body temperature, pain 
perception and neuroendocrine functions. 
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1.8.6.5 GC excess 
The range of GC target tissues is clearly exemplified by conditions of GC excess, due to 
either hypersecretion of endogenous steroids (Cushing’s syndrome/disease, Newell-Price et 
al., 2006) or prolonged administration of exogenous GC therapies (Figure 1-22). In these 
circumstances, the adverse effects associated with GC function become exaggerated, causing 
a plethora of harmful pathologies. The adipose-tissue effects of GC result in a redistribution 
of fat to the abdominal area (central obesity), face (moon-face) and upper back (buffalo-
hump). GC-induced proteolysis causes muscle weakness, whilst excessive stimulation of 
mechanisms increasing circulating glucose lead to hyperglycaemia, insulin resistance and 
steroid diabetes. Other metabolic effects of GC excess result in hypertension, increased 
cholesterol, altered serum lipids, salt and water retention. 
  
Figure 1-22 Systemic side-effects of GC excess. During, Cushing’s syndrome, resulting from an adrenal 
tumour or hyperplasia, endogenous cortisol levels become elevated, resulting in prolonged and excessive effects 
in target tissues. These can also occur as a result of exogenous GC administration 
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Furthermore, the immunologic effects which serve to limit inflammation and assist wound 
healing are paradoxically reversed during GC excess, with immunodeficiency, poor wound 
healing, loss of connective tissue, easy bruising, retarded growth and development and 
osteoporosis. Other endocrine-related changes include menstrual irregularities in females and 
infertility. Finally, depression and impaired cognitive function can also occur. 
Importantly, recent findings indicate that not only substantive, long-term changes, but also 
subtle variations in the GC milieu, if sustained, are capable of inducing potentially hazardous 
effects and can contribute to the pathogenesis of hypertension, cardiovascular disease, insulin 
resistance, obesity and T2D (De Kloet et al., 1998, Gold et al., 2002, Seckl, 2004). 
1.9 GC and skin 
Pioneering research regarding the potent immunomodulatory benefits of GC was first reported 
by Hench and co-workers following systemic therapy in patients with rheumatoid arthritis 
(Hench et al., 1949). Following the introduction of topical hydrocortisone in the early 1950s, 
GC therapy revolutionized the treatment of a wide variety of dermatological disorders. 
However, alongside the desired therapeutic effects (anti-inflammatory, immune-suppressant, 
anti-allergic), evidence began to emerge for several adverse side-effects particularly with 
chronic or inappropriate use (increased infection, muscular myopathy, osteoporosis, HPA 
insufficiency, metabolic defects, cardiovascular complications, glaucoma). In skin, 
detrimental thinning was the predominant side-effect, first identified by Epstein and co-
workers reporting five patients with atrophic striae in the groins following topical GC 
treatment (Epstein et al., 1963). Subsequently, the adverse effects of GC in skin biology have 
been extensively documented, including in vitro effects on dermal fibroblasts and 
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keratinocytes, consequences of topical and systemic steroid therapy and dermal phenotype 
during endogenous GC excess - Cushing’s syndrome. 
1.9.1 In vitro effects 
Primary human fibroblasts treated with the synthetic GC dexamethasone display reduced 
expression of elastin mRNA (Kahari, 1994). GC treatment (including cortisol and 
dexamethasone) also induces cellular toxicity primarily in keratinocytes but also in 
fibroblasts, with varying degrees of potency depending on the GC used (Korting et al., 1995). 
Furthermore, studies conducted using the human keratinocyte cell line HaCat and primary 
dermal fibroblasts demonstrated adverse outcomes regarding cellular proliferation, 
chemotaxic migration and fibroblast contraction of collagen lattice gels when treated with 
synthetic GC (Hein et al., 1994, Wach et al., 1998), although growth inhibition is not 
associated with increased foreskin fibroblast apoptosis (Hammer et al., 2004). Moreover, 
dexamethasone treatment protects foreskin fibroblasts against TNF-α-/UV-radiation-/cell-
permeable ceramide-induced apoptosis (Hammer et al., 2004), whilst foreskin keratinocytes 
fail to respond to dexamethasone-induced changes in proliferation or apoptosis (including 
protection). Decreased rates of proliferation are due to anti-mitotic effects in both cell types 
(Fischer and Maibach, 1971, Hein et al., 1994). 
GC-induced alterations in ECM components have also been reported. In human skin 
fibroblasts, hyaluronic acid production is inhibited by dexamethasone (0.5-10nmol/L), an 
effect reversed by the GR inhibitor RU486 (Smith, 1988). Furthermore, human skin tissue 
explants treated with hydrocortisone lead to reduced epidermal hyaluronan turnover and 
content in addition to epidermal thinning and reduced keratinocyte DNA synthesis (Agren et 
al., 1995). More recently, dexamethasone-treated human dermal fibroblasts exhibited a rapid, 
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near-complete inhibition of hyaluronan synthase 2 (HAS-2) expression with decreased 
message stability (Zhang et al., 2000).  
Reductions in fibroblast procollagen type 1 and TIMP1 have also been described following 
dexamethasone treatment, tilting the balance of collagen metabolism away from accumulation 
(Slavin et al., 1994). The in vitro functional consequences of GC treatment are described in 
more detail in Chapter 5. 
1.9.2 Exogenous therapy 
1.9.2.1 Topical 
The GC-induced dysregulation of genes involved in maintenance of skin homeostasis, 
integrity and function (e.g. elastin) is believed to contribute to the adverse side-effects 
associated with topical GC therapy. Of these, skin thinning is the most widely reported, 
consisting of reductions in both epidermal and dermal thickness as markers of dermal atrophy 
in rodent (Gniadecki et al., 1994, Faergemann et al., 2002) and human studies (Lehmann et 
al., 1983, Kolbe et al., 2001, Korting et al., 2002). Interestingly, GC-induced skin thinning in 
rats is reversible following prior treatment with the GR inhibitor RU486, whilst the anti-
inflammatory effects on ear edema following croton oil treatment were unaffected (Iwasaki et 
al., 1995). This uncoupling of GC anti-inflammatory and atrophogenic functions suggests that 
the former may be more extensively regulated through non-genomic mechanisms, identifying 
GR inhibitors as potential therapeutic agents to minimize adverse effects during GC treatment 
of inflammatory skin conditions (Schacke et al., 2004).  
Further GC-induced morphological alterations include a flattening of the DEJ (Lehmann et 
al., 1983, Kimura and Doi, 1999), decreased microvasculature, decreased keratinocyte size 
(Kolbe et al., 2001) and rearrangements of the dermal ECM involving ground substance 
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resorption with subsequent fibrous network collapse and collagen/elastic fiber reorientation 
(Lehmann et al., 1983). Epidermal corneocyte layers are also reduced and contain fewer 
intercellular lipid lamellae, with reductions in granular layer keratohyalin granules also 
reported (Sheu et al., 1997). Additionally, mast cell numbers become virtually absent 
(Lehmann et al., 1983) - likely contributing to associated reduction in wound healing 
capabilities. 
At a molecular level, topical GC induced a marked decrease in collagen type I and III 
propeptides and type I mRNA in suction blister fluid and human skin (Oikarinen et al., 1998, 
Nuutinen et al., 2003). Tropocollagens I and III were also drastically reduced following 
subcutaneous dexamethasone injections in rats, with decreases in latent and active collagenase 
(and corresponding mRNA) and TIMP1 and TIMP2 mRNA also reported (Oishi et al., 2002). 
Recently, hyaluronic acid turnover in human dermis has been evaluated following topical 
dexamethasone treatment. In support of earlier in vitro studies, HAS-2 expression was 
markedly decreased with a concomitant decrease in dermal hyaluronan content (Gebhardt et 
al., 2010), while hyaluronidase expression and activity was unaffected. 
Consequently, topical GC treatment results in skin atrophy characterized by a profound 
increase in transparency of skin, a cigarette-paper-like consistency with increased fragility, 
tearing, and bruising (Kimura and Doi, 1999), hypersensitivity to toxicity stimuli (dimethyl 
sulphoxide and sodium hydroxide), reduced ceramide, cholesterol and free fatty acid content 
and increased transepidermal water loss (Figure 1-23, Sheu et al., 1999, Kolbe et al., 2001). 
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Figure 1-23 Adverse effects of GC therapy. Chronic topical/systemic treatment with GC causes a suppression 
in fibroblast and keratinocyte proliferation and ECM production. Keratinocyte lipid (free fatty acids, cholesterol, 
ceramides) production is reduced, resulting in fewer intercellular lipid layers, stratum corneum thinning and 
increased transepidermal water loss (blue arrow). Reduced dermal integrity and increased water loss ultimately 
lead to a compromise in barrier function with reduced tensile strength and elasticity (Schoepe et al., 2006) 
1.9.2.2 Systemic 
Systemic GC therapy is associated with a similar range of side-effects in skin as observed 
with topical treatments. Female patients on chronic oral GC treatment for a variety of dermal 
pathologies including dermatomyositis, pemphigus vulgaris, pyoderma gangrenosum, and 
urticarial vasculitis and demonstrated decreased skin thickness in the upper arm, dorsal and 
ventral forearm regions compared to age-matched controls, whilst male patients also 
displayed a decrease at the upper arm site (Werth et al., 1998). Furthermore, the authors 
observed a decrease in procollagen-1 mRNA in GC-treated patients. Other studies have also 
reported decreased collagen type I and III content in human dermis following systemic GC 
therapy, proposed to be attributable to decreased synthesis, rather than increased degradation 
(Autio et al., 1993, Autio et al., 1994). 
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1.9.3 Endogenous glucocortioid excess 
GC-induced skin atrophy is also a common pathological feature in conditions of endogenous 
GC excess (e.g. Cushing’s syndrome, Sowers and Lippman, 1985). Murine models of this 
disorder, with chronic pituitary-adrenal activation driven by continuous CRH production, 
display skin thinning (in addition to other Cushingoid phenotypes) resulting from CRH-
ACTH induced GC hypersecretion (Stenzelpoore et al., 1992). In humans, skin thinning is 
present in >80% of young hypercortisolaemic patients and is a key diagnostic factor in 
distinguishing Cushing’s syndrome from simple obesity (Newell-Price et al., 2006). 
Interestingly, dermal fibroblasts from patients with Cushing’s syndrome display a gain-of 
function phenotype with increased proliferative capacity, increased collagen gel contraction 
ability and similar collagen production rates compared to gender- and age-matched normal 
controls (Pratsinis et al., 2001, Zervolea et al., 2005, Kletsas et al., 2007), suggesting the 
dermal atrophy associated with this disorder is exclusively due to the hypercortisolaemic 
milieu in vivo and may be reversible following restoration of normal extracellular cortisol 
concentrations.  
1.9.4 Summary 
Overall, these adverse effects of GC on skin cell function, following local and systemic 
therapy or resulting from endogenous GC excess, ultimately culminate in skin that has 
compromised integrity and barrier function (Sheu et al., 1997, Kato et al., 2003), which is 
prone to infection and suffers from reduced rates of wound healing. Clearly, these adverse 
effects offset the immunological advantages of GC treatment and require further research into 
developing specialized compounds capable of dissociating the anti-inflammatory and 
anthropogenic capabilities with increased benefit/risk potential. 
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1.10  A role for GC in ageing? 
Strong evidence now exists for the contribution of GC dysregulation to the ageing process. 
Whilst acute HPA activation and GC secretion is essential during stress adaptation, excessive 
exposure to sustained, elevated stress hormone levels has been linked to psychiatric, 
reproductive, immune, metabolic and cardiovascular disorder predisposition (McEwen, 1998). 
Basal circulating GC levels are reported to increase significantly with age in ~40% humans, 
with a similar proportion displaying only moderate increases and the remainder displaying an 
opposing correlation (Lupien et al., 1996). In older people, impaired HPA sensitivity to GC 
feedback is also documented (Wilkinson et al., 2001) in addition to greater serum cortisol 
levels in the evening and night-time, although circadian rhythmicity is still present to some 
extent (Van Cauter et al., 1996, Ferrari et al., 2001). Cortisol levels in cerebrospinal fluid are 
also raised in older individuals (Guazzo et al., 1996). Interestingly, the increase in circulating 
cortisol is maintained in centenarians, suggesting their longevity more likely results from 
genetically predetermined improved adaptive mechanisms of coping with the consequences of 
raised GC levels, rather than from a protective lack of GC hypersecretion with age (Genedani 
et al., 2008). Similarly in rats, a loss in circadian corticosterone secretion patterns has been 
documented in some (but not other) strains with increasing age, with elevated morning and 
reduced nocturnal secretion (Honma et al., 1996, Audige et al., 2002). The causes of this large 
inter-individual variation are likely to be genetically predetermined (Linkowski et al., 1993, 
Franz et al., 2010) as with many other aspects of longevity. Conclusively, age-related 
hypercortisolism and increased GC resistance has also been documented in other species such 
as baboons (Sapolsky and Altmann, 1991). 
Pathologically, the increase in GC production and altered sensitivity with advancing age is 
thought to directly contribute to several age-related conditions including osteoporosis - 
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independently of more traditional causes such as oestrogen decline (Manolagas, 2010, 
Weinstein et al., 2010, Hardy and Cooper 2010), depression and cognitive dysfunction 
(Sapolskey et al., 1986, Sapolsky, 1999, Ferrari and Magri, 2008, Wolkowitz et al., 2010), 
sarcopenia (Dardevet et al., 1995, Savary et al., 1998) and inflammatory disease (Heffner, 
2011). 
Additionally, alterations in pre-receptor GC metabolism have recently been reported with age 
in human bone and mouse hippocampus, with increases in 11β-HSD1 expression that may 
elevate GC exposure and contribute to age-associated osteoporosis and cognitive impairment 
(Cooper, 2002, Holmes et al., 2010). 
Conversely, levels of GR are thought to decrease with age, potentially as a compensatory 
mechanism for the increased circulatory and pre-receptor-driven local GC concentrations 
(Sharma and Dutta, 2006). Indeed, polymorphisms in the GR have been described which 
induce GC resistance and insulin sensitivity, lower cholesterol, reduce immunological 
markers of mortality (C-reactive protein) and may prolong lifespan (van Rossum et al., 2002, 
2004). 
1.11 Rationale and aims 
Clearly, many similarities exist in skin between the consequences of ageing (both 
chronologically intrinsic and superimposed extrinsic) and those of GC excess (of exogenous 
topical and systemic, or endogenous overproduction) covering many aspects of skin biology. 
These include similarities in morphological alterations involving epidermal/dermal 
organization, cellular composition, proliferative responses and differentiation capabilities, 
molecular changes in ECM components such as collagens and their regulatory proteins 
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(MMPs, TIMPs etc.) and downstream consequences on barrier function, homeostatic control, 
mechanistic integrity and immunological capabilities (Kahan et al., 2009). 
Although the effects of GC in respect to dermal atrophy have been extensively documented, 
there is only a limited literature describing the pre-receptor regulation of GC availability in 
skin. Furthermore, the skin-specific metabolism of cortisol in cells and tissue according to 
donor age and site has not been investigated, despite evidence supporting a role for GC 
dysregulation in the ageing process. The ability of pre-receptor metabolism to regulate GC 
target genes in skin also requires addressing. 
Therefore, the primary aims of this thesis are to: 
1. Characterize the localization, expression, activity and regulation of 11β-HSDs in murine 
and human skin. 
2. Investigate 11β-HSD1 expression and activity in human dermal fibroblasts and human skin 
tissue explants from PP (intrinsic ageing) and PE (intrinsic and extrinsic ageing) anatomical 
locations from young and aged donors and in skin tissue explants from young and aged mice. 
3. Examine the pre-receptor regulation of GC target genes through 11β-HSD1 in human 
dermal fibroblasts and skin tissue explants. 
Based on the principal hypothesis that 11β-HSD1 expression and activity increase in skin as a 
function of age, locally amplifying GC concentrations through pre-receptor reactivation from 
cortisone, the secondary aim of this thesis is: 
4. To characterize the dermal phenotype of the 11β-HSD1-null young and aged mouse 
compared to WT young and aged animals with regards to markers of ageing. 
The secondary hypothesis being that aged 11β-HSD1-null mice will have a dermal phenotype 
more similar to young WT and knockout animals than aged WT littermates. 
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CHAPTER 2  MATERIALS AND METHODS 
The general reagents and protocols used throughout this thesis are presented here, with 
specific modifications to individual experiments detailed in their respective chapters. Unless 
otherwise stated, chemicals were purchased from Sigma Chemicals Co. Ltd. Poole, UK. 
2.1 Human cell and tissue preparation 
2.1.1 Primary human dermal fibroblasts 
Frozen stocks of primary human dermal fibroblasts (HDF) from PP (inner upper arm, n=12) 
and PE (outer lower arm, n=15) sites from donors of varying age (years ± S.D, 45.9±20.3, 
n=27) and gender (5 male, 11 female) were obtained with ethical approval and informed 
consent from Unilever Discover, Bedford, UK. 
2.1.1.1 Materials 
Phosphate buffered saline (PBS): two tablets of PBS in 400ml distilled water. Autoclave 
and store at 4ºC. 
PBS ethylenediaminetetraacetic acid (EDTA): 400μl 0.5M EDTA into 400ml PBS. 
Autoclave and store at 4ºC. 
Complete media: RPMI-1640 supplemented with 1% (vol/vol) non-essential amino acids, 
1% penicillin/streptomycin, 1% sodium pyruvate, 2mmol/l L-glutamine and 10% fetal calf 
serum (FCS, Labtech International, Sussex, UK). 
Trypsin: Trypsin diluted 1/20 into PBS EDTA. 
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2.1.1.2 Methods 
Frozen vials were thawed at 37ºC and the cells were transferred immediately to 5ml PBS (in a 
15ml falcon tube), mixed by inversion and centrifuged at 300g for 5min. Following removal 
of PBS, pellets were resuspended in 10ml pre-warmed complete fibroblast media, seeded in 
75cm
2
 flasks and incubated at 37ºC in a 5% CO2 atmosphere. Media was replaced every two 
days until the cell monolayer reached confluence (Figure 2-1). 
 
Figure 2-1 HDF in culture 
At this point media was discarded, the cells were rinsed briefly in 5ml PBS before replacing 
with 2ml trypsin and incubating at 37ºC in a 5% CO2 atmosphere for 5min. Flasks were 
firmly “tapped” to fully resuspend the cells before neutralizing immediately in 5ml media. 
Following centrifugation at 300g for 5min and discarding media, pellets were resuspended in 
30ml fresh media and passaged into three new 75cm
2
 flasks. 
Fibroblasts were maintained in this manner up to a maximum of 5 passages. Frozen stocks 
were regularly replenished by trypsinising cells at 80% confluence, resuspending the pellet in 
1ml FCS with 10% dimethyl sulphoxide. All experiments were performed at 80% confluence. 
2.1.2 Human skin biopsies 
Following application and approval by the Black Country Research Ethics Committee 
(09/H1202/024), University Hospital Birmingham Research and Development (RRK3890) 
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and the Wellcome Trust Clinical Research Facility (CRF) Scientific Advisory Committee 
(study 1010) healthy young (20-30 years) and older (60-75 years) volunteers were recruited 
from the University of Birmingham and Birmingham “1000 Elders” Group respectively. 
Subsequently, an ethical amendment was approved to include anyone over 60 years in the 
older age group. After recruitment, volunteers were provided with a Letter of Invitation and 
Patient Information Sheet. Interested volunteers were registered with the CRF in advance and 
signed Consent Forms under supervision by Dr Abd Tahrani before undergoing the 45min 
procedure. Upon procedure completion, volunteers were provided with a Biopsy Aftercare 
Sheet and GP Letter. Exclusion criteria were as follows: 
  Pregnancy 
 Significant past medical history including diabetes, epilepsy and current or 
past history of active sepsis 
 Non-Caucasian 
 Pre-existing skin conditions e.g. eczema and psoriasis 
 GC therapy in the past 12 months 
 Smoking or history of smoking within the past 10 years 
 Warfarin medication 
 Current participation in another study 
40 volunteers completed the process, consisting of 20 young (years ± S.D, 25.7±3.0, 9 female 
and 11 male) and 20 older (72.2±8.2, 11 female and 9 male) donors. 
2.1.2.1 Materials 
Surgical trays: For each procedure, surgical trays lined with Supadrape (Westfield Medical 
Ltd., Radstock, UK) were prepared, containing dressing scissors, pointed forceps, 50 sheets 
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7.5 x 7.5cm cotton gauze (On Call Medical Supplies, Exmouth, UK) and two pieces of 
Supadrape prepared with a 5 x 5cm central opening. Items were wrapped in the tray lining, 
sealed with autoclave tape and trays were wrapped in Supadrape prior to autoclaving. 
Biopsy materials: two Stiefel 3mm Biopsy Punch, two termous 19G 1.5in cream needle, two 
termous 25G 5/8in orange needle (Medisave, Weymouth, UK), two 2ml 2% lidocaine + HCl 
(National Veterinary Services, Stoke-on-Trent, UK), two 9 x 10cm mepore dressing, two 5 x 
5cm inadine dressing, sterile gloves (On Call Medical Supplies, Exmouth, UK), two 5ml 
syringe and 100% ethanol spray. 
2.1.2.2 Methods 
The following procedure was conducted by Dr Abd Tahrani (with personal assistance) under 
sterile conditions. Surgical areas consisted of the midpoint PE side of the lower arm (site 1) 
and the midpoint PP side of the upper arm (site 2), avoiding scars and hyperpigmented areas.  
Site 1 was cleaned with 100% ethanol and covered with Supadrape containing a 5 x 5cm 
central opening. Lidocaine was loaded into the syringe using a 19G cream needle and injected 
into the site using a 25G orange needle. Following dispersion of lidocaine, the site was tested 
for numbness prior to obtaining two 3mm punch biopsies (using cotton gauze to contain 
bleeding). Samples were placed into 1.5ml eppendorfs containing complete media. 
Gauze was applied under pressure until bleeding subsided and the area was dressed with an 
inadine patch followed by a mepore dressing. The procedure was then repeated on site 2. 
Samples were analysed immediately or snap-frozen in liquid nitrogen and stored at -80ºC. 
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2.2 Mouse tissue preparation 
2.2.1 Animal housing 
All mice were group housed under controlled temperature (21-23ºC) and light 12h light, 12h 
dark cycle; lights on at 0700h) with ad libitum access to standard rodent chow and water. 
Animal procedures were approved under the British Home Office Animals (Scientific 
Procedures) Act 1986. 11β-HSD1-null mice were generated as previously described 
(Semjonous et al., 2011) with C57BL/6 WT littermates used as controls. All studies were 
performed on tissue from male mice. 
2.2.1.1 Materials 
10% neutral buffered formalin (NBF): 4g sodium monophosphate and 6.5g sodium 
diphosphate was dissolved in 900ml distilled water before adding 100ml 37% formaldehyde. 
Stored in the dark at room temperature. 
2.2.1.2 Methods 
All animal tissue used in this thesis was surplus waste material from experiments designed by 
other researchers within our group. Skin tissue from mice that had been recently sacrificed by 
cervical dislocation was obtained from the lower dorsal region following hair removal with 
clippers (Figure 2-2). Tissue was obtained from WT young (11-20 weeks, n=6) and aged (91-
99 weeks, n=5) and 11β-HSD1-null young (11-20 weeks, n=4) and aged (91-99 weeks, n=4) 
mice. Samples were dissected into 4-10mg pieces and processed immediately, submerged in 
1ml 10% NBF and stored in the dark at room temperature or snap-frozen in liquid nitrogen 
and stored at -80ºC. 
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Figure 2-2 Anatomical location of mouse skin tissue explant site. Skin was excised from the lower dorsal 
region (X) from recently sacrificed animals 
2.3 Messenger RNA detection and quantification 
2.3.1 Isolation of cellular RNA 
Cellular RNA was extracted using the TriReagent system, following the manufacturer’s 
guidelines. 
2.3.2 Isolation of skin tissue RNA 
Tissue RNA was extracted using an RNeasy Fibrous Tissue kit (Qiagen, Crawley, UK) using 
a PowerGen 125 homogenizer (Fisher Scientific, Loughborough, UK) according to the 
manufacturer’s protocol. 
2.3.3 Generation of cDNA by reverse transcription 
Following spectrophotometric quantification and quality control, ~500ng RNA was used in a 
final volume of 25μl to generate cDNA using the MultiscribeTM Reverse Transcriptase kit 
according to the manufacturer’s guidelines (Applied Biosystems, California, USA). Reaction 
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mix consisted of 2.5μl Reaction Buffer (10x), 5μl MgCl2 (2.5mM), 5μl dNTPs (1μM), 1.25μl 
random hexamers, 0.5μl RNase inhibitor, 1.55μl reverse tanscriptase (50U/μl) and made up to 
25μl with nuclease-free water. Reactions lacking RNA were used as internal negative 
controls. Reactions occurred as follows: 24ºC for 10min, 37ºC for 60min, 48ºC for 30min and 
95ºC for 5min. cDNA was stored at -20ºC. 
2.3.4 Quantification by real time PCR 
2.3.4.1 Principle 
Quantitative real-time polymerase chain reaction (qPCR) is a method permitting accurate 
measurement of specific DNA sequences from cell and tissue samples (Bustin, 2000). The 
TaqMan method employed in this thesis utilises the detection of a fluorescence signal during 
the amplification of a specific target. A target-specific probe (5'-fluorescently labelled and 3'-
quencher labelled) anneals to a DNA sequence between the forward and reverse primers. 
With both the fluorophore and quencher hybridized to the cDNA in close proximity, no signal 
is emitted. 
As the reaction PCR reaction progresses, the 5'-3' exonuclease activity of Taq polymerase 
degrades the probe, freeing the fluorescent reporter from the quencher and resulting in a 
detectable signal (Figure 2-3). This signal accumulates with each successive PCR cycle and, 
during the exponential phase of the cycle, is recorded as the threshold cycle (Ct) value. This 
value is inversely proportional to the starting DNA target copy number (as a greater starting 
amount of template will induce a detectable signal in a fewer number of amplification cycles). 
Moreover, qPCR can utilise multiplex reactions, where a target gene sequence is analysed 
simultaneously to an internal reference gene (such as ribosomal 18S rRNA) labelled with a 
different fluorophore. This permits relative quantification of target, resulting in a ΔCt value 
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(target gene Ct value - reference gene Ct value) which allows for different starting cDNA 
concentrations by normalising to an internal reference. Comparison of the ΔCt between 
different samples results in a ΔΔCt value (Figure 2-4) which enables fold-change (x) between 
samples (e.g. treated sample is x-fold of untreated sample) to be deducted from the following 
equation: x = 2 
- ΔΔCt 
= 2
 - (Ct target gene - Ct control gene)
treated
 - (Ct target gene - Ct control gene)
untreated. 
A
B
C
D
 
Figure 2-3 The TaqMan qPCR assay. (A) During denaturation, the primers and probe anneal. The close 
proximity of the fluorescent reporter (circle) to the quencher (pentagon) prevents signal emission. (B) 
Polymerisation proceeds at the same temperature as the annealing step. (C) The polymerase displaces and 
hydrolyses the labelled probe. (D) The fluorescent dye is released from its proximity to the quencher, and 
fluorescence is detected. This signal is directly proportional to the number of molecules present at the end of the 
previous or beginning of the current cycle 
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Figure 2-4 Mathematical basis of the 2-ΔΔCT method. The 2-ΔΔCT method enables relative quantitation (treated 
sample is X fold of control sample) through measurements of crossing thresholds (CT). As described in the text, 
the comparative differences between the target gene (TG) of interest and an endogenous control gene (CG) for 
each sample enable a relative quantitative comparison between the samples. Note that the endogenous control 
genes (dotted lines) should not vary significantly in CT with treatment. Reproduced from Van Guilder et al., 
2008 
2.3.4.2 Methods 
All qPCR reagents were obtained from Applied Biosystems, California, USA. qPCR analyses 
were performed using an ABI 7500 system (Perkin-Elmer, Cambridge, UK) in 10μl final 
reaction volumes consisting of 5μl TaqMan Universal PCR mastermix (2x), 0.5μl inventoried 
FAM-labelled target gene multiplexed with VIC-labelled 18S ribosomal rRNA primers and 
probe (20x, 25nM final concentration each primer and probe), 3μl nuclease-free water and 1μl 
cDNA (~25-50ng). 
Reactions occurred in 96-well optical plates as follows: 50ºC for 2min, 95ºC for 10min, 44 
cycles of 95ºC for 10min followed by 60ºC for 1min. Raw data was obtained as Ct values (the 
cycle number at which logarithmic PCR plots cross a given threshold line in the exponential 
reaction phase) and used to determine ΔCt values. Assays were performed in duplicate and 
the average ΔCt taken for each sample. All data was analysed at this stage prior to 
transformation through the 2
-ΔΔCT
 method. 
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2.4 11β-HSD isozyme activity assays 
2.4.1 Materials 
3
H-cortisol stock: specific activity 100Ci/mmol, 1mCi/ml (Du Pont, NEN, Netherlands) 
diluted 1/20 in ethanol for working solution. 
3
H-corticosterone stock: specific activity 100Ci/mmol, 1mCi/ml (Du Pont, NEN, 
Netherlands) diluted 1/20 in ethanol for working solution. 
3
H-cortisone/
3
H-dehydrocorticosterone stock: generated in-house. 20μl of 3H-cortisol/3H-
corticosterone stock was incubated with 250mg of human/mouse placenta (exhibiting high 
11β-HSD2 activity) and 500μM NAD+ cofactor in 500μl 0.1M potassium phosphate buffer 
(pH 7.4) in 10ml glass tubes at 37ºC (shaking waterbath) for 3h. Steroids were extracted by 
adding 5ml dichloromethane, capping and vortexing for 10sec prior to phase separation by 
100g centrifugation for 10min. Aqueous phase and protein interface was removed by 
aspiration and steroids were concentrated under blowing air at 55ºC for 30min. Steroids were 
resuspended in 100μl dichloromethane and spotted onto silica plates prior to thin layer 
chromatography (TLC) separation in a 186:14ml chloroform:ethanol mobile phase (90min). 
Plates were air-dried in a fume hood for 10min and scanned briefly using a Bioscan 200 
Imager (LabLogic, Sheffield, UK) to localize the tritiated steroids. The silica surrounding the 
3
H-cortisone/
3
H-dehydrocorticosterone was scraped into fresh glass tubes and eluted 
overnight in 300μl ethanol at 4ºC. Silica was pelleted by centrifugation at 100g for 5min and 
the ethanol was removed to a clean storage vial. Tritiated steroid concentration was 
determined by spotting 2μl onto a new silica plate and repeating the TLC procedure to 
establish experimental working volumes.
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2.4.2 Methods 
2.4.2.1 HDF studies 
HDF 11β-HSD activity was measured at 80% confluence in a 6-well plate format. Assays 
were performed in duplicate (with post-assay cells from one well contributing to total protein 
estimation and the other used for RNA extraction) and the average activity calculated. 
2ml of fresh complete media containing 200pmol (100nM) substrate (2μl 10-4M 
cortisone/cortisol in ethanol) enriched with 20,000 cpm tritiated substrate tracer (1.25pmol) 
was added to each well and incubated at 37ºC in 5% CO2 for 24h. Media was transferred to a 
10ml glass tube containing 5ml dichloromethane and following capping, steroids were 
extracted into the organic phase by vortexing for 10sec. The phases were separated by 
centrifugation at 100g for 10min and the aqueous layer (consisting of media and protein 
interface) was then removed by aspiration. The organic phase was evaporated at 55ºC under 
blowing air (30min) and dried steroids were subsequently resuspended in 50μl 
dichloromethane before spotting onto silica plates (2cm from the bottom edge and 1.5cm 
apart). One drop of non-tritiated standard solution (1mg/ml each of cortisone and cortisol in 
ethanol) was also added to each spot for visualisation of steroid separation. 
Steroids were separated by TLC in a mobile phase of 184:16ml chloroform:ethanol (90min), 
removed from the TLC tanks to dry in a fume hood (10min) and visualised under UV to 
confirm steroid separation. Plates were analysed by scanning for 10min/spot using a Bioscan 
System 200 Imaging Scanner (LabLogic, Sheffield, UK) and percentage conversion was 
calculated using region counts for individual peaks. Following cellular protein estimation, 
activity was expressed as amount of substrate converted (pmol) per mg protein per hour. 
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2.4.2.2 Tissue 
Human/mouse skin tissue (4-10mg wet weight weighed prior to onset of assay) 11β-HSD 
activity was measured in 10ml glass tubes with 500μl of fresh complete media containing 
100pmol (200nM) substrate (1μl 10-4M cortisone/cortisol for human samples or 
corticosterone/11-DHC for mouse samples in ethanol) enriched with 20,000 cpm tritiated 
substrate tracer (1.25pmol) and incubated at 37ºC in 5% CO2 for 24h (uncapped). 
Subsequently, tissue was discarded (or snap-frozen for further analysis where stated) and 
following addition of 5ml dichloromethane, samples were processed as described above to 
determine steroid conversion. Activity was expressed as fmol/mg tissue/h. 
2.5 Protein estimation 
Total soluble protein from cell extracts (required to normalise 11β-HSD enzyme activity 
levels) was determined using the Bio-Rad RC DC (detergent compatible) protein assay kit 
(Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). This colorimetric assay determines 
protein concentration following detergent solubilisation, similarly to the well-documented 
Lowry assay where protein reacts with an alkaline copper tartrate solution followed by the 
reduction of Folin reagent (Lowry et al., 1951). The standard assay is used with samples 
having protein concentrations between 0.1 and 2.0 mg/ml, measured at 650-750 nm with a 
standard laboratory microplate reader. 
2.5.1 Method 
Following removal of media for 11β-HSD substrate conversion determination, cells were 
rinsed briefly in PBS to remove traces of media. PBS was replaced with 250μl distilled water 
and freeze-thawed to release intracellular protein. The average absorbance of duplicate 
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samples of unknown concentration was determined using a BSA standard curve equation 
(Figure 2-5). 
y = 0.1511x + 0.0585
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Figure 2-5 Protein standard curve. The absorbance of 0, 0.25, 0.5, 1 and 2mg/ml BSA in distilled water was 
measured (n=10) and the average absorbance was calculated for each concentration to give the reference 
standard curve. 
5μl of sample (the same volume was used for standard curve) was added to each well (96-well 
plate) followed by 25μl reagent A (alkaline copper tartrate) and 200μl reagent B (Folin 
reagent). The plate was incubated at room temperature for 15min before reading at 690nm on 
a Victor3 1420 multi-label counter (Perkin Elmer, Beaconsfield, UK). Concentrations were 
read off the standard curve and expressed as mg/ml. 
2.5.2 Statistics 
Experimental data were analysed using GraphPad Prism software (GraphPad Software Inc., 
California, USA). A parametric Student’s T-test was used to compare data displaying a 
normal distribution (paired tests were used as appropriate). Non-parametric data was analysed 
using a Mann-Whitney Rank Sum Test. The null hypothesis was rejected at a significance 
level of p<0.05 (95% confidence). 
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CHAPTER 3  CHARACTERIZATION OF 11β-HSDs IN SKIN 
3.1 Introduction 
3.1.1 Skin as a neuro-immuno-endocrine organ 
Among the many functions typically attributed to skin, its ability to respond to and 
regulate local and systemic endocrine processes is often overlooked. This seems 
somewhat surprising considering the broad spectrum of abnormalities associated with, 
and in some instances, the primary manifestation of certain endocrine disorders in 
skin, including Cushing's syndrome, adrenal insufficiency, diabetes, acromegaly, 
hypopituitarism, hypo/hyperthyroidism, sex hormone excess/deficiency and others 
(Feingold and Elias, 1987, 1988). 
Endocrine regulatory functions of skin include the ability of human epidermal 
keratinocytes to convert the pro-hormone thyroxine (T4) to active triiodothyronine 
(T3) through deiodination (Kaplan et al., 1988) and the photochemical generation of 
the steroid hormone vitamin D3 (cholecalciferol) from 7-dehydrocholesterol in the 
stratum basale and stratum spinosum (Bouillon et al., 1995). The simplicity of these 
examples is misleading, indeed skin forms a complex bridge between many scientific 
disciplines as integrated models of analysis such as the neuro-immuno-cutaneous-
endocrine (NICE) network (O’Sullivan et al., 1998), are beginning to emerge. 
Associations between nervous system perturbations and skin disease are often seen in 
clinical practice (Koblenzer, 1996) such as the exacerbation of psoriasis, acne, eczema 
and urticaria by stress (Gupta et al., 1994). Evidence for the mechanisms underlying 
the connection of abstract stress with a physical clinical (i.e. cutaneous) manifestation 
centres around shared specific communication molecules common to both the nervous 
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and immune systems that were identified over two decades ago (Wierdermann, 1987) 
and since then neuropeptides have gained prominence as a primary signalling 
mechanism linking the two systems (Reichlin, 1993). In skin, neuropeptides have 
been identified in both cutaneous nerve fibres and all cells examined including 
keratinocytes, immunocytes, fibroblasts, Langerhans cells, and endothelial cells 
(Wallengren et al., 1987, Scholzen et al., 1998, Di Cornite et al., 2007). 
3.1.2 Steroidogenesis in skin 
In addition to responding to and regulating many elements of neuro-immuno-
endocrine function, studies are emerging that demonstrate de novo steroid production 
in skin through the steroidogenic pathway. Keratinocytes are an abundant storage 
depot for cholesterol - the common steroidal precursor - and are also able to 
synthesize it (Menon et al., 1985), while certain rate-limiting components of the 
steroidogenesis pathway, such as steroidogenic acute regulatory (StAR) protein, have 
also been identified in human epidermis by immunofluorescence histochemistry 
(Slominkski et al., 2004). The complete CYP11A1 complex, encoding the 
mitochondrial enzyme P450scc which converts cholesterol to pregnenolone in three 
mono-oxygenase reactions, has been identified in human epidermis and keratinocytes 
(Slominkski et al., 2004, Thiboutot et al., 2003). Another study reported the presence 
of CYP11A1, CYP17A1 (17α-hydroxylase) and CYP21A2 (21α-hydroxylase) in skin, 
but failed to detect CYP11B1 (11β-hydroxylase), the final enzyme in the sequence of 
cortisol synthesis (Slominksi et al., 1996). Others demonstrated the 21α-hydroxylation 
of progesterone to deoxycorticosterone and associated metabolites in immortalized 
keratinocytes (Slominski et al., 2002). 
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More recently, Hannen et al demonstrated the expression of CYP11A1, CYP17A1, 
3β-HSD1, CYP21 and CYP11B1 protein in primary cultures of human keratinocytes 
(Hannen et al., 2011). Furthermore, this study revealed co-migration of tritiated 
pregnenolone metabolites with progesterone, 17α-hydroxyprogesterone, 17α-
hydroxypregnenolone, corticosterone, cortisone and physiologically relevant amounts 
of cortisol suggesting the steroidogenesis pathway in keratinocytes is active. In 
addition to keratinocytes, hair follicles have been reported to express elements of the 
HPA axis and to synthesise cortisol (Ito et al., 2005), sebocytes demonstrate the 
transformation of 22R-hydroxycholesterol to 17-hydroxypregnenolone (Thiboutot et 
al., 2003), whilst melanocytes have also been shown to produce corticosterone and 
cortisol (Slominski et al., 2005). In dermal fibroblasts, treatment with progesterone 
was also shown to increase cortisol production (Slominsky et al. 2006). 
Skin is also known to express enzymes involved in sex steroid steroidogenesis such as 
the P450 aromatase encoded by CYP19 in dermal fibroblasts (Harada, 1992), hair 
follicles and sebaceous glands (Sawaya and Penneys, 1997), the 17β-hydroxysteroid 
dehydrogenases which interconvert androstenedione/testosterone, oestrone/oestradiol 
and dehydroepiandrosterone/androstenediol in the basement layer of the epidermis 
(Hikima and Maibach, 2007), sebaceous glands and hair follicles (Labrie et al., 2000) 
and 5α-reductase which converts testosterone into the more potent metabolite 
dihydrotestosterone (Labrie et al., 2000). Only aldosterone synthase, encoded by 
CYP11B2 and responsible for the conversion of corticosterone to the 
mineralocorticoid aldosterone has not been detected in skin. Collectively, these 
studies confirm that skin should indeed be perceived as the largest organ with 
endocrine function in the human body. 
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3.1.3 Cortisol metabolism in human skin 
Whilst Hannen et al were able to demonstrate that skin is capable of de novo cortisol 
synthesis from pregnenolone (Hannen et al., 2011), levels produced were low (1.0 ± 
0.2 nmol/L over a 24h period) and just within the range required to activate the GR 
(Dong et al., 2006, Charmandari et al., 2008). However, cortisol concentrations can 
be modulated at a cell-specific level by the action of 11β-HSD isozymes which 
activate (11β-HSD1) and inactivate (11β-HSD2) cortisol from and to cortisone 
respectively and it is through this mechanism that cells are able to regulate exposure 
to GC. 
Regulation of 11β-HSD activity by a component of human skin was first reported by 
Hammami and Siiteri in primary whole-cell cultures of foreskin fibroblasts which 
exhibited predominantly oxoreductase [11β-HSD1] activity with limited 
dehydrogenase activity (Hammami and Siiteri, 1991). 
In contrast, initial studies conducted on isolated human sweat gland ducts and 
epidermis revealed significant dehydrogenase activity in the former [11β-HSD2], less 
in the latter and 10-fold lower levels of oxoreductase activity [11β-HSD1] in both 
structures (Kenouch et al., 1994). Here, the co-localization of 11β-HSD 
dehydrogenase activity with MR protein and mRNA expression was in agreement 
with its postulated function as a protective mechanism to prevent illicit activation of 
the MR by cortisol. Subsequent studies confirmed the activity of 11β-HSD2 in human 
eccrine glands (Bocchi et al., 2004). 
Following Northern blotting with sheep kidney-isolated 11β-HSD2 cDNA, RNA 
expression was also detected in ovine skin although relatively weak compared to 
kidney, placenta and adrenal tissues (Agarwal et al., 1995). Similarly, mRNA 
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expression of cloned 11β-HSD2 was detected in human breast skin, again to a lesser 
extent compared to kidney, colon and pancreas (Brown et al., 1996). 
Initial immunohistochemical studies localized 11β-HSD2 to the arterioles (Smith et 
al., 1996), eccrine sweat glands, to a lesser extent to the epidermis and was absent in 
the sebaceous glands and hair follicles in human skin (Smith et al., 1996). Eccrine 
gland 11β-HSD2 co-localization with MR (luminal cells) and absence of staining in 
epidermis, sebaceous and apocrine glands (including MR) was confirmed by another 
study (Hirasawa et al., 1997). 
In comparison to 11β-HSD2, studies investigating expression, activity and 
localization of 11β-HSD1 in human skin are relatively sparse. Recently, Hardy et al 
reported 11β-HSD1 mRNA expression in primary dermal fibroblasts cultures from 
human knee tissue explants (Hardy et al., 2006). However, the authors also failed to 
detect 11β-HSD oxoreductase activity, in contrast to data reported previously for 
cultured foreskin fibroblasts (Hammami and Siiteri, 1991). Recent 
immunohistochemical studies localized 11β-HSD1 to the epidermal stratum 
spinosum, dermis and hair follicles (Hennebert et al., 2007), although the activity data 
in these studies is difficult to interpret as analyses were conducted on tissue 
homogenates, ameliorating 11β-HSD1 oxoreductase activity (as apparent from the 
order of magnitude increase in dehydrogenase compared to oxoreductase activity) and 
preventing its discrimination from 11β-HSD2. 
Collectively, these limited studies into 11β-HSD localization, expression and activity 
were predominantly conducted in human skin cells (dermal fibroblasts) or using ex 
vivo human skin tissue explants with no comparable data available for other species, 
including mouse. 
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3.1.4 Skin of mice and men 
The laboratory mouse remains the most widely used animal model for biological 
research based on several advantages including easy housing and maintenance with 
associated economical benefits, availability of many transgenic models permitting 
unparalleled opportunities to study disease pathophysiology including many models 
of human disease (Bedell et al., 1997). This is also applicable to many areas of 
dermatological research such as wound healing (Scheid et al., 2000), hair loss (Porter, 
2003), pressure ulcers (Wassermann et al., 2009) and carcinogenesis (Fraga et al., 
2004). Furthermore, the severe combined immunodeficient (SCID) mouse model has 
been used extensively to study a wide range of dermatoimmunological conditions 
including psoriasis (Raychoudhuri et al., 2004, Nickoloff, 2000), chickenpox 
(Niizuma et al., 2003), T-cell migration (Carballido et al., 2003), skin graft rejection 
(Briscoe et al., 1999) and allergy (Herz et al., 1998). 
The relatively short lifespan of mice also endows their use as tool to study many 
aspects of ageing. In a dermal context, this has been applied to studies of wound 
healing rates (Chang et al, 2007, Agah et al., 2004, Ashcroft et al., 1997), photo-
ageing (Bissett et al., 1990, Boyer et al., 1992, Bernstein et al., 1995, Haratake et al., 
1997), structure (Jensen et al., 2005, Damodarasamy et al., 2004, Boyer et al., 1991, 
Ghadially et al., 1996), antioxidant capacity (Treiber et al., 2011, van Remmen et al., 
2003) and nutrition (Liang et al., 2010, Taylor et al., 1995, Reed et al., 1996). 
Whilst mouse models have been invaluable as tools to develop our understanding of 
skin biology and disease, there are several key differences between the skin of mice 
and men that require consideration. Mouse skin is covered in dense hair that follows 
the same cycling process as human hair: anagen (growth), catagen (regression), and 
telogen but progresses dorsally from cranial to caudal (Figure 3-1) and is highly 
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complex (Paus et al., 1999, Plikus and Chuong, 2008) while human hair cycling 
occurs in a mosaic-like manner.  
 
Figure 3-1 Hair cycle wave progression in mice. The region with the most advanced anagen hair 
follicles (anagen VI in this case) probably started the hair cycle earliest. Adjacent hair follicles to the 
left are seen in gradient stages from anagen V to I. This represents a spreading wave of hair cycle 
activation. A boundary of the hair cycle domains forms when a skin region does not respond to the 
spreading wave and remains in telogen. The blank arrow is used to point to the direction of the 
spreading waves (Plikus and Chuong, 2008) 
Additionally, human hair is either vellus (penetrating to the superficial dermis) or 
terminal (penetrating to the deep dermis and is pigmented) and can switch between 
forms in an androgen-sensitive manner whilst mouse hair cannot (Porter, 2003). 
Another major difference is that mouse skin lacks eccrine sweat glands (potentially 
relevant to our research due to the high expression of 11β-HSD2 in these structures) 
and rete ridges/dermal papillae which are both abundant in human skin. Furthermore, 
mouse skin contains the panniculus carnosus, a thin muscle layer underlying the 
dermis which is absent in human skin and aids wound contraction following injury, 
while in human skin, wound repair occurs via re-epithelialisation and granulation 
tissue formation. Gender differences are also more prominent in mouse skin (Azzi et 
al., 2005) and must be controlled for. 
Despite these considerations, if correctly accounted for by appropriate study design, 
mouse models will continue to play a crucial role in progressing our understanding of 
many human diseases including those that apply to skin. 
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3.2 Aims 
Previous studies have demonstrated that skin is able to respond to, regulate and 
synthesize key hormones involved in local and systemic neuro- immuno- and 
endocrine signalling. As GC are known to influence a variety of biological processes 
in skin and local GC concentrations are tightly regulated by the cell-specific 
expression and activity of 11β-HSDs, it is not surprising that that the localization of 
these enzymes in skin tissue and primary cultures of dermal fibroblasts has been 
attempted. However, whilst there is a substantial volume of data regarding 11β-HSD2 
and its co-expression with several MR-rich regions of the human skin - highlighting 
its role in protecting these aldosterone-sensitive areas from inappropriate GC 
activation, the data reported for 11β-HSD1 is relatively limited and in some cases 
(such as the levels of activity in dermal fibroblasts), controversial. Our study 
therefore aimed to characterize expression, activity and localization of 11β-HSDs 
in human skin. 
The advantages of utilizing mice as models of human diseases and to further our 
understanding of biological processes are well-known and include applications for 
dermatological conditions and ageing. Our research group has developed several 
transgenic knockout models for 11β-HSD1 - however the characterization of 11β-
HSDs in murine skin in thus far unreported. Therefore, our study aimed to 
determine the expression, activity and localization of 11β-HSDs in mouse skin in 
comparison to human skin. 
While alterations in the expression of 11β-HSDs in skin have the capacity, through 
altering local GC levels, to modulate a variety of dermatological processes in normal 
physiology and disease, their regulation has not been investigated with two 
exceptions. Dexamethasone (100nM) was found to upregulate 11β-HSD oxoreductase 
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and dehydrogenase activities in cultured human foreskin fibroblasts while a range of 
other hormones (oestradiol, progesterone, testosterone and triiodothyronine) had little 
effect on either reaction (Hammami and Siiteri, 1991). Additionally, 11β-HSD 
oxoreductase activity and 11β-HSD1 mRNA expression was induced in HDF (knee) 
following treatment with the pro-inflammatory cytokines IL-1 and TNF-α while IL-4 
and IFN-γ had no effect (Hardy et al., 2006). These limited studies suggest that GC 
and certain pro-inflammatory cytokines have the potential to escalate local GC 
activation by upregulating 11β-HSD1 expression and activity. Our studies will also 
aim to confirm the regulation of 11β-HSD, H6PD and GR-α expression in HDF. 
3.3 Materials and Methods 
3.3.1 Sample preparation and culture 
3.3.1.1 Human and mouse skin tissue 
Human arm skin biopsies were obtained according to section 2.1.2.  
Human knee skin tissue explants were obtained during knee arthoplasty with informed 
consent and local ethical approval from patients fulfilling the American College of 
Rheumatology criteria for rheumatoid or osteoarthritis, in collaboration with Dr 
Rowan Hardy (School of Clinical and Experimental Medicine, University of 
Birmingham, UK). 
Mouse skin tissue explants (WT) were obtained according to section 2.2. 
3.3.1.2 Primary human dermal fibroblasts 
Cultures of HDF were prepared according to section 2.1.1. In addition, samples were 
treated as follows: 
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GC treatment: Upon reaching 80% confluence in a 6-well format, media was 
replaced with 2ml fresh media containing 100nM cortisol or 100nM dexamethasone 
(2μl 10-4M per well) in ethanol (final ethanol concentration <0.1%). Treatments were 
conducted in duplicate and controls were included in each experiment, treated with an 
equal volume of ethanol alone. Plates were incubated at 37ºC in 5% CO2 for 48h. 
TNF-α treatment: Cells were treated with 10nm/ml TNF-α as for GC treatment. 
When determining the effect of GC on 11β-HSD1 activity, treatment was also 
maintained for total activity assay duration. 
3.3.2 Real-time PCR gene expression 
RNA extraction, reverse transcription and qPCR were conducted according to section 
2.3. The following primer and probe reagents were used (Applied Biosystems, 
California, USA unless otherwise stated): 
Human: 11β-HSD1 (designed and previously optimised in-house) antisense primer 
5'-AGG-AAA-GCT-CAT-GGG-AGG-ACT-AG-3', sense primer 5'-ATG-GTG-AAT-
ATC-ATC-ATG-AAA-AAG-ATT-C-3' (900nmol/reaction), probe 5'-CAT-GCT-
CAT-TCT-CAA-CCA-CAT-CAC-CAA-CA-3' (100-200nm/reaction), 11β-HSD2 
(Hs00388669_m1), GR-α (Hs00230813_m1), GR-β (Hs00354508_m1) and H6PD 
(Hs00188728_m1). 
Mouse: 11β-HSD1 (Mm00476182_m1), 11β-HSD2 (Mm0049254_m1), GR-α 
(Mm00433832_m1) and H6PD (Mm00557617_m1). 
Target gene expression assays were used in a multiplex format with 18S rRNA 
control reagents (Applied Biosystems, California, USA). 
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3.3.3 11β-HSD activity assays 
11β-HSD oxoreductase and dehydrogenase activity assays were conducted for human 
and mouse skin tissue and HDF according to section 2.4. 
3.3.4 Immunohistochemistry 
3.3.4.1 Subjects 
Paraffin-embedded human arm skin tissue sections were obtained from Unilever 
Discover, Bedford, UK following local ethical approval and informed consent. 
Mouse skin tissue explants stored in 10% NBF according to section 2.2.1.2 were 
paraffin embedded and sectioned by Dr Charlie Shaikh (Birmingham Midland Eye 
Centre, City Hospital, Birmingham, UK). 
3.3.4.2 Materials 
Antigen retrieval: 0.1g calcium chloride in 10ml distilled water (10X stock) stored at 
4°C. 1ml calcium chloride stock and 200µl trypsin (2.5%) in 9ml distilled water (final 
trypsin concentration 0.05%) pH to 7.8 and stored in 1ml aliquots at -20°C. 
TBS: 121.2g Tris and 160.4g sodium chloride pH to 7.6 made up to 2l with distilled 
water (10X stock) and stored at 4°C. 
TBSAT: 10ml TBS stock, 3g bovine serum albumin and 50µl Triton X-100 made up 
to 100ml with distilled water and stored in 5ml aliquots at -20°C. 
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3.3.4.3 Methods 
Paraffin embedded slides were de-waxed by immersion in two 2min xylene washes 
followed by two 2min 100% ethanol washes and rehydrated in distilled water for 
10min taking care not to allow tissue to dry out between transfers. 
Tissue was circled with hydrophobic marker, immersed in ~100µl antigen retrieval 
solution and incubated at 37°C for 20min. Slides were rinsed under running distilled 
water for 10min followed by inactivation of endogenous peroxidase activity by 
incubating in 240ml methanol and 4.3ml hydrogen peroxide for 15min before rinsing 
again under running water. 
Sections were blocked in ~100µl TBSAT containing 10% serum from the same host 
species used to derive secondary antibody (goat serum) for 1h at room temperature. 
Blocking solution was replaced with 1:20 dilution (in blocking solution, ~30µg/ml) of 
rabbit anti-human 11β-HSD1 primary polyclonal antibody (Cayman Chemical, 
Michigan, USA) and incubated at room temperature for 1h. Rabbit isotype-matched 
(IgG) antibody at the same concentration as the primary was used as a negative 
control. Slides were washed by gentle agitation in three 1X TBS and 0.05% Tween-20 
(TBST) 10min washes. 
Sections were incubated with 1:200 dilution (in blocking solution, ~1.25µg/ml) of 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary polyclonal 
antibody (Dako, Glostrup, Denmark) and incubated at room temperature for 30min. 
Slides were washed in three 10min TBST washes. 
Slides were visualised using a 3,3'-diaminobenzidine (DAB) kit according to 
manufacturer’s protocol (Vector Laboratories Inc. California, USA), counterstained 
with Mayer’s haematoxylin (where appropriate) and dehydrated by immersion in two 
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2min 100% ethanol washes followed by two 2min xylene washes prior to mounting in 
VectaMount (Vector Laboratories Inc. California, USA) and coverslipping. 
11β-HSD2 immunohistochemistry was conducted as for 11β-HSD1, using a sheep 
anti-human 11β-HSD2 primary polyclonal antibody (The Binding Site, Birmingham, 
UK) in donkey serum blocking solution, a HRP-conjugated donkey anti-goat 
secondary (Dako, Glostrup, Denmark) and a sheep isotype control. 
3.4 Results 
3.4.1 Expression, activity and localization of 11β-HSDs in human skin 
Expression of 11β-HSD1, 11β-HSD2, GR-α and H6PD (ΔCt ± S.D) was analyzed in 
mRNA isolated from full-thickness human arm skin tissue biopsies (Figure 3-2). 
Expression of 11β-HSD2, GR-α and H6PD mRNA was comparable (14.5±1.6, 
15.0±1.6 and 14.1±1.4 respectively, n=21) with 11β-HSD2 expression ~20-fold 
higher than 11β-HSD1 (14.5±1.6 vs. 19.0±2.0 respectively, p<0.01, n=21). 
Accordingly, 11β-HSD dehydrogenase activity was also higher than oxoreductase 
activity in ex vivo human skin samples (fmol/mg/h, 85.5 vs. 45.3 respectively, p<0.05, 
Figure 3-3) and was further increased following incubation with the 11β-HSD1-
specific inhibitor LJ2 to 152.6 fmol/mg/h (p<0.05) with a concomitant partial 
decrease in 11β-HSD1 oxoreductase activity to 14.7 fmol/mg/h (p<0.05), 
demonstrating the close relationship between the two 11β-HSD isozymes in 
regulating local GC availability. Immunohistochemical analyses in human arm skin 
sections using a rabbit polyclonal antibody against 11β-HSD1 localized protein 
expression to epidermal keratinocytes, dermal fibroblasts, microvasculature, hair 
follicle cells, eccrine sweat glands and sebaceous glands, while only negligible 
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staining was detected following replacement of the primary antibody with an 
equimolar isotype control (Figure 3-4). 
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Figure 3-2 Expression of 11β-HSD1, 11β-HSD2, GR-α and H6PD in human arm skin tissue 
biopsies. Following normalizing for levels of the housekeeping gene 18S rRNA, 11β-HSD2, GR-α and 
H6PD expression was found to be comparable (ΔCt ± S.D, 14.5±1.6, 15.0±1.6 and 14.1±1.4, n=21) 
while 11β-HSD2 expression was significantly higher than 11β-HSD1 (14.5±1.6 vs. 19.0±2.0, n=21). 
Significance *** = p<0.001 
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Figure 3-3 11β-HSD activity in human knee skin tissue. In accordance with greater 11β-HSD2 
expression, mean 11β-HSD dehydrogenase (DEH) activity (fmol/mg/h) was greater than oxoreductase 
(OXO) activity in human skin (85.5 vs. 45.3, n=4). Furthermore, co-treatment with an 11β-HSD1-
specific inhibitor (LJ2) reduced oxoreductase activity while dehydrogenase activity increased (45.3 vs. 
14.7 and 85.5 vs. 152.6 respectively, n=3). Significance * = p<0.05 
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Figure 3-4 11β-HSD1 immunohistochemistry in human skin. Protein expression was detected using 
an 11β-HSD1 polyclonal antibody in paraffin-embedded sections of human skin (n=3). (A, C, D) 
Positive staining was detected in epidermal keratinocytes (E), dermal fibroblasts (arrows) and 
microvasculature (arrowheads). (E) Staining was also detected in hair follicles (HF), eccrine sweat 
glands (EG,) and (F) in sebaceous glands (SG). (B) Negligible staining was observed in equimolar 
isotype control-treated sections. Scale bar 100μm 
Expression of 11β-HSD2 was also detected by immunohistochemistry (sheep 
polyclonal antibody) in human epidermal keratinocytes and vasculature above isotype 
control background levels (Figure 3-5).  
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Figure 3-5 11β-HSD2 immunohistochemistry in human skin. Protein expression was detected using 
an 11β-HSD2 polyclonal antibody in paraffin-embedded sections of human skin (n=3) counterstained 
with Mayer’s haematoxylin. (A) Positive staining was detected in epidermal keratinocytes (E) and 
microvasculature (arrowheads). (C) Sections of human kidney were used as a positive control. (B, D) 
Negligible staining was observed in equimolar isotype control-treated sections. Scale bar 100μm 
3.4.2 Expression, activity and localization of 11β-HSDs in mouse skin 
Murine skin displayed strong mRNA expression (ΔCt ± S.D) of GR-α, which was 
greater than for H6PD (12.7±1.7 vs. 16.2±1.3, p<0.001, n=7, Figure 3-6). 11β-HSD1 
mRNA expression was lower compared to H6PD (17.9±1.0 vs. 16.2±1.3, p<0.01, 
n=7, Figure 3-6) but in contrast to human skin, expression of 11β-HSD2 was virtually 
absent from mouse skin, detectable at low levels in only 2 out of 7 samples (23.9±1.2, 
Figure 3-6). As expected, the near-absence of 11β-HSD2 mRNA expression in mouse 
skin translated to almost exclusive 11β-HSD oxoreductase (n=11) compared to 
dehydrogenase (n=3) activity (fmol/mg/h ± S.D, 340±154.8 vs. 36.7±11.5, p<0.01, 
Figure 3-7). Moreover, treatment with the 11β-HSD1-specific inhibitor LJ2 confirmed 
a reduction in oxoreductase activity (340±154.8 vs. 60±55.8, p<0.001, n=11), whilst 
only a marginal increase in dehydrogenase activity was recorded (36.7±11.5 vs. 
73.3±15.3, p<0.05, n=3). 
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Figure 3-6 Expression of 11β-HSD1, 11β-HSD2, GR-α and H6PD in mouse dorsal skin tissue 
samples. Following normalizing for levels of the housekeeping gene 18S rRNA, GR-α expression (ΔCt 
± S.D) was greater than H6PD (12.7±1.7 vs. 16.2±1.3, n=7) which in turn was greater than 11β-HSD1 
(16.2±1.3 vs. 17.9±1.0, n=7). Furthermore, expression of 11β-HSD2 was only weakly detectable in 2/7 
samples (23.9±1.2). Significance ** = p<0.01, *** = p<0.001 
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Figure 3-7 11β-HSD activity in mouse dorsal skin tissue. In accordance with lower 11β-HSD2 
mRNA expression, mean 11β-HSD oxoreductase (OXO) activity far exceeded dehydrogenase (DEH) 
activity (fmol/mg/h ± S.D, 340±154.8, n=11 vs. 36.7±11.5, n=3). Furthermore, treatment with an 11β-
HSD1-specific inhibitor (LJ2) substantially reduced oxoreductase activity (340±154.8 vs. 60±55.8, 
n=11), while dehydrogenase activity displayed only a negligible increase (36.7±11.5 vs. 73.3±15.3, 
n=3). Significance * = p<0.05, ** = p<0.01, *** = p<0.001 
Immunohistochemical analyses in mouse dorsal skin sections using a rabbit 
polyclonal antibody against 11β-HSD1 localized protein expression to epidermal 
keratinocytes, dermal fibroblasts, hair follicle cells, sebaceous glands, 
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microvasculature, adipose tissue and panniculus carnosus skeletal muscle, while only 
negligible staining was detected following replacement of the primary antibody with 
an equimolar isotype control (Figure 3-8). 
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Figure 3-8 11β-HSD1 immunohistochemistry in murine skin. Protein expression was detected using 
an 11β-HSD1 polyclonal antibody in paraffin-embedded sections of mouse skin (n=8). (A, C, D, E, F) 
Positive staining was detected in epidermal keratinocytes (E), dermal fibroblasts (arrows), hair follicle 
cells (HF), sebaceous glands (SG), microvasculature (arrowheads), adipose tissue (AT) and panniculus 
carnosus skeletal muscle (PC). (B) Negligible staining was observed in equimolar isotype control-
treated sections. Scale bar 100μm 
11β-HSD2 expression was undetectable by immunohistochemistry in mouse skin 
(Figure 3-9). 
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Figure 3-9 11β-HSD2 immunohistochemistry in murine skin. (A) Protein expression was 
undetectable using an 11β-HSD2 polyclonal antibody in paraffin-embedded mouse skin sections (n=3) 
counterstained with Mayer’s haematoxylin. (B) Negligible staining was observed in equimolar isotype 
control-treated sections. Scale bar 100μm 
3.4.3 Expression and activity of 11β-HSDs in primary human dermal 
fibroblasts 
Following identification of protein expression by immunohistochemistry in dermal 
components of mouse and human skin, expression of 11β-HSD1, 11β-HSD2, GR-α 
and H6PD mRNA was analysed in HDF. Compared to expression in full-thickness 
human arm skin biopsy mRNA extracts, GR-α levels in HDF (n=18) were higher (ΔCt 
± S.D, 9.3±1.2 vs. 15.0±1.6, p<0.001) indicative of a potentially highly sensitive GC-
responsive cell (Figure 3-10).  
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Figure 3-10 Expression of 11β-HSD1, 11β-HSD2, GR-α and H6PD in primary cultures of human 
dermal fibroblasts. Following normalizing for levels of the housekeeping gene 18S rRNA, GR-α 
mRNA expression was significantly more abundant than H6PD (ΔCt ± S.D, 9.3±1.2, n=18 vs. 
12.0±0.9, n=19) with 11β-HSD1 expression higher than 11β-HSD2 (22.6±2.4, n=27 vs. 24.0±1.7, 
n=18). Significance * = p<0.05, *** = p<0.001 
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Although HDF mRNA levels of 11β-HSD1 (n=27) and 11β-HSD2 (n=18) were both 
lower than whole skin extracts (22.6±2.4 vs. 18.9±2, p<0.001 and 24.0±1.7 vs. 
14.5±1.6, p<0.001 respectively), the expression of the 11β-HSD1 cofactor NADPH-
supplying enzyme H6PD (n=19) was also elevated (12.0±0.9 vs. 14.1±1.4, p<0.001, 
Figure 3-10). This, combined with the high expression of GR-α and greater abundance 
of 11β-HSD1 compared to 11β-HSD2 mRNA expression (22.6±2.4 vs. 24.0±1.7, 
p<0.05, Figure 3-10) suggests that HDF may be capable of rapidly elevating local GC 
concentrations through an autocrine positive-feedback mechanism. 
Consistent with the relatively low mRNA expression of 11β-HSD1 and 11β-HSD2, 
11β-HSD oxoreductase activity was undetectable over 50% of HDF cultures at 
baseline (12/20), while dehydrogenase activity was undetectable in all HDF cultures 
tested (data not shown). Activity detectable at baseline in the remaining samples was 
highly variable (fmol/mg/h ± S.E, 710±263, n=8) and undetectable following co-
incubation with the 11β-HSD1-specific inhibitor LJ2 (data not shown). Furthermore, 
activity was shown to increase in a substrate dose-dependant manner (Figure 3-11). 
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Figure 3-11 11β-HSD1 activity dose response in HDF. 11β-HSD1 activity was shown to increase in a 
substrate dose-dependant manner relative to the lowest substrate dose (2nM) with an ~10-fold and ~40-
fold increase in activity following a 10- and 100-fold increase in substrate concentration respectively 
(n=3). Significance * = p<0.05, *** = p<0.001 
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3.4.4 Regulation of 11β-HSDs in HDF 
The ability of HDF to regulate local GC concentrations through modulation of 11β-
HSD expression was investigated following treatment with GC and the pro-
inflammatory cytokine TNF-α. Expression of 11β-HSD1 mRNA was upregulated by 
treatment with the synthetic GC dexamethasone (ΔCt ± S.D, 23.2±2.9 vs. 22.0±3.5, 
p<0.05, n=11) and to a comparable degree by the endogenous GC cortisol (22.4±2.5 
vs. 20.3±2.5, p<0.001, n=22). As the latter is more physiologically relevant, it was 
used in place of dexamethasone to further demonstrate downregulation of 11β-HSD2 
(23.6±1.4 vs. 25.6±1.5, p<0.001, n=16) and GR-α (9.3±1.2 vs. 10.8±1.7, p<0.001, 
n=18) while H6PD mRNA expression was not significantly altered (12.0±0.9 vs. 
12.4±0.7, p=19). 
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Figure 3-12 Regulation of 11β-HSD1, 11β-HSD2, GR-α and H6PD mRNA expression by GC in 
HDF. Treatment with 200nM dexamethasone (DEX) or cortisol (F) upregulated 11β-HSD1 expression 
(ΔCt ± S.D, 23.2±2.9 vs. 22.0±3.5, n=11 and 22.4±2.5 vs. 20.3±2.5, n=22 respectively), while 11β-
HSD2 and GR-α were downregulated by cortisol treatment (23.6±1.4 vs. 25.6±1.5, n=16 and 9.3±1.2 
vs. 10.8±1.7, n=18 respectively). Expression of H6PD was unaffected by cortisol treatment (12.0±0.9 
vs. 12.4±0.7, n=19). Significance * = p<0.05, *** = p<0.001 
Dexamethasone treatment also induced 11β-HSD1 activity (to a variable degree) in 
several HDF that had undetectable levels at baseline (fmol/mg/h ± S.E, 724±324, 
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n=5). Additionally, activity was induced to a comparable extent as seen with 11β-
HSD1 mRNA expression in HDF where baseline activity was measurable (3.4±2.0 
fold increase in activity relative to untreated control, n=5, data not shown). Similarly, 
treatment with cortisol stimulated a similar induction in 11β-HSD1 activity in several 
(but not all) HDF cultures with undetectable baseline activity, again with considerable 
variation between samples (972±370 fmol/mg/h ± S.E, n=8). 
Furthermore, treatment with the pro-inflammatory cytokine TNF-α caused a near-
significant increase in 11β-HSD oxoreductase activity compared to GC treatment 
alone (pmol/mg/h ± S.E 2.6±1.0 vs. 1.4±0.7, p=0.07, n=4), and a synergistic increase 
in combination with GC treatment (Figure 3-13). 
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Figure 3-13 11β-HSD1 activity following dexamethasone, TNF-α or combined treatment in HDF. 
Treatment with the pro-inflammatory cytokine TNF-α upregulated 11β-HSD1 activity to a greater 
degree than dexamethasone (DEX) treatment alone, although this did not quite reach statistical 
significance (fmol/mg/h ± S.E 2625±1042 vs. 1405±704, n=4, p=0.07). Combined treatment resulted in 
a synergistic increase (6468±1723) compared to either DEX or TNF-α treatment alone. Significance * 
= p<0.05 
In summary, whilst baseline 11β-HSD dehydrogenase levels were undetectable, 
oxoreductase activity in HDF was highly variable but inducible by GC/TNF-α 
treatment/co-treatment (including in samples with undetectable baseline levels). 
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3.5 Discussion 
Our initial immunohistochemical characterization studies describe the localization of 
GC-metabolizing 11β-HSD protein expression to several discrete components of 
human and murine skin. 11β-HSD1 protein expression was detected in epidermal 
keratinocytes, particularly the stratum spinosum (located just above the basal stratum 
basale layer) supporting immunohistochemical and enzymatic activity data reported 
by others (Hennebert et al., 2007, Kenouch et al., 1994). Subsequently, previously 
unreported expression was also confirmed in mouse epidermal cells which in contrast 
to the highly organized human equivalent typically comprise a single keratinocyte 
layer. 
Convincing expression was also detected in the hair follicle ORS cells from both 
species, in congruence with this layer being continuous with the stratum spinosum of 
the epidermis. Whilst one previous study has also reported 11β-HSD1 protein 
expression in human skin hair follicles (Hennebert et al., 2007), albeit more 
ambiguously than our data, evidence for expression in the murine counterpart is 
completely exempt from published literature. Furthermore, expression of 11β-HSD1 
protein was observed in the hair follicle auxiliary sebaceous gland structures in both 
human and murine skin - a finding previously unreported for either species. 
In the dermis, 11β-HSD1 protein expression was associated with dermal fibroblasts in 
both species. Although prior studies have reported mRNA expression in primary 
cultures of HDF (Hammami and Siiteri, 1991, Hardy et al., 2006), our results provide 
additional supporting evidence for in situ protein expression in these cells, whilst 
being the first group to confirm a similar finding in mouse skin. Additionally, 
components of human and murine dermal microvasculature such as inner endothelial 
and outer VSMCs were found to express 11β-HSD1 protein, again previously 
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unreported for the integumentary circulatory system but extensively characterized in 
other vasculature (aorta, uterine, chorionic etc.) with known regulatory functions for 
vascular tone and blood pressure (Brem et al., 1995, Alzamora et al., 2000, Hammer 
and Stewart, 2006). Finally, 11β-HSD1 protein expression was also detected in human 
eccrine sweat glands (absent from mouse skin), consistent with previously reported 
11β-HSD oxoreductase activity in these structures (Kenouch et al., 1994). 
Sub-dermal expression of 11β-HSD1 protein in mouse skin included adipose tissue, 
known to exhibit 11β-HSD oxoreductase activity (Livingstone et al., 2009) and the 
panniculus carnosus skeletal muscle (absent from human skin). Whilst expression in 
the latter has not been reported previously or in skeletal muscle derived from other 
anatomical locations in the mouse, expression and activity in human skeletal muscle 
has been confirmed (Morgan et al., 2009). In human samples, subcutaneous adipose 
expression was undetectable due to the limited depth of the biopsies. 
Expression of 11β-HSD2 protein was also detectable in human epidermal 
keratinocytes, consistent with previous studies demonstrating 11β-HSD 
dehydrogenase activity and 11β-HSD2 protein expression in this layer (Kenouch et 
al., 1994, Smith et al., 1996). Our results also identified 11β-HSD2 protein expression 
in dermal microvasculature as previously reported (Smith et al., 1996). 
Although our findings demonstrated protein expression from both 11β-HSD isoforms 
in human skin, 11β-HSD dehydrogenase activity was ~2-fold greater than 11β-HSD 
oxoreductase activity, supported by our data indicating 11β-HSD2 mRNA expression 
levels exceeding those for 11β-HSD1. Kenouch et al. also reported greater 11β-HSD 
dehydrogenase compared to oxoreductase activity in isolated eccrine sweat gland 
ducts and epidermis (Kenouch et al., 1994) while Bocchi et al. demonstrated 11β-
HSD dehydrogenase levels in sweat gland ducts isolated from 4mm armpit punch 
Chapter 3 Characterization of 11β-HSDs in skin 
116 
biopsies (Bocchi et al., 2004) comparable to those we identified in whole skin 
biopsies, suggesting that eccrine glands may contribute the majority of 11β-HSD 
dehydrogenase activity in human skin. Consistent with this, we found almost 
exclusive 11β-HSD oxoreductase activity and predominantly 11β-HSD1 compared to 
11β-HSD2 mRNA expression in mouse skin, known to be largely devoid of eccrine 
sweat glands except in the foot pads and toes (Johns et al., 1995). 
Although our results suggest 11β-HSD oxoreductase activity levels in skin are several 
orders of magnitude lower than those observed in established GC-activating tissues 
such as omental adipose (Bujalska et al., 1997) there are several confounding factors 
that make a direct comparison challenging. For example, the 11β-HSD dehydrogenase 
activity in skin contributes to a net 11β-HSD oxoreductase activity that may be a large 
underestimate of the GC-activating capacity at a cellular level, reflecting the 
compartmentalized nature of skin compared to the relatively homogenous 
organization of omental adipose tissue that, additionally, is also devoid of 11β-HSD 
dehydrogenase activity.  
Furthermore, as activity is often expressed as amount of substrate converted (e.g. 
fmoles) per unit tissue weight (e.g. mg) per unit time (e.g. h), the proportion of tissue 
mass attributable to cells (and cell type) is also important. In the example stated, 
omental tissue mass is composed mostly of cells (adipocytes, fibroblasts, 
macrophages and endothelial cells), while skin consists mostly of structural proteins 
(collagen, elastin, GAGs etc.) and a substantial amount of water with the cellular 
component contributing a much smaller fraction to the total tissue mass. Indeed, 11β-
HSD1 mRNA expression in omental adipose tissue (Tomlinson et al., 2002) is more 
comparable to our observations in skin. However, at 13-fold greater levels it remains 
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likely that 11β-HSD oxoreductase activity in adipose cells is still greater than skin 
cells (although cell type variation is still unaccounted for). 
Finally, the large difference in 11β-HSD oxoreductase activity between skin and 
adipose may be due to its tissue-specific functional role. In simple obesity, 
accumulation of visceral fat (and increased local GC activation capacity) leads to a 
protective systemic decrease in 11β-HSD1 activity as indicated by a reduction in the 
urinary tetrahydrocortisol + 5 alpha-tetrahydrocortisol: tetrahydrocortisone ratio not 
seen in obese diabetics (Valsamakis et al., 2004). In skin, 11β-HSDs are more likely 
to function at an autocrine or paracrine level, where cells highly sensitive to local GC 
concentration may only require small changes in GC availability to alter functional 
properties, such as during an inflammatory response or wound healing.  
Our results indicate that GR-α mRNA is expressed in whole skin extracts at a higher 
but comparable level to that reported for omental adipose tissue (Bujalska et al., 
2007), whilst we report that expression in HDF cultures is over 300-fold greater. It 
remains to be elucidated whether this large increase is due to the altered phenotype of 
HDF in culture or is an indication of GR-α mRNA expression in dermal fibroblasts in 
vivo, with the lower level of expression in whole skin attributable to reduced or absent 
expression in other resident skin cells. Interestingly, a similar situation exists for 
H6PD mRNA expression, with levels described by us in whole skin similar to those 
found in omental adipose tissue (Bujalska et al., 2007) but elevated in HDF cultures. 
These observations suggest that dermal fibroblasts may have the capacity to regulate 
GC signalling in response to certain, currently unknown external stimuli. 
In contrast to GR-α and H6PD, mRNA expression of 11β-HSD1 and 11β-HSD2 was 
found to be lower in HDF cultures compared to skin tissue, supported by the absence 
of 11β-HSD dehydrogenase and lower 11β-HSD oxoreductase activity levels in HDF 
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compared to tissue. This suggests that under culture conditions, dermal fibroblasts 
exhibit a phenotype tailored towards GC response rather than generation. Following 
treatment of HDF with GC we found 11β-HSD1 mRNA expression and activity to be 
upregulated, initiating a positive-feedback auto-regulatory loop that enables HDF to 
increase local GC concentrations. Concomitantly, the expression of 11β-HSD2 
mRNA in HDF is downregulated, preventing the inactivation of newly generated 
cortisol to its inactive form (cortisone). Whilst GR-α mRNA is also downregulated, 
expression levels are still much higher than baseline levels in human skin biopsies. 
The positive-feedback upregulation of 11β-HSD oxoreductase activity by GC has also 
been reported for primary cultures of foreskin fibroblasts. Hammami and Siiteri 
reported a ~3-fold increase in activity following 100nM dexamethasone treatment, a 
similar induction to that observed in our studies, although untreated cells exhibited 
much greater baseline activity compared to our observations in arm skin-derived HDF 
(Hammami and Siiteri, 1991). This discrepancy is likely due to the anatomical origin 
of the cells used, with genital skin being a site of “immune privilege” - able to tolerate 
the introduction of antigen without eliciting an inflammatory immune response. High 
production of anti-inflammatory GC (through elevated 11β-HSD1 activity) is one 
likely mechanism though which inflammation in specific regions (also including the 
brain and ocular environment) is minimized, protecting these vital structures from the 
potentially damaging effects of an inflammatory immune response. Additionally, 11β-
HSD1 mRNA expression in HDF derived from knee skin reported by Hardy et al. was 
similar to our findings, with 11β-HSD oxoreductase activity also being undetectable 
in all donors tested, further supporting this notion (Hardy et al., 2006). 
Interestingly, we observed mRNA expression of 11β-HSD1 in HDF to be highly 
variable. Similarly, 11β-HSD oxoreductase conversion (cortisone to cortisol) also 
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fluctuated between donors from undetectable levels in the majority of samples 
through various degrees of activity in others. Experimental conditions were unlikely 
to account for this variation as all cells used were at an early passage (passage 2-5) 
and maintained under the same culture conditions. Furthermore, this large variation in 
11β-HSD1 mRNA expression and activity was maintained following GC-induced 
upregulation, suggesting some primary cultures are capable of attaining a greater level 
of GC-activation than others. 
In addition to regulation of 11β-HSD1 expression and activity by GC, we investigated 
regulation by the pro-inflammatory cytokine TNF-α. This was found to act in synergy 
with GC, further amplifying 11β-HSD oxoreductase activity and hence the GC-
activating potential of HDF, with functional implications that may include limiting 
inflammation and initiating resolution of an inflammatory response (e.g. during sun 
exposure or wound healing). 
In summary, our initial studies characterizing 11β-HSDs in the skin are in support of 
the view that the integumentary system should be considered an endocrine organ in its 
own right. We provide evidence to reinforce limited existing immunohistochemical 
data (Hennebert et al., 2007) demonstrating expression of 11β-HSD1 protein in key 
compartments of human skin (epidermal stratum spinosum, hair follicle ORS cells 
and dermal fibroblasts). Additionally, we describe previously unreported localization 
to dermal vasculature, eccrine sweat glands and sebaceous glands. We also provide 
previously unreported quantitative real-time PCR mRNA expression and supporting 
activity data for both 11β-HSD isozymes in human skin, which are in agreement with 
limited studies reporting activity in isolated compartments of skin e.g. eccrine sweat 
gland ducts and epidermis (Kenouch et al., 1994, Bocchi et al., 2004) and mRNA 
expression by Northern analysis (Brown et al., 1996). We report expression and 
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activity results for 11β-HSDs in HDF cultures supporting previously published data 
(Hardy et al., 2006) and demonstrating a previously unreported level of variation in 
11β-HSD1 mRNA expression and activity between different donors. Furthermore, we 
present supporting evidence for the ability of HDF to enhance local GC 
concentrations through positive-feedback upregulation of 11β-HSD1 mRNA 
expression and activity following GC and TNF-α stimulation, similarly to previous 
reports (Hammami and Siiteri, 1991, Hardy et al., 2006). 
Finally, we demonstrate similar findings and provide initial reports of 11β-HSD1 
mRNA expression, activity and protein localization in murine skin. Although we 
highlight major differences compared to human skin (e.g. lack of eccrine sweat glands 
and concomitant negligible 11β-HSD2 expression and activity), the presence of 11β-
HSD1 in similar compartments of human skin (epidermis, dermal fibroblasts, hair 
follicles, sebaceous glands and microvasculature) opens an avenue for investigating 
the functional consequences of 11β-HSD1 genetic manipulation and identification of 
novel roles for GC in skin homeostasis and pathological processes. 
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CHAPTER 4  AGE / SITE-DEPENDANT EXPRESSION OF 11β-
HSDs IN SKIN 
4.1 Introduction 
4.1.1 11β-HSD dysregulation and disease 
Maintenance of homeostasis is crucial for many biological systems especially those 
under endocrine control. As described in Chapter 1 (Section 4), GC are master 
regulators of a wide variety of systems and their availability is tightly controlled 
through several mechanisms including at a pre-receptor level, by 11β-HSD 
metabolism.  
4.1.1.1 Endocrine disorders 
The role of pre-receptor metabolism of GC is best exemplified by the monogenic 
endocrine disorders of apparent cortisone reductase deficiency (ACRD) and AME 
characterized by functionally inactivating mutations in the 11β-HSD1 co-factor 
supplying enzyme H6PD (Lavery et al., 2008) or 11β-HSD2 respectively (Cooper and 
Stewart 1998). Recently, dominant negative heterozygous mutations in 11β-HSD1 
have also been described, explaining the genetic cause of true cortisone reductase 
deficiency (CRD) in these patients (Lawson et al., 2011).  
Extensive animal studies have offered further insights into the consequences of 
targeted deletion or overexpression of these enzymes. Phenotypically, mice lacking 
11β-HSD1 are largely normal, with a compensatory activation of the HPA axis 
manifesting with adrenal hyperplasia and elevated basal corticosterone levels in some 
(but not other) strains (Kotelevtsev et al., 1997, Harris et al., 2001, Carter et al., 
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2009). Upon closer evaluation it was discovered that this model is resistant to 
hyperglycaemia upon high-fat feeding or stress challenge with improved glucose 
tolerance, a more favourable lipoprotein profile and resistance to diet-induced obesity 
(Kotelevtsev et al., 1997, Morton et al., 2001, 2004). Interestingly, 11β-HSD1-null 
mice also display improved age-related cognitive function compared to WT 
counterparts (Yau et al., 2001). Conversely, adipose-specific overexpression of 11β-
HSD1 manifests as a full metabolic syndrome in mice with central obesity, glucose 
intolerance, T2D, dyslipidaemia, hyperphagia and hypertension (Masuzaki et al., 
2001, 2003). Similarly, 11β-HSD1 overexpression in mouse liver results in modest 
insulin resistance, fatty liver, dyslipidaemia and hypertension (Paterson et al., 2004). 
In contrast to the subtle cardio-protective phenotype of 11β-HSD1 knockout animals, 
H6PD-null mice exhibit a progressive myopathy. Additionally, mice display 
consistently elevated circulating corticosterone and ACTH levels and raised urinary 
dehydrocorticosterone metabolites resulting from a switch in 11β-HSD1 activity 
(oxoreductase to dehydrogenase) presumably due to the absence of NADPH co-factor 
regeneration within the ER lumen (Lavery et al., 2006, 2007, 2008, Bujalska et al., 
2008). 
As expected, the 11β-HSD2-null mouse displays similar characteristics to its human 
equivalent AME, with hypokalaemia, hypochloraemia, hypotonic polyuria, and 
marked hypertension, primarily resulting from unregulated activation of MR by 
corticosterone (Kotelevtsev et al., 1999). Alternatively, cardiomyocyte-specific 
overexpression of 11β-HSD2 in mice results in cardiac hypertrophy, fibrosis and heart 
failure - a phenotype ameliorated by MR-selective (but not GR) blockade, suggesting 
that although 11β-HSD2 protects the MR from inappropriate GC activation by 
inactivating corticosterone/cortisol, a certain degree of GC signaling via the MR is 
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necessary for normal cardiomyocyte function, although mechanistic details behind 
this hypothesis require elucidation (Qin et al., 2003). Whilst excessive GC signaling is 
known to contribute to osteoporosis, studies utilizing selective 11β-HSD2 
overexpression in rodent osteoblasts revealed detrimental effects on bone volume and 
architecture in a gender-specific manner, suggesting a threshold GC requirement also 
exists for optimal bone formation and remodeling, corroborating the cardiomyocyte 
data (Sher et al., 2004). 
In addition to the pathological consequences of altered pre-receptor GC metabolism in 
the monogenic disorders of CRD, ACRD and AME, and insights obtained from 
genetic manipulation in rodents (that accurately recapitulate many aspects of these 
human conditions), emerging evidence also implicates GC-metabolizing enzyme 
dysregulation in the etiology and progression of the metabolic syndrome. For 
example, 11β-HSD1 is differentially expressed according to adipose depot, with 
greater activity in omental compared to subcutaneous fat (Bujalska et al., 1997), 
suggesting a plausible mechanism where central adiposity persists in the absence of 
increased circulatory GC levels and redefines simple obesity as “Cushing’s disease of 
the omentum”. 11β-HSD1 expression has also been found to positively correlate with 
BMI, percentage body fat, and omental adipose tissue area in human females 
(Michailidou et al., 2007) and with BMI in subcutaneous depots (Kannisto et al., 
2004). Furthermore, overexpression of 11β-HSD2 in visceral adipose tissue confers a 
degree of resistance to adipose deposition in mice on a high fat diet (Kershaw et al., 
2005). 
11β-HSD1 dysregulation has also been implicated in diabetes and insulin resistance, 
where a potentially protective, compensatory decrease in cortisol: cortisone urinary 
metabolite ratio (indicative of decreasing 11β-HSD1 activity) with increasing obesity 
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in controls was found to be lacking in patients with T2D (Valsamakis et al., 2004). 
Selective 11β-HSD1 inhibitors have demonstrated encouraging results in mouse 
models of metabolic syndrome, increasing insulin sensitivity whilst decreasing body 
weight, triglycerides and cholesterol and remarkably in slowing atherosclerosis 
progression (Alberts et al., 2003, Hermanowski-Vosatka et al., 2005). 
4.1.1.2 Immune dysfunction 
The role of GC as regulators of inflammation and immune function is also now 
known to involve direct modulation by 11β-HSDs (Chapman et al., 2009), with 
postulated roles during the local acute inflammatory response that influence the 
course and outcome of inflammation resolution (Gilmour et al., 2006). Data suggest 
that during a normal immune response 11β-HSD1 expression and activity is 
“switched on” following response of immune cells (i.e. differentiation) to pro-
inflammatory stimuli such as cytokines (IL-4, IL-13) and LPS (Thieringer et al., 
2001). Furthermore, 11β-HSD1 expression is associated with monocyte commitment 
to a Th1 lineage (Martinez et al., 2006). Following monocyte induction (with GM-
CSF and IL-4), 11β-HSD1 activity is maintained in differentiated dendritic cells 
during innate immune system signalling but declines upon adaptive immune response 
signal activation, demonstrating an intricate and highly sensitive orchestration of local 
GC levels based on both the differentiation status of immune cells and on 
microenvironment conditions (Freeman et al., 2005). 
Conversely, 11β-HSD2 expression is negligible compared to 11β-HSD1 in normal 
immune cells from both mice (Gilmour et al., 2006) and humans (Thieringer et al., 
2001, Freeman et al., 2005) but has been shown to be transiently expressed in 
peripheral blood mononuclear cells from patients with early rheumatoid arthritis 
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(Olsen et al., 2004) and upregulated in transformed B-cell lines derived from patients 
with rheumatoid arthritis compared to those derived from their unaffected twins (Haas 
et al., 2006). Additionally, differences in GC activation have been demonstrated in 
synovial cells from patients with rheumatoid or osteoarthritis (with greater 
reactivation in the latter, Schmidt et al., 2005), while GC activation was shown to 
positively correlate with inflammation in rheumatoid arthritis (Hardy et al., 2008). 
Moreover, the IL-10-induced upregulation of 11β-HSD1 in normal human 
macrophages was abolished in those derived from rheumatoid arthritis subjects 
(Antoniv and Ivashkiv, 2006).  
While chronically increased GC activation appears to be a feature of persistent 
inflammation, studies in the 11β-HSD1-null mouse indicate that impaired GC 
activation also leads to excessive inflammation and altered resolution following 
induction of sterile peritonitis (Gilmour et al., 2006). 
4.1.1.3 Dysregulation during ageing 
The inevitable decline of the immune system with ageing is well documented. 
However, recent studies in murine lymphocytes suggest that this is coupled with an 
increase in 11β-HSD1 expression and activity (Zhang et al., 2005), suggesting a 
mechanism through which increased GC activation may lead to decreased GC 
sensitivity and contribute to immune system dysfunction with advancing age. 
Similarly, 11β-HSD1 activity was shown to increase as a function of age in human 
primary osteoblasts (Cooper et al., 2002) and was further elevated by GC treatment 
resulting in a positive-feedback increase in local GC concentrations that may 
contribute to the decline in bone strength with increasing age and the increased risk of 
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fracture in elderly patients on systemic GC therapy. 11β-HSD1 expression is also 
reported to increase with advancing age in mouse bone (Weinstein et al., 2010). 
More recently, increases in 11β-HSD1 expression have been reported in subcutaneous 
fat from older (post-menopausal) compared to younger (pre-menopausal) women 
providing further evidence for increased local GC activation as a general 
characteristic of the ageing process (Andersson et al., 2009). Conversely, Li et al 
describe an increase in omental but not subcutaneous 11β-HSD1 expression with 
increasing age in children, with no age-associated differences at either site in adults 
(Li et al., 2007). 
Holmes et al also describe increased 11β-HSD1 expression with age in mouse 
hippocampus and parietal cortex, correlating with age-related cognitive impairment 
measured by performance in a water maze. Furthermore, ageing transgenic mice with 
forebrain-specific 11β-HSD1 overexpression also exhibit a premature, age-associated 
cognitive decline (Holmes et al., 2010). These results may explain the enhanced 
hippocampal long-term potentiation and spatial learning in aged 11β-HSD1-null mice 
reported by Yau and colleagues (Yau et al., 2007). Subsequently, it was reported that 
both partial deficiency (11β-HSD1 heterozygote) and temporary inhibition of 11β-
HSD1 activity induced cognitive function improvements in ageing mice (Sooy et al., 
2010). 
Studies investigating whether renal 11β-HSD2 activity also increases in an attempt to 
counteract the increasing 11β-HSD1 levels with age revealed that this is not the case 
(at least in rats, Audige et al., 2002). Moreover, in rat Leydig cells, 11β-HSD2 
expression is reported to decrease during ageing, suggesting a loss of protective 
activity normally provided through blunting the suppressive effects of GC on Leydig 
cell steroidogenesis (Koeva et al., 2009). It would be interesting to investigate 
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whether this is also coupled with an increase in Leydig cell 11β-HSD1 expression 
with ageing, resulting in a “double-whammy” effect, further exacerbating local GC 
concentrations and potentially contributing to the decreasing levels of testosterone 
observed with advancing age. 
4.2 Aims 
Previous studies clearly demonstrate that dysregulation of local pre-receptor GC 
metabolism (through changes in expression of 11β-HSDs) can contribute to the onset 
and progression of many pathological conditions, ranging from metabolic disease to 
alterations in immune system function. Over the past decade, evidence has emerged 
linking local GC production to the ageing process. 
Several groups have now reported increases in 11β-HSD1 expression and activity 
with advancing age in a range of tissues including human subcutaneous fat 
(Andersson et al., 2009), murine lymphocytes (Zhang et al., 2005), bone (Weinstein 
et al., 2010) and brain (Holmes et al., 2010), since our group initially reported this 
phenomenon in human osteoblasts (Cooper et al., 2002). The lack of compensatory 
concomitant increase in GC inactivation by 11β-HSD2 in rat kidney (Audige et al., 
2002), and, conversely, evidence for an increase in 11β-HSD2 expression with age in 
rat Leydig cells (Koeva et al., 2009) suggest that the uninhibited increase in GC 
reactivation by 11β-HSD1 may be a generalised effect of the ageing process - offering 
a potential target to combat generic ageing-associated diseases. 
Although the adverse effects of increased GC skin exposure are well documented 
during endogenous Cushing’s syndrome or exogenous therapeutic treatment with GC 
(both systemic and topical), the potential for increased local endogenous production 
though increased 11β-HSD1 activity in skin ageing has not been investigated. 
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Therefore, the current study aimed to determine expression and activity of 11β-
HSDs in HDF and human full-thickness skin tissue biopsies derived from donors 
of varying age and in skin tissue explants from young and old mice. 
Extrinsic ageing is thought to superimpose on intrinsic (chronological) ageing and in 
skin is largely attributable to photo-ageing. The mechanisms underlying both forms of 
ageing are believed to be largely similar (and exacerbated with additional extrinsic 
insults), however to date no studies have been conducted to examine pre-receptor GC 
metabolism in the context of extrinsic ageing. The current study aimed to address 
this issue by comparing 11β-HSD expression and activity in extrinsically- and 
intrinsically-aged (PE and PP respectively) HDF and human full-thickness skin 
tissue biopsies. 
Previously we reported that 11β-HSD1 activity in primary cultures of HDF is largely 
undetectable due to low levels of 11β-HSD1 mRNA expression, although this 
expression is readily inducible by GC treatment. Here, we aimed to determine the 
GC-mediated positive-feedback in 11β-HSD1 mRNA expression and activity in 
HDF from donors of varying age. 
Finally, GC signalling is also largely dependant on GR and 11β-HSD1 co-factor 
(NADPH) availability. We therefore sought to investigate the expression of GR and 
H6PD in HDF, human skin biopsies and mouse skin explants alongside 11β-HSDs. 
4.3 Materials and methods 
4.3.1 Sample preparation and culture 
Human skin tissue biopsies, mouse skin tissue explants and HDF were prepared 
according to sections 2.1 and 2.2. HDF were treated with cortisol according to section 
3.3.1.2. 
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4.3.2 11β-HSD activity assays 
Human arm skin biopsy 11β-HSD oxoreductase assays were conducted according to 
section 2.4. However, activity was not normalised for wet tissue weight as we 
determined this to be an inappropriate correction, particularly when comparing PE to 
PP sites where we observed increased tissue weight in the former in both young (mg 
wet tissue ± S.D, 8.3±1.6 vs. 5.7±1.6, p<0.001, n=20) and older (7.2±1.4 vs. 5.4±1.6, 
p<0.001, n=20) donors. There was also a significant decrease in PE tissue weight in 
older compared to young donors (8.3±1.6 vs. 7.2±1.4, p<0.05, n=20), but no 
difference with age in PP samples (5.7±1.6 vs. 5.4±1.6, p=20). Importantly, tissue 
weight did not positively correlate with 11β-HSD oxoreductase % conversion of 
cortisone to cortisol within the same site in either age group (Figure 4-1). 
Moreover, the surface area of the punch biopsies was standardised to a 3mm diameter, 
with the changes in weight attributable to increased biopsy depth. As the majority 
cells in skin are located in the epidermis and upper dermis, with the lower dermis 
composed mostly of ECM proteins (e.g. collagen), correcting activity for tissue 
weight would give an inaccurate representation of activity at a cellular level. 11β-
HSD oxoreductase activity for these samples was therefore presented as % conversion 
as a measure of ability of cells within the tissue to activate GC. 
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Figure 4-1 11β-HSD oxoreductase activity according to tissue weight in human skin biopsies. No 
correlation between tissue weight and corresponding 11β-HSD oxoreductase % conversion of cortisone 
to cortisol was observed for either PE or PP samples in both age groups (n=20 each group) 
For human knee skin and mouse skin tissue explants, where the surface area of the 
tissue taken was not standardised by punch biopsy, and where comparisons between 
sites were not made, correction for tissue weight was more appropriate. 
4.3.3 Real-time PCR gene expression 
RNA extraction, reverse transcription and qPCR were conducted according to section 
2.3, using the primers and probes described in section 3.3.2. 
4.3.4 Quantitative immunohistochemistry 
4.3.4.1 Subjects 
Frozen human arm skin tissue sections were obtained from Unilever Discover, 
Bedford, UK following local ethical approval and informed consent. 
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4.3.4.2 11β-HSD1 monoclonal antibody validation 
Quantitative immunohistochemistry studies were conducted using a mouse anti-
human 11β-HSD1 monoclonal antibody (Abcam, Cambridge, UK) previously only 
tested by western blotting against the recombinant full length tagged protein used as 
immunogen (size 58kDa). As no data was available on the detection of endogenous 
protein, our validation studies investigated the ability to detect 11β-HSD1 derived 
from human tissues, compared to the polyclonal antibody used in section 3.3.4.3. 
Western blotting: Human liver microsomes were isolated by ultracentrifugation as 
previously reported (Niculescu and Van Schaftingen, 1998). Microsomal pellets were 
resuspended in RIPA buffer (50mM Tris pH 7.4, 150mM sodium chloride, 1mM 
EDTA pH8 and 1% NP-40) stabilised with protease inhibitor cocktail according to 
manufacturer’s guidelines (Roche, Lewes, UK) and ~5μg protein (made up to 15μl 
with distilled water) was mixed with 15μl 2X loading buffer (1.25ml 0.5M Tris 
pH6.8, 2ml 10% SDS, 1ml glycerol, 0.5ml β-mercaptoethanol, 0.25ml distilled water 
and enough bromophenol blue to sufficiently colour the buffer) and heated to 95ºC for 
5min. Samples were loaded on graded 4-20% Tris-HCl SDS PAGE ready gels (Bio-
Rad, California, USA) and run at 200V for 1h immersed in Tris-Glycine-SDS PAGE 
Buffer (Geneflow, Fradley, UK) in a Mini-Protean Tetra Cell system according to 
manufacturer’s guidelines (Bio-Rad, California, USA).  
Following separation, proteins were transferred to an Immobilon-P PVDF membrane 
(0.45 µm, 26.5 cm x 3.75 m roll, Millipore Ltd., Watford, UK) at 100V for 1h 
immersed in Tris-Glycine Electro-blotting Buffer (Geneflow, Fradley, UK) using a 
Mini Trans-Blot Module according to manufacturer’s protocol (Bio-Rad, California, 
USA). Membranes were incubated in 5ml blocking buffer consisting of 20% milk 
powder in PBS 0.1% Tween-20 (PBST) under agitation at room temperature for 1h, 
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rinsed briefly in PBST, and incubated with mouse anti-human 11β-HSD1 monoclonal 
antibody diluted 1:500 (1-5μg/ml) in PBST or rabbit anti-human 11β-HSD1 
polyclonal antibody (Cayman Chemical, Michigan, USA) diluted 1:200 (3μg/ml) in 
PBST overnight at 5ºC under constant agitation. 
Membranes were washed in PBST (three 15min washes) and incubated with 
secondary antibody (HRP-conjugated goat anti-mouse or anti-rabbit, Dako, Glostrup, 
Denmark) diluted 1:2000 in PBST, at room temperature for 1h under constant 
agitation. Following a further three 15min washes, membranes were incubated with 
Amersham ECL Western Blotting Detection Reagent (1ml per membrane) according 
to manufacturer’s guidelines (GE Healthcare, Little Chalfont, UK), exposed to Kodak 
MXB photographic film (G.R.I, Rayne, UK) and developed in a dark room. 
A single 34kDa band was detected corresponding to monomeric 11β-HSD1 
protein on membranes incubated with either polyclonal or monoclonal primary 
antibody, confirming the ability of the latter to detect endogenous protein. 
Immunohistochemistry: in situ 11β-HSD1 protein detection in frozen human skin 
sections was conducted by immunohistochemistry according to section 3.3.4, using 
the monoclonal primary antibody and an alkaline phosphatase conjugated goat anti-
mouse secondary antibody (Dako, Glostrup, Denmark). Fast Red TR/Naphthol AS-
MX Tablets were used to visualise the staining according to manufacturer’s 
guidelines. Slides were not dehydrated (as this would remove the alcohol-soluble 
stain), but air-died for 10min and mounted in aqueous mounting media before 
coverslipping. Staining was observed as for the polyclonal antibody (section 3.4.1) in 
epidermal keratinocytes, dermal fibroblasts, microvasculature, hair follicles, eccrine 
sweat glands and sebaceous glands with negligible staining observed using equimolar 
isotype control-treated sections (Figure 4-2). 
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Figure 4-2 11β-HSD1 immunohistochemistry in human skin. Protein expression was detected using 
an 11β-HSD1 monoclonal antibody in frozen sections of human skin (n=14). (A, B, C) Positive 
staining was detected in epidermal keratinocytes (E), dermal fibroblasts (arrows, inset) and 
microvasculature (arrowhead). Staining was also detected in hair follicles (HF), eccrine sweat glands 
(EG,) and sebaceous glands (SG). (D) Negligible staining was observed in equimolar isotype control-
treated sections. Sections at 10X magnification 
4.3.4.3 Quantitation 
Stained sections were photographed using a Nuance multispectral imaging system 
(CRi, part of Caliper Life Sciences Ltd., Runcorn, UK). The system utilizes an 
optimized, high-throughput tunable filter distinctly matched to the bandwidths of 
common molecular markers (e.g. Sigmafast fast red). 
Nuance image analysis software was used to annotate the DEJ and the stratum 
corneum/granulosum interface. The software was programmed to detect the intensity 
of staining from the DEJ to the stratum corneum (5 layers) and from the DEJ to the 
bottom of the image in layers of fixed width (Figure 4-3). Epidermal staining was 
defined as the total stain in all 5 layers, while dermal staining was defined as the total 
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stain in the first 5 layers from the DEJ down into the dermis, in order to avoid 
inclusion of staining from confounding structures such as microvasculature, glands 
and hair follicles. Nuance software was also able to determine average epidermal 
thickness based on the annotations described above. 
 
Figure 4-3 Nuance image analysis of immunohistochemically stained slides. Nuance software splits 
images taken with the spectral camera into user-defined layers, enabling quantification of 11β-HSD1 
protein staining on a layer by layer basis (if desired) 
4.4 Results 
4.4.1 Intrinsic ageing 
4.4.1.1 11β-HSD1 expression increases in HDF from older donors 
11β-HSD1 mRNA expression displayed a positive correlation with donor age in PP 
HDF cultures (n=12, r
2
=0.59, p<0.01, Figure 4-4). While PE HDF followed a similar 
trend, this did not reach statistical significance. 
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Figure 4-4 Age-related variation of 11β-HSD1 mRNA expression in HDF. Following normalizing 
for levels of the housekeeping gene 18S rRNA, 11β-HSD1 expression was found to increase with 
increasing donor age in PP HDF (n=12). Although a similar trend was observed for PE HDF this did 
not reach statistical significance 
Indeed, 11β-HSD1 mRNA expression in PP HDF increased by over 140-fold between 
the lowest expressing donor (29 years, ΔCt 27.6) and highest expressing donor (75 
years, ΔCt 20.4). Interestingly, 11β-HSD2 mRNA expression was also found to 
increase with donor age in PP HDF (n=10, r
2
=0.63, p<0.01, data not shown), although 
to a lesser degree than 11β-HSD1, with a 26-fold increase between the lowest 
expressing donor (33 years, ΔCt 26.5) and highest expressing donor (65 years, ΔCt 
21.8). Similarly to 11β-HSD1, 11β-HSD2 mRNA expression did not correlate with 
donor age in PE HDF (n=8, data not shown). Moreover, expression of the 11β-HSD1 
cofactor- (NADPH) generating enzyme H6PD and GR-α did not correlate with donor 
age in either PE (n=9 and n=8 respectively) or PP (n=10) HDF (data not shown). 
Following treatment with 100nM cortisol, the age-dependant increase in 11β-HSD1 
expression was not only maintained in PP HDF (n=9, r
2
=0.6, p<0.05, Figure 4-5), but 
also induced in PE HDF (n=6, r
2
=0.81, p<0.05, Figure 4-5). Additionally, there was a 
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much greater difference (~560-fold induction) in PP HDF between the lowest 
expressing donor (28 years, ΔCt 26.6) and highest expressing donor (75 years, ΔCt 
17.5). Furthermore, cortisol treatment abolished the correlation between 11β-HSD2 
mRNA expression and donor age in PP HDF (n=9) with the lack of correlation 
between 11β-HSD2 PE HDF (n=8), H6PD and GR-α (PP n=10 and PE n=9) and 
donor age also remaining unaffected (data not shown). 
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Figure 4-5 Age-related response of 11β-HSD1 mRNA expression in HDF following 100nM cortisol 
treatment. Following normalizing for levels of the housekeeping gene 18S rRNA, 11β-HSD1 
expression was found to increase with increasing donor age in PP (n=9) and PE (n=6) HDF 
4.4.1.2 11β-HSD1 activity is induced by GC in HDF from older donors 
In order to determine whether the increase in 11β-HSD1 mRNA expression with 
donor age in HDF resulted in a similar increase in enzyme function, 11β-HSD1 
activity assays were performed in the presence and absence of 100nM cortisol 
stimulation. Whilst 11β-HSD1 activity was undetectable in the majority of 
unstimulated HDF cultures (Chapter 3), following 100nM cortisol treatment, 11β-
HSD1 activity was induced in older donor-derived HDF but remained negligible in 
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young donor-derived HDF (pmol/mg/h ± S.D, 1.4±1.1 vs. 0.06±0.08 respectively, 
p<0.05, n=5 Figure 4-6, A). This was endorsed by a comparable response in 11β-
HSD1 mRNA expression with higher levels in older compared to younger donors 
(ΔCt ± S.D, 16.6±1.6 vs. 21.4±2.0 respectively, p<0.01, n=5, Figure 4-6, B). 
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Figure 4-6 Age-related response of 11β-HSD1 activity and mRNA expression in HDF following GC 
treatment. (A) 100nM cortisol treatment induced detectable activity (pmol/mg/h) in HDF (all PE) from 
older (n=5) but not younger (n=5) donors (1.4±1.1 vs. 0.06±0.08 respectively, p<0.05). (B) A similar 
effect was observed in the corresponding levels of 11β-HSD1 mRNA expression (ΔCt ± S.D) following 
normalizing for 18S rRNA housekeeper expression, with higher levels in older compared to younger 
donors (16.6±1.6 vs. 21.4±2.0 respectively). Significance * = p<0.05, ** = p<0.01 
4.4.1.3 11β-HSD oxoreductase activity is greater in skin from older 
donors 
Whilst 11β-HSD1 mRNA expression and activity - particularly following positive-
feedback stimulation with cortisol - demonstrated a clear positive correlation with 
donor age in HDF, we sought to determine if this was also the case in vivo. 11β-HSD1 
activity assays conducted on 3mm punch biopsies from young (20-30 years) and older 
donors (over 60 years) revealed a similar increase in 11β-HSD oxoreductase activity 
in older compared to younger donors in both PP (% conversion 100nM cortisone to 
cortisol ± S.D, 9.5±3.3 vs. 6.7±2.0, p<0.01) and PE (11.5±3.0 vs. 9.1±3.0, p<0.05) 
samples (Figure 4-7). 
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Figure 4-7 Age-related variation of 11β-HSD oxoreductase activity in 3mm human skin punch 
biopsies. Activity (% conversion 100nM cortisone to cortisol ± S.D) was found to be greater in biopsies 
obtained from older (n=20) compared to younger (n=20) donors from both PP and PE sites (9.5±3.3 vs. 
6.7±2.0, p<0.01 and 11.5±3.0 vs. 9.1±3.0, p<0.05 respectively) 
Although 11β-HSD oxoreductase activity increased with donor age, levels of 11β-
HSD1 mRNA expression remained comparable between young and aged donors in 
skin biopsies derived from both PP (mean age ± S.D, 27.8±1.3, n=4 and 67.5±5.4, 
n=4, ΔCt ± S.D, 19.5±1.2 vs. 19.6±2.0 respectively) and PE (mean age ± S.D, 
25.7±3.4, n=6 and 69.2±6.1, n=5, ΔCt ± S.D, 18.8±2.2 vs. 19.2±2.3 respectively) 
sites. Furthermore, no significant difference between young and aged donors was 
observed, from skin biopsies derived from either site, for mRNA expression of 11β-
HSD2 (PP, mean age ± S.D, 27.8±1.3, n=4 and 67.5±5.4, n=4, ΔCt ± S.D, 15.7±1.0 
vs. 15.0±1.1 respectively, PE, mean age ± S.D, 25.7±3.4, n=6 and 67.3±6.7, n=3, ΔCt 
± S.D, 15.0±0.4 vs. 15.2±0.6 respectively), GR-α (PP, mean age ± S.D, 27.8±1.3, n=4 
and 67.5±5.4, n=4, ΔCt ± S.D, 16.0±0.6 vs. 14.6±1.1 respectively, PE, mean age ± 
S.D, 25.9±3.1, n=7 and 67.3±6.7, n=3, ΔCt ± S.D, 15.3±1.5 vs. 16.1±0.3 respectively) 
or H6PD (PP, mean age ± S.D, 27.8±1.3, n=4 and 67.5±5.4, n=4, ΔCt ± S.D, 14.7±0.8 
vs. 14.4±0.7 respectively, PE, mean age ± S.D, 25.7±3.4, n=6 and 67.3±6.7, n=3, ΔCt 
± S.D, 14.6±1.0 vs. 15.0±0.2 respectively). 
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4.4.1.4 11β-HSD1 expression/activity is greater in skin from older mice 
As 11β-HSD1 expression and activity was also detected in murine skin, we examined 
whether the increase in 11β-HSD oxoreductase activity with donor age in humans 
may also occur in mice. Indeed, we observed a higher level of oxoreductase activity in 
older (91-99 weeks, n=5) compared to younger (11-20 weeks, n=6) mice (pmol/mg/h 
± S.D, 0.44±0.15 vs. 0.26±0.11 respectively, p<0.05, Figure 4-8). Furthermore, 
oxoreductase activity positively correlated with 11β-HSD1 mRNA expression in 
mouse skin (r
2
=0.6, p<0.05, n=7, Figure 4-8), but not H6PD or GR-α (data not 
shown). 
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Figure 4-8 Age-related variation in 11β-HSD oxoreductase activity and 11β-HSD1 mRNA 
expression in full-thickness mouse skin explants. (A) Results confirmed increased oxoreductase 
activity in older (91-99 weeks, n=5) compared to younger (11-20 weeks, n=6) mouse skin (pmol/mg/h 
±S.D, 0.44±0.15 vs. 0.26±0.11 respectively, p<0.05). (B) Activity also positively correlated with 11β-
HSD1 mRNA in tissue-matched samples (n=7, r2=0.6, p<0.05). Significance * = p<0.05 
4.4.2 Extrinsic ageing 
As 11β-HSD1 expression and oxoreductase activity were shown to increase with 
donor age in HDF and ex vivo skin biopsies (from both PP and PE sources) we next 
investigated whether this was also the case for donor-matched PE compared to PP 
samples. 
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4.4.2.1 11β-HSD1 expression is greater in HDF from PE skin 
11β-HSD1 mRNA expression was analysed in HDF obtained from donor-matched PP 
(inner upper arm) and PE (lower outer arm) skin. Results indicated a 6.5-fold increase 
in mRNA expression in PE compared to PP samples (ΔCt ± S.D, 21.6±2.7 vs. 
23.7±2.3 respectively, p<0.001, n=10, Figure 4-9). This was also maintained 
following 100nM cortisol treatment (19.4±2.5 vs. 22.2±2.5 respectively, p<0.001, 
n=10, data not shown). 
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Figure 4-9 Site-related variation of 11β-HSD1 mRNA expression in HDF. (A) Following 
normalizing for levels of the housekeeping gene 18S rRNA, 11β-HSD1 mRNA expression was 
increased in PE compared to donor-matched PP HDF (ΔCt ±S.D, 21.6±2.7 vs. 23.7±2.3 respectively, 
p<0.001, n=10). (B) This corresponded to a 6.5-fold increase in expression in PE samples. Significance 
*** = p<0.001 
Conversely, mRNA expression between PP and PE samples was comparable for 11β-
HSD2 (ΔCt ±S.D, 24.5±1.6 vs. 24.3±1.7 respectively, n=6), GR-α (ΔCt ±S.D, 9.7±1.1 
vs. 9.1±0.9 respectively, n=6) and H6PD (ΔCt ±S.D, 11.9±1.2 vs. 12.1±0.7 
respectively, n=7), as was the case following 100nM cortisol treatment (ΔCt ±S.D, 
11β-HSD2, 25.6±1.3 vs. 26.0±0.9 respectively, n=5, GR-α, 10.9±1.7 vs. 11.0±1.8 
respectively, n=7, H6PD, 12.5±0.8 vs. 12.4±0.7 respectively, n=7, data not shown). 
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4.4.2.2 11β-HSD1 protein expression is increased in PE human skin 
Quantitative analysis of immunohistochemical staining intensity revealed increased 
11β-HSD1 protein expression in donor-matched PE compared to PP samples in both 
the epidermal (0.076±0.042 vs. 0.048±0.034 respectively, p<0.05, Figure 4-10 A) and 
dermal compartments (0.0076±0.004 vs. 0.0043±0.0021 respectively, p<0.05, Figure 
4-10 B). As expected, endogenous melanin staining (used as a positive control) was 
also increased in the PE samples (0.023±0.018 vs. 0.0083±0.0043 respectively, 
p<0.01, Figure 4-10 C). Further image analysis demonstrated upregulation of 11β-
HSD1 protein expression in the epidermal keratinocytes and induction from negligible 
levels in dermal fibroblasts from PE samples (Figure 4-11). 
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Figure 4-10 Site-related variation of 11β-HSD1 protein expression in human skin sections. (A) 
Epidermal 11β-HSD1 protein expression (as determined by intensity of immunohistochemical staining, 
A.U±S.D) was greater in donor-matched PE compared to PP skin sections (0.076±0.042 vs. 
0.048±0.034 respectively, p<0.05, n=14). (B) Dermal 11β-HSD1 protein expression was also elevated 
in PE samples (0.0076±0.004 vs. 0.0043±0.0021 respectively, p<0.05, n=14). (C) Endogenous 
epidermal melanin used as a positive control also showed increased staining in PE samples 
(0.023±0.018 vs. 0.0083±0.0043 respectively, p<0.001, n=14). Significance * = p<0.05, ** = p<0.01 
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Figure 4-11 Immunohistochemistry of 11β-HSD1 protein expression in PP and PE human skin 
sections. 11β-HSD1 staining was increased in PE epidermal keratinocytes (E) and in dermal fibroblasts 
(arrows) compared to donor-matched PP sections (n=14). Melanin staining (M) was also greater in PE 
sections. D, dermis. 20 X magnification 
The average donor age (± S.D) for these samples was 63.6±6.7 years (n=14), with 
samples from younger donors unfortunately unavailable for comparison of 11β-HSD1 
protein expression. 
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4.4.2.3 11β-HSD oxoreductase activity is greater in PE human skin 
Subsequently, we aimed to determine whether the increase in 11β-HSD1 mRNA 
expression in donor-matched PE compared to PP HDF may also be the case for 
human skin 11β-HSD oxoreductase activity in vivo. Results demonstrated increased 
activity in donor-matched PE compared to PP samples from both young (% 
conversion 100nM cortisone to cortisol ± S.D, 9.1±3.0 vs. 6.7±2.0 respectively, 
p<0.001, n=20) and older (11.5±3.0 vs. 9.5±3.3 respectively, p<0.05, n=20) donors 
(Figure 4-12). 
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Figure 4-12 Site-related variation in 11β-HSD oxoreductase activity in human 3mm punch biopsies. 
Conversion of cortisone to cortisol was found to be greater in donor-matched PE compared to PP 
samples from both young (% conversion 100nM cortisone to cortisol ± S.D, 9.1±3.0 vs. 6.7±2.0 
respectively, p<0.001, n=20) and older (11.5±3.0 vs. 9.5±3.3 respectively, p<0.05, n=20) donors. The 
significant increase in activity in site-matched older compared to young samples previously described 
in section 4.4.1.3 is also illustrated for completion (dotted lines). Significance * = p<0.05, ** = p<0.01 
Expression of 11β-HSD1, 11β-HSD2, GR-α and H6PD was also analysed and neither 
exhibited a site-specific alteration in expression in full-thickness human skin biopsies 
(data not shown). 
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4.5 Discussion 
Our results provide new evidence for an increase in GC generation in skin during 
ageing - including increased 11β-HSD1 mRNA expression in HDF, increased 11β-
HSD oxoreductase activity and 11β-HSD1 expression following GC treatment in 
HDF, increased 11β-HSD oxoreductase activity in human full-thickness skin biopsies 
and increased 11β-HSD oxoreductase activity and 11β-HSD1 expression in mouse 
full-thickness skin biopsies. These findings are supported by results from other 
research groups reporting a similar age-associated increase in GC-activating 11β-
HSD1 in other tissues. 
Zhang et al demonstrated a ~2-fold increase in 11β-HSD oxoreductase activity and 
11β-HSD1 protein expression in CD4+ T-cells from old (>16 month) compared to 
young (~3 month) female BALB/c mice (Zhang et al., 2005). Although our studies 
were conducted in male mice, we report a consistent increase in 11β-HSD 
oxoreductase activity and 11β-HSD1 mRNA expression in full-thickness skin from 
mice of a comparable age and using a similar 11β-HSD enzymatic activity assay 
method. An increase in 11β-HSD1 mRNA expression (of a similar magnitude to our 
observations) in older (>31 month) male and female mouse vertebrae has also been 
reported (Weinstein et al., 2010). Furthermore, 11β-HSD1 mRNA expression has also 
been shown to increase modestly with age in old (24-27 month) male mouse 
hippocampus and parietal cortex, although the young control animals were relatively 
older (6 months) than those used in our studies and could explain much smaller 
increase in 11β-HSD1 mRNA expression (Holmes et al., 2010). GR expression was 
also found to be unaffected by age in this study, supporting our observations. Overall, 
these animal studies are in agreement with our findings in mouse skin. 
Chapter 4 Age / site-dependant expression of 11β-HSDs in skin 
145 
In human studies, Cooper and colleagues reported a positive correlation of 11β-HSD 
oxoreductase activity (independently of gender) with donor age in primary cultures of 
trabecular bone osteoblasts (from ~1pmol/mg/h in young to ~7pmol/mg/h in older 
donors), although 11β-HSD1 mRNA expression only revealed a trend towards an 
increase with age (Cooper et al., 2002). Our studies demonstrate a similar magnitude 
of increase in 11β-HSD oxoreductase activity in human skin tissue explants although 
at much lower levels (from ~30fmol/mg/h in young to ~150fmol/mg/h in older 
donors). This large difference in oxoreductase activity is likely attributable in part to 
the absence of 11β-HSD2 mRNA expression reported by Cooper et al in osteoblasts 
which is known to be present in human skin (as demonstrated by us and others), 
inactivating cortisol back to cortisone and resulting in an apparently lower overall 
activity. More recently, a modest increase in 11β-HSD1 mRNA expression in 
abdominal subcutaneous adipose tissue from postmenopausal compared to pre-
menopausal females has been reported (Andersson et al., 2009), although activity was 
not significantly different between the groups. This may be due to the activity assay 
being measured solely in the dehydrogenase direction in homogenized tissue, with 
potential interference from 11β-HSD2 - an issue not addressed elsewhere in the paper. 
In contrast, Li et al., failed to detect a similar age-related increase in adults but 
reported a weak association between 11β-HSD1 mRNA expression and age in 
omental fat in children (Li et al., 2007), although this was hypothesised to be due to 
increasing adiposity during early development. These limited humans studies are also 
in general agreement with our findings in human skin reporting an increase in 11β-
HSD1 mRNA expression and 11β-HSD oxoreductase activity as a function of donor 
age in subcutaneous adipose tissue and primary cultures of osteoblasts. 
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Although 11β-HSD1 oxoreductase activity was undetectable in the majority of HDF 
cultures, we observed an age-dependant increase in detectable activity in old but not 
young donor-derived HDF following GC treatment. This is likely due to the higher 
baseline levels of 11β-HSD1 mRNA expression in HDF from older donors resulting 
in significantly greater expression levels following GC-induced upregulation and thus 
detectable oxoreductase activity. This positive-feedback auto-regulation of local GC 
metabolism by GC themselves may magnify the exposure of HDF to GC during 
ageing whilst simultaneously predisposing older individuals to greater GC exposure 
following treatment with exogenous GC or in states of raised endogenous GC levels 
(e.g. following physical or emotional stress). This may explain, in part, the increased 
incidence of skin atrophy in the elderly resulting from topical GC therapy (Oikarinen 
and Autio, 1991). 
The increase in GC-reactivation potential with advancing age due to elevated 11β-
HSD1 expression and 11β-HSD oxoreductase activity in the periphery (including 
skin) may mimic, at a tissue-specific level, the reduced central GC responsiveness 
(measured by DEX inhibition of LPS-induced cytokine production) reported to occur 
with ageing following stress (Rohleder et al., 2002), leading to an impaired protective 
response in the elderly against detrimental increases of pro-inflammatory cytokines. 
Decreased HPA-axis sensitivity to negative feedback cortisol inhibition with ageing 
(Wilkinson et al., 1997) is believed to further exaggerate adrenal cortisol secretion 
leading to a blunting of the diurnal cortisol section pattern with elevated evening 
levels (Van Cauter et al., 1996). Due to the large surface area of skin it may even be 
plausible that increased GC reactivation at this site (coupled with a lack of 
compensatory increase in renal 11β-HSD2 activity with age, Audige et al., 2002) 
could contribute to the elevated systemic cortisol levels with age. Studies have also 
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demonstrated a link between Alzheimer’s disease and decreased GC sensitivity in the 
skin (Linder et al., 1993), while Alzheimer’s disease has been associated with 
increased GC production and altered cortisol metabolism (Rasmuson et al., 2001) and 
11β-HSD1 expression increases in mouse brain have recently been implicated in 
declined cognitive function with age (Holmes et al., 2010). These studies suggest 
indirectly that increased GC reactivation with advancing age may indeed lead to 
decreased GC sensitivity in peripheral tissues such as skin, although 11β-HSD1 
expression in the brain and skin of Alzheimer’s patients remains to be investigated. 
Reduced GC sensitivity in skin may in turn contribute to ineffective control of 
inflammatory mediators, persistent inflammation and reduced wound healing - 
frequently reported in elderly individuals. Furthermore, the persistent inflammation 
and uncontrolled levels of inflammatory mediators (e.g., TNF-α, IL-1) resulting from 
decreased central and peripheral sensitivity to GC with age may also contribute to 
further exacerbating GC insensitivity though the upregulation of 11β-HSD1 (Cooper 
et al., 2001) potentially resulting in a vicious cycle with increasing GC accumulation 
(both local and central), decreased beneficial anti-inflammatory function and 
increased adverse side-effects. 
In contrast to the limited but slowly accumulating evidence for an increase in local 
GC levels with intrinsic ageing through the upregulation of 11β-HSD1, there have 
been no previous studies examining changes in the levels of this enzyme with respect 
to extrinsic ageing. Our studies investigating intrinsic ageing in skin offered an 
opportunity to examine whether 11β-HSD1 may also be involved in potentiating the 
accelerated ageing associated with the primary causative agent of extrinsic ageing, 
UV radiation. Intriguingly, our results demonstrate that 11β-HSD1 mRNA expression 
is indeed consistently higher in donor-matched HDF from PE compared to PP skin, 
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while levels of 11β-HSD2, GR-α and H6PD remain relatively similar between the two 
sites. Furthermore, 11β-HSD oxoreductase activity was also higher in donor-matched 
PE compared to PP skin ex vivo strongly supporting the in vitro evidence for a 
causative role of 11β-HSD1-induced GC accumulation in both intrinsic and extrinsic 
skin ageing. Additionally, our results demonstrate a larger, more statistically 
significant difference between PE and PP sites in younger volunteers. The more 
comparable activity between sites in older volunteers is as a result of increased 
enzyme activity in PP samples with age, supporting the concept of extrinsic ageing 
superimposing on intrinsic ageing. Although 11β-HSD1 mRNA expression was 
comparable between donor-matched PE and PP samples, our immunohistochemical 
studies revealed increased 11β-HSD1 protein expression in the former. This was 
observed in both epidermal keratinocytes and dermal fibroblasts. 
It remains possible that the differences observed between PE and PP 11β-HSD1 
mRNA expression and 11β-HSD activity are due to differences resulting from the 
physical anatomical separation rather than in response to different environmental 
conditions. Studies have reported differential gene expression patterns in dermal 
fibroblasts obtained from different body sites. Chang et al described notable groups of 
differentially expressed genes including ECM synthesis, metabolism, and cell 
signalling pathways that control proliferation, cell migration, and fate determination 
suggesting that fibroblasts at different locations in the body should be considered 
distinct differentiated cell types (Chang et al., 2002). However, this study has several 
limitations including a lack of gender- and age-controlled site-matched repeats 
making the results difficult to interpret in the context of site alone. Experimental 
replicates (multiples of same-donor samples) were used in lieu of biological replicates 
and in some cases mRNA expression profiles were more comparable between 
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different sites from different donors (e.g. abdomen and arm) than site-matched 
experimental replicates from the same donor suggesting certain anatomical sites may 
be more similar than the study implies. Unsurprisingly, the greatest expression profile 
differences existed between foetal- and adult-derived samples, with adult abdomen, 
arm, back and thigh samples showing relatively similar patterns of expression. 
Furthermore, dermal fibroblasts were passaged for at least 10 population doublings 
before mRNA harvest, introducing another potential source of variation into the study. 
Our studies examining differential 11β-HSD1 mRNA expression in HDF derived 
from PP and PE sites were designed to limit the impact of potential confounding 
factors such as these. For example, sites were restricted to the same site (arm) and 
cultured cells were maintained at a consistently low passage. Although our results in 
tissue do not indicate that the increased 11β-HSD1 mRNA expression and associated 
enzymatic activity are a direct consequence of UV exposure, the fact that this 
difference was especially poignant in young donors supports the notion that this effect 
is not caused by anatomical demarcation alone. Furthermore, another study 
investigating positional demarcation in dermal fibroblasts revealed a lack of strong 
evidence for differential expression related to fibroblast position along the dorsal-
ventral axis (Rinn et al., 2006) offering additional support with regards to the validity 
of our observations at these sites. The studies by Rinn et al also reported largest 
differences between foetal- and adult-derived (lung) tissue and relatively similar 
clustering of expression between HDF derived from adult wrist, forearm, elbow and 
upper arm in addition to a lack of an expression gradient along the limbs (in spite of 
lacking same-site inter-individual repeats) further supporting the sites chosen for our 
studies to examine the effect of UV exposure as being comparatively similar. 
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Our results support previous studies suggesting a role for increased local GC 
generation (through 11β-HSD1) during intrinsic ageing, demonstrating for the first 
time that this is also occurring in mouse and human skin. Intriguingly, our data 
provides evidence that this may also be the case with extrinsic ageing in humans - 
offering a novel common mediator through which extrinsic ageing may superimpose 
on intrinsic ageing. In parallel with the adverse effects associated with 11β-HSD 
dysfunction in diseases of metabolism and immunity, emerging data, including those 
presented here, suggest that similar pathways may be involved in the aetiology of 
ageing and photo-ageing.  
In human bone-derived primary osteoblast cultures, increased intracellular 11β-HSD 
oxoreductase activity with age is postulated to contribute to the increase in fracture 
risk for idiopathic and GC-induced osteoporosis that occurs with ageing (Cooper et 
al., 2002), in line with the well-known deleterious effects of GC on bone metabolism. 
In addition to similar age-related changes in murine bone 11β-HSD1 expression, 
targeted overexpression of 11β-HSD2 in bone cells protected transgenic animals from 
age-induced osteoblast/osteocyte apoptosis, decrease in bone formation rate and 
associated microarchitecture erosion, decreased vasculature volume and reduced 
strength (Weinstein et al., 2010), suggesting that realigning the imbalance of GC 
metabolism that occurs with ageing may lead to dramatic improvements in age-
associated decrements in bone function. Indeed, pharmacological inhibition of 11β-
HSD1 in vivo has been shown to decrease biochemical markers of bone resorption in 
young individuals (Cooper et al., 2000) but this has yet to be investigated in older 
subjects. Similarly in mouse brain, the increased levels of 11β-HSD1 with age shown 
to correlate with impaired cognitive performance appear to be causal, as transgenic 
mice with targeted overexpression of increased intracellular 11β-HSD1 in the 
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forebrain displayed premature age-associated cognitive decline (Holmes et al., 2010), 
potentially implicating 11β-HSD1 in the age-associated memory impairments also 
occurring in humans. Our results suggest that the degeneration of skin with advancing 
age also involves local increases in GC generation through 11β-HSD1, although the 
11β-HSD1-specific regulation of GC target genes in skin has yet to be investigated. 
Currently, theories to explain these recently emerging data remain speculative and 
highly complex. One plausible explanation is that of inflamm-ageing, whereby age-
associated increases of pro-inflammatory cytokines (Daynes et al., 1993, Chen et al., 
2003, Bruunsgaard and Pedersen, 2003, Viel et al., 2001, Casolini et al., 2002) may 
contribute to increased local GC activation by being potent activators of 11β-HSD1 
expression and reductase activity (Cooper et al., 2001).  
Hormonal alterations that occur with ageing are also possible contributors to local GC 
metabolism dysregulation. One such hormonal alteration is the decrease in adrenal 
secretion of DHEA and subsequently its sulphated circulating form DHEAS (Sulcova 
et al., 1997). The 7α-hydroxlation of DHEA to the active metabolite 7α-hydroxy-
DHEA has been shown to occur in a variety of GC-target tissues including brain 
(Rose et al., 1997), spleen, thymus, intestine, colon, caecum, muscle (Morfin and 
Courchay, 1994), prostate (Martin et al., 2001), joints (Dulos et al., 2004) and skin 
(Morfin and Courchay, 1994, Khalil et al., 1993). Furthermore, 11β-HSD1 has 
recently been shown to interconvert 7α-hydroxy-DHEA and 7β-hydroxy-DHEA via 
the 7-oxo-DHEA intermediate (Muller et al., 2006), raising the possibility that DHEA 
functions via its metabolites as a tissue-specific anti-GC, limiting the effects of GC 
particularly following inflammation (Dulos et al., 2004). Decreasing circulating levels 
of DHEA with age could lead to a shift in substrate availability for 11β-HSD1 
favouring cortisone over DHEA metabolites and thus contributing to increased local 
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production of GC during ageing (Muller et al., 2006). Additional complexity is 
introduced when considering the large degree of inter-dependence and cross-talk 
between systemic processes - one simplified example of such is the potential role that 
DHEAS plays in protecting against inflamm-ageing during youth through the 
suppression of cytokines such as IL-6 (Daynes et al., 1993). Decreasing levels of 
DHEA/S with ageing may therefore contribute to elevated local GC concentrations 
through multiple mechanisms. 
The age-related decline in GH and IGF-1 levels may also contribute to increased 11β-
HSD1 levels in older individuals. GH, through IGF-1, inhibits 11β-HSD1 activity and 
enhanced cortisone to cortisol conversion occurs with a reduction in GH levels. This 
was demonstrated by studying patients with acromegaly (GH excess) who exhibited a 
relatively low THF+allo-THF/THE ratio (indicative of low systemic 11β-HSD 
oxoreductase activity) which increased following lowering of GH (and consequently 
IGF-I) levels (Moore et al., 1999). Conversely, studies reported increased global 11β-
HSD oxoreductase activity in GH-deficient patients with hypopituitarism (Weaver et 
al., 1994). Interestingly, the dermal phenotype varies greatly between the two 
disorders. Skin puffiness due to excessive GAG accumulation and oedema, psoriasis 
(epidermal hyperproliferation), increased vasoconstriction (Ben-Shlomo and Melmed, 
2006), hyperelasticity, excessive collagen deposition (Braham et al., 2002) and 
excessive sweating (Lange et al., 2001) are common symptoms in patients with 
acromegaly. In contrast, GH deficiency typically manifests in skin with reduced 
sweating and epidermal thinning (Lange et al., 2001), symptoms also commonly 
associated with ageing skin. 
It is likely that a combination of immune, hormonal and other changes that occur 
during ageing act in concert to trigger the increase in 11β-HSD1 expression and 
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oxoreductase activity. Notably, the autocrine upregulation of 11β-HSD1 by GC may 
also be involved in maintaining and exacerbating local GC concentrations with 
advancing age. Our results are in support of the view that 11β-HSD1 levels escalate 
with age independently of tissue type, with skin being the most recent addition to this 
trend. Although the mechanisms underlying this observation are complex and still 
poorly understood, 11β-HSD1 dysfunction during ageing is emerging as a potential 
key mediator of the ageing process, common to the gradual degeneration of multiple 
tissues and gaining prominence as a possible therapeutic target to combat systemic 
ageing.  
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CHAPTER 5  PRE-RECEPTOR REGULATION OF GC TARGET 
GENES IN SKIN 
5.1 Introduction 
5.1.1 Overview 
The local availability of GC is controlled in a tissue-specific manner by isozymes of 
the enzyme 11β-HSD. In skin, GC are known to regulate a broad range of target genes 
including collagen, hyaluronic acid and TIMPs, resulting in detrimental alterations to 
skin structure and function (section 1.9). However, the molecular mechanisms 
underlying these alterations have not been examined in detail, with the effects of GC 
on several elements of skin biology such as collagen biosynthesis and maintenance of 
homeostasis still awaiting elucidation. Moreover, the pre-receptor regulation of 
known GC target genes in skin has not been investigated to date. The lack of 
knowledge in this area combined with our previous findings revealing an increase pre-
receptor GC signalling potential in skin during ageing (Chapter 4) prompted the 
studies presented in this chapter. 
5.1.2 Collagen processing and organization in skin 
Following translation, individual procollagen-α chains undergo a series of 
modifications that result in the highly organized structure present in the dermal ECM 
(Figure 5-1). Firstly, proline and lysine amino acids are hydroxylated by prolyl-4 
(P4HA1, P4HA2, P4HA3, and P4HB), prolyl-3 (LEPRE1, LEPREL1 and LEPREL2) 
and lysyl hydroxylases (PLOD1, PLOD2 and PLOD3) to form the hydroxyproline 
and hydroxylysine residues characteristic of collagen (Myllyharju, 2008). The 
collagenous domains of the α-chains then fold into a triple-helical structure, stabilized 
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by the hydroxyproline residues, and the trimeric molecules are then secreted from the 
rough endoplasmic reticulum into the extracellular milieu assisted by chaperone 
proteins such as hsp47 (SERPINH1).  
 
Figure 5-1 Collagen processing pathway. Following transcription of collagen genes (1), expressed 
mRNA transcripts are translated to procollagen peptides (2) which undergo several post-translational 
modifications including hydroxylation of proline and lysine residues (3), triple helix formation and 
association with chaperones such as hsp47 (4) which aid export through the Golgi network and 
secretion into the extracellular milieu. Here, propeptides undergo cleavage of non-collagenous peptide 
domains through the action of C- and N-terminus endopeptidases (5) with subsequent assembly in a 
quarter-staggered formation (typical of fibrillar collagens). Tensile properties are attributable to the 
action of lysyl oxidases which catalyze the formation of lysine and hydroxylysine-derived 
intramolecular and intermolecular cross-links (6). Degradation of collagen may then occur during 
tissue remodelling through the action of MMPs (orange crescent, 7). Reproduced from Chen and 
Raghunath, 2009 
Non-collagenous peptide extensions at both ends of the newly secreted collagen 
molecules are then cleaved by specific proteases (e.g. ADAMTS2, BMP1) and 
assembled into their tissue-specific supramolecular organization. Although the 
alignment of collagen molecules in the ECM occurs spontaneously, for example in a 
quarter-stagger arrangement in the case of fibrillar collagens, the necessary tensile 
strength is attained through the actions of lysyl oxidases (LOX) and lysyl oxidase-like 
enzymes (LOXL1, LOXL2, LOXL3 and LOXL4) which catalyze the formation of 
cross-links at lysine and hydroxylysine residues (Uzawa et al., 2003). 
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5.1.3 Maintenance of skin homeostasis 
Over recent years, much progress has been made establishing mechanisms and 
paracrine interactions between different cell types in the skin to maintain tissue 
homeostasis and barrier function, best exemplified by examining the process of tissue 
repair and regeneration following acute injury during wound healing - known to be 
adversely affected by GC. This highly complex and delicately orchestrated process 
can be generalized into the early inflammatory response phase, the granulation mid-
phase (including epidermal re-epithelialisation and dermal connective tissue 
generation) and the late tissue remodelling phase (Figure 5-2). 
 
Figure 5-2 Epidermal-mesenchymal signalling in wound healing. Promoted by the initial 
inflammatory response keratinocyte-derived IL-1 stimulates dermal fibroblasts to secrete several 
mediators that signal back in a double paracrine manner to regulate keratinocyte phenotype (e.g. 
stimulating proliferation for re-epithelialisation). Concomitantly, IL-1, through NF-κB, blocks 
fibroblast differentiation preventing premature ECM remodelling. As inflammatory signalling begins to 
subside, there is a shift towards increased TGF-β signalling which synergises with mechanical tension 
build-up to induce fibroblast activation (characterized by increased α-SMA expression typical of 
myofibroblasts). Thus, epidermal-mesenchymal cross-talk in skin is highly coordinated, enabling 
efficient remodelling and healing and maintaining effective barrier function. Adapted from Werner et 
al., 2007. 
5.1.3.1 Inflammation as the first response 
Studies examining excisional wound healing in mice demonstrated strong induction of 
IL-1β followed by TNF-α mRNA expression 8 hours post-injury, persisting until mid-
Chapter 5 Pre-receptor regulation of glucocorticoid target genes in skin 
157 
phase (Hubner et al., 1996). These pro-inflammatory cytokines are produced by 
initially by granulocytes (Feiken et al., 1995) and maintained thereafter by activated 
macrophages and keratinocytes (Hubner et al., 1996). Surprisingly, Mori et al. 
reported accelerated wound healing in TNF-receptor p55 knockout mice displaying 
enhanced angiogenesis, collagen production and epithelial wound closure with 
increased TGF-β1, connective tissue growth factor, VEGF-1, VEGF receptor-1 and 
VEGF-2 expression observed (Mori et al., 2002). Moreover, reduced neutrophil and 
macrophage infiltration was observed, supported by other studies suggesting a 
beneficial effect on wound healing in mice with reduced leukocyte infiltration 
(Ashcroft et al., 1999) and a negative effect in mice with exaggerated leukocyte 
infiltration (Ashcroft et al., 2000).  
Whilst these animal studies suggest a redundant role for TNF-α signalling in wound 
repair, other early inflammatory mediators play a more active part. Post-injury 
keratinocyte-derived IL-1 has been shown to stimulate fibroblasts to secrete KGF, IL-
6 and GM-CSF (Waelti et al., 1992, Maas-Szabowski and Fusenig 1996, Maas-
Szabowski et al., 1999), a process delicately regulated by the c-jun and JunB AP-1 
subunits (Szabowski et al., 2000). 
5.1.3.2 Regulation of granulation 
The importance of fibroblast-derived KGF in promoting epidermal proliferation is 
highlighted by a dominant-negative mutation in the KGF receptor expressed in basal 
keratinocytes of transgenic mice. These animals exhibited epidermal thinning, hair 
follicle abnormalities, dermal fibrosis, and a severe delay in wound re-
epithelialisation (Werner et al., 1994), whilst subsequent studies involving KGF 
mutant mice revealed little effect on wound healing (Guo et al., 1996) suggesting 
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other fibroblast-derived factors capable of KGF receptor activation (e.g. FGF10) may 
be compensating for the lack of KGF. 
Similarly, mice deficient in IL-6 display a severely compromised excisional wound 
healing phenotype, with fewer leukocyte numbers, decreased angiogenesis and 
reduced collagen accumulation (Lin et al., 2003) which was rescued following IL-6 
administration (Gallucci et al., 2000). Therefore, the epidermal-mesenchymal 
interaction can be described as a double paracrine cross-talk, with keratinocyte-
derived IL-1 stimulating dermal fibroblasts to secrete a host of factors that feedback to 
keratinocytes and alter their phenotype to promote the wound healing process. 
Concomitant with phenotype transition from a resting state to one promoting re-
epithelialisation, keratinocytes are stimulated to secrete autocrine-acting growth 
factors such as TGF-α, an EGFR ligand also associated with the hyperproliferative 
epidermis recognized as a hallmark of psoriasis (Elder et al., 1989). However, its role 
in wound healing may also be dispensable as mice lacking TGF-α exhibit normal 
healing with the exception of sites, such as the ear (where supporting granulation 
tissue in the dermis does not form) suggesting that other growth factors present during 
the granulation process (e.g. HB-EGF) are able to compensate (Kim et al., 2001). 
Indeed, mice with keratinocyte-targeted inactivation of HB-EGF display delayed 
epithelial wound closure (Shirakata et al., 2005). 
In addition to immediate availability from de-granulating platelets, PDGF is 
synthesised by keratinocytes de novo during the granulation phase of tissue repair 
with reduced PDGF signalling reported in models of reduced wound healing such as 
diabetic mice (Beer et al., 1997). 
Whilst several of the growth factors secreted during wound repair are derived 
primarily from either keratinocytes or dermal fibroblasts, some are expressed in both 
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cell types following injury. Activins fall into this category, homo- or hetero-dimeric 
polypeptides that are part of the TGF-β family (Hubner et al., 1996). Although in 
vitro studies reported a growth inhibitory effect of activins on keratinocyte 
proliferation (Seishima et al., 1999), wound healing was enhanced following 
keratinocyte-specific overexpression (Munz et al., 1999). This discrepancy may be 
explained by a requirement for mesenchymal cross-talk, highlighting the challenge 
faced when attempting to collate in vitro and in vivo effects. This is further supported 
by studies comparing the mRNA expression profiles of dermal fibroblasts grown in 
isolation or in the presence of HaCaTs, with differential expression of a host of 
growth factor, ECM, protease, and intracellular structural protein transcripts 
(Shephard et al., 2004). Conversely to studies by Munz et al., mice overexpressing the 
soluble activin antagonist follistatin in the epidermis displayed a severe delay in 
wound healing but decreased resultant scarring (Wankell et al., 2001) demonstrating 
the capacity of growth factors to affect multiple aspects of wound healing. 
5.1.3.3 Fibroblast-driven tissue remodelling 
Fibroblasts differentiating into myofibroblasts initiate the late-phase of wound 
healing, with a strong induction in contractile properties as they align in parallel to the 
mechanical tension building up in the newly formed granulation tissue. During 
differentiation, fibroblasts acquire expression of α-SMA, driven by exposure to 
mechanical tension through endothelin-1 (Hinz et al., 2001) and TGF-β (Desmouliere 
et al., 1993), but inhibited by IL-1 which is present in the early stages of wound repair 
(Shephard et al., 2004). Indeed, NF-κB activation (following IL-1 and TNF-α 
stimulation) was found to be a principal inhibitor of TGF-β signalling (Bitzer et al., 
2000). 
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5.1.3.4 Summary 
These studies demonstrate that molecular mediators of wound healing play specific 
roles in regulating the sequential phases of repair, through double paracrine 
mesenchymal-epidermal cross-talk. Increasing our understanding of the highly 
complex interactions involved in maintaining tissue homeostasis may enable 
manipulation to improve wound healing. For example, increased keratinocyte 
proliferation and decreased apoptosis in transgenic animals overexpressing a 
dominant-negative type II TGF-β receptor mutant in basal keratinocytes improved 
wound closure rates (Amendt et al., 2002). 
5.1.4 GC-mediated inhibition of wound healing 
Although GC are known to reduce wound healing as observed during topical or 
systemic therapy, in conditions of endogenous GC excess (Cushing’s syndrome) and 
following physical or emotional stress (DeVries et al., 2006), the mechanisms 
involved in this inhibition are less well defined. 
5.1.4.1 GC signalling in wound healing 
The anti-inflammatory properties of GC are well documented and occur through 
several mechanisms (Figure 5-3) including directly blocking the transcription of 
inflammatory proteins by NF-κB and AP-1 and by inducing the expression of anti-
inflammatory proteins such as IκB, annexin-1, and MAPK phosphatase-1 (Rhen and 
Cidlowski, 2005). 
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Figure 5-3 Anti-inflammatory GC signalling mechanisms. Activated GR targets pro-inflammatory 
pathways (e.g. NF-κB) to decrease downstream cytokine expression. Concomitantly, AP-1 signalling 
through c-Jun and c-Fos transcription factors decreases expression of tissue remodelling mediators (e.g. 
MMPs). The inability to dissociate GC anti-inflammatory and anti-remodelling properties may 
contribute to the adverse effects on wound healing when tissues are exposed to excessive GC 
concentrations (e.g. stress, GC therapy, Cushing’s syndrome). Reproduced from Rhen and Cidlowski, 
2005 
Recently, cortisol synthesis in the epidermis was shown to be increased following 
tissue injury and after treatment with IL-1. Furthermore inhibition of cortisol 
synthesis during wound healing increased IL-1 production suggesting it is initially 
activated as an anti-inflammatory negative feedback mechanism (Stojadinovic et al., 
2007, Vukelic et al., 2011). Interestingly, this study also reported a slight decrease in 
11β-HSD2 between 0-24h and a large increase in expression by 48h post-wounding, 
indicative of a regulatory mechanism to limit active GC availability. Recently, 
inhibition of wounding-induced de novo GC generation by metyrapone (CYP11B1 
enzyme inhibitor) was shown to promote wound healing, suggesting the adverse 
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effects of local GC generation outweigh the anti-inflammatory functions (Vukelic et 
al., 2011). 
In collagen gel models of tissue remodelling, GC were found to enhance fibroblast 
contractility through inhibition of endogenous PGE production (Skold et al., 1999) - 
suggesting, in addition to their anti-inflammatory effects, they may function to 
regulate several aspects of wound healing, including the promotion of fibroblast 
contractility in the later stages of wound repair. Conversely, if present early in the 
wound healing process, GC have been demonstrated to interfere with EGF signalling 
to inhibit healing (Lee et al., 2005) by forming an overriding repressosome that 
signals keratinocytes to “stop” their activating cycle required for re-epithelialisation 
and retire to the normal differentiation pathway. Thus the presence of GC in the 
dermal environment prior to wounding or the completion of re-epithelialisation (such 
as during topical GC therapy or Cushing’s syndrome) may impair keratinocyte 
functions in healing by presenting them with a premature “stop” signal. Further 
supporting this theory, mice exposed to restraint stress prior to wound healing 
displayed an attenuated immediate IL-1β and KGF response post-wounding, and 
exaggerated IL-1α and IL-1β levels indicative of persistent inflammation later in the 
healing process (Mercado et al., 2002), suggesting that stress induces alterations in the 
kinetics of cutaneous proinflammatory cytokine and growth factor gene expression 
which could impair the quality of healing tissues. Moreover, administration of IL-6 to 
GC-immunosuppressed mice reversed the impairment in wound healing observed in 
these animals but, interestingly, delayed healing in vehicle-treated control mice 
(Gallucci et al., 2001) further highlighting the presence of a delicate homeostatic 
system dependant on the existence of a sensitive equilibrium between pro-
inflammatory mediators and anti-inflammatory GC. 
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5.1.4.2 GC interference with mesenchymal-epidermal signalling 
GC have also been shown to interfere with several growth factor signalling pathways 
during wound healing. GC inhibit KGF signalling (Brauchle et al., 1995, Chedid et 
al., 1996, Mercado et al., 2002) and induce a keratinocyte proliferation-repressing 
switch in EGF signalling (Lee et al., 2005) during early wound healing. In addition, 
while all three TGF-β isoforms and their receptors are induced during normal wound 
healing, GC-treated mice display reduced TGF-β1, TGF-β2 and TGF-β2 receptor and 
increased TGF-β3 and TGF-β1 receptor mRNA expression (Frank et al., 1996). In the 
epidermis, increased TGF-β3 in GC-treated mice was postulated to contribute to the 
premature onset of keratinocyte differentiation and inhibition of epithelial cell 
proliferation resulting in a severe delay in re-epithelialisation seen in these animals. 
Moreover, exogenous application of TGF-β1 in the treatment of impaired wound 
healing in rats was sufficient to reverse the GC-induced impediments even when 
administered 24h in advance (Beck et al., 1993). Whilst the adverse effects of GC 
treatment prior to wounding are clearly exemplified by these studies, a beneficial 
regulatory role for GC during normal wound healing cannot be excluded. For 
example, whist reducing the initial inflammatory stages of the repair process, 
endogenous GC-induced inhibition of TGF-β signalling may enforce the effects of IL-
1, acting in synergy to prevent premature tissue remodelling processes. As 
inflammation subsides, TGF-β signalling increases promoting the later stages of 
wound repair by suppressing GR-mediated transcriptional activity in a positive-
feedback manner and contributing to the neuroprotective, anticatabolic and pro-
wound healing properties of the TGF-β family of proteins (Ichijo et al., 2005). 
Furthermore, IGF-1 signalling has also been recognized as an important component of 
tissue repair (Sorensen et al., 2003, Todorvic et al., 2008). Studies have indicated that 
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the wound microenvironmental IGF-1 system is also adversely affected by GC pre-
treatment in rats with reduced IGF-1, IGF-1 receptor and IGF-BP3 mRNA expression 
rescued by co-treatment with the GR blocker RU486 (Bitar, 2000). Interestingly, this 
study also reported similar effects in diabetic rats, raising the possibility that GC 
excess may be a mechanism contributing to non-healing ulcers in sufferers of the 
condition. Remarkably, RU486 treatment in diabetic rats restored the IGF-1 system to 
a comparable degree as insulin treatment (Bitar, 2000). Similarly to TGF-β, 
administration of IGF-1 to GC-treated rats was able to reverse the wound healing 
impairments observed (Suh et al., 1992). 
5.1.4.3 Adverse effects on tissue remodelling 
Aberrant GC signalling has also been shown to interfere directly with mediators of 
tissue remodelling. In vivo studies revealed that systemic GC treatment resulted in a 
near-complete inhibition of the elastin-degrading, macrophage-specific, 
metalloelastase (MMP12) mRNA - normally expressed post re-epithelialisation in 
deep layers of reconstituted dermis clustering around vascular structures (Madlener et 
al., 1998), whilst levels of stromelysin-1 (MMP3), 92-kDa gelatinase (MMP9), 
collagenase and TIMP1 were only weakly modulated. Furthermore, stromelysin-2 
(MMP10), normally induced by KGF in basal keratinocytes at the wound edge, was 
found to be excessively upregulated during wound healing in GC-treated mice 
(Madlener et al., 1996). However, this upregulation is likely as a result of GC 
modulation of MMP10 regulators other than KGF as another study reported decreased 
KGF expression in GC-treated mice (Brauchle et al., 1995). Indeed, increased 
MMP10 expression may be attributable, in part, to GC-induced IL-6 suppression 
(Gallucci et al., 2001). 
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The destructive effects of excessive GC signalling in skin is also supported by the 
phenotype of a transgenic mouse overexpressing GR in the epidermis (and other 
stratified epithelia) under control of the keratin K5 promoter, manifesting as variable-
sized skin lesions ranging from epidermal hypoplasia and underdeveloped dysplastic 
hair follicles to a complete absence of this tissue (Perez et al., 2001). 
Collectively, these studies demonstrate that GC are capable of differentially regulating 
individual MMPs, and their regulators in the dermis, as well as the finely-balanced 
mesenchymal-epidermal interactions - suggesting that inappropriate GC signalling 
may cause a dysfunction in the maintenance of homeostasis in skin resulting in wound 
healing impediments and compromising barrier function. 
5.1.5 11β-HSD1 inhibitors and disease 
Increased pre-receptor potentiation of GC signalling is now recognized to play a 
primary role in the progression of several metabolic disorders and as such, 11β-HSD1 
inhibitors are gaining support as useful therapeutic tools. 
5.1.5.1 Type 2 diabetes 
Stimulation of hepatic glucose production is a key function of GC in a manner 
antagonistic to insulin-mediated peripheral tissue (e.g. adipose and muscle) glucose 
uptake. Furthermore, GC stimulate lipolysis and increase fatty acid mobilization. 
Excessive circulating cortisol levels (e.g. Cushing’s disease) lead to a host of 
metabolic complications including visceral obesity, insulin resistance, glucose 
intolerance, dyslipidaemia, hypertension and increased cardiovascular risk. However, 
it is widely accepted that GC concentration can also be modulated locally though the 
action of 11β-HSDs. 
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Studies investigating tissue-specific generation of cortisol (independently of adrenal 
secretion) through 11β-HSD1 as a causative agent in T2D have reported an ~2-fold 
increase in adipose tissue activity derived from obese individuals (Rask et al., 2002, 
Kannisto et al., 2004). Together with a wealth of evidence from rodent studies 
implicating 11β-HSD1 in obesity and metabolic disease (Kotelevtsev et al., 1997, 
Morton et al., 2001, Masuzaki et al., 2001, Masuzaki et al., 2003, Morton et al., 2004, 
Paterson et al., 2004, Kershaw et al., 2005), support has been rapidly accumulating 
for clinical trials targeting 11β-HSD1 in these disorders. 
Initially trialled in hyperglycaemic mice, 11β-HSD1 inhibitors were shown to reduce 
fasting blood glucose levels, improve insulin sensitivity and prevent progression of 
atherosclerosis (Hermanowski-Vosatka et al., 2005, Veniant et al., 2009). Although 
trials in man using the liquorice-derived compound carbenoxolone produced modest 
improvements in insulin sensitivity (Walker et al., 1995) and glucose production rates 
(Andrews et al., 2003) the non-specific inhibition of both 11β-HSD isozymes causing 
potential side-effects such as AME (through decreased 11β-HSD2 activity) called for 
the development of more effective, specific 11β-HSD1 inhibitors. Subsequent trials in 
healthy controls demonstrated that 11β-HSD1 inhibitors were safe, well-tolerated and 
specific, reducing hepatic 11β-HSD1 activity by 37% over 11 days using PF-915275 
(Courtney et al., 2008). 
Recently, a landmark trial has demonstrated increased potency, with complete hepatic 
and adipose inhibition of 11β-HSD1 by the specific inhibitor INCB13739 leading to 
improved hyperglycaemia in patients with T2D inadequately controlled by metformin 
monotherapy, with additional benefits regarding the lipid profile of patients with 
hyperlipidaemia or hypertriglyceridaemia (Rosenstock et al., 2010). Importantly, 
compensatory HPA axis activation occurred (as indicated by elevated ACTH output) 
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but generally remained within the reference range with daily rhythmicity, basal 
cortisol homeostasis, testosterone in men, and free androgen index in women 
remaining unchanged by INCB13739. A slight elevation in testosterone was observed 
in females and whist no clinical symptoms of androgen excess were recorded; trials of 
longer duration will be required to fully assess the potential severity of adverse side-
effects in women relating to this measure. 
5.1.5.2 11β-HSD1 inhibitors in other disorders 
The promising results demonstrated recently for the ability of selective 11β-HSD1 
inhibitors to improve clinical measures of T2D in humans has raised the possibility 
that these compounds could also be applicable to other disorders in which 
dysregulation of 11β-HSD1 has been reported.  
These include age-related cognitive impairment such as Alzheimer’s disease where 
animal studies have demonstrated improved cognition and increased long-term 
potentiation in aged 11β-HSD1 knockout mice relative to age-matched controls (Yau 
et al., 2007). Additionally, carbenoxolone has also been shown to improve verbal 
memory in elderly men and T2D (Sandeep et al., 2004), reflecting the beneficial 
effects seen for this non-selective 11β-HSD1 inhibitor for direct outcomes of T2D. 
Recently, Mohler et al published evidence for improved cognitive function in rodents 
following acute administration of two specific 11β-HSD1 inhibitors. Following 
treatment, animals exhibited improved memory consolidation and recall in inhibitory 
avoidance and increased CREB phosphorylation (a transcription factor involved in 
cognition) in the cingulate cortex in addition to improvements in short-term memory 
in rat social recognition testing (Mohler et al., 2011). Interestingly, these studies were 
conducted in young animals demonstrating that acute GC modulation can impact 
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performance in otherwise healthy subjects, building on previous observations of 
cognitive enhancement with a selective 11β-HSD1 in older rodent subjects after 
chronic lifelong treatment or lasting several days (Sooy et al., 2010). 
Dysregulation of 11β-HSD1 may also be involved in inflammatory conditions such as 
rheumatoid arthritis. During an adjuvant-induced inflammatory response in joint 
synovium tissue of Lewis rats, 11β-HSD1 mRNA expression and 11β-HSD 
oxoreductase activity is upregulated leading to amplification of local GC 
concentrations that could reduce inflammation (Ergang et al., 2010). This induction 
appears to occur via pro-inflammatory cytokine stimulation as treatment with TNF-α 
and IL-1 antagonists reduced 11β-HSD1 upregulation in addition to improving the 
clinical symptoms (Ergang et al., 2010). Furthermore, blockade of GC signalling 
through carbenoxolone treatment caused an exacerbation of arthritis with an 
upregulation of pro-inflammatory cytokines (e.g. TNF-α, COX-2), raising the 
possibility that altered modulation of GC through 11β-HSDs at a tissue-specific level 
may contribute to persistent non-resolving inflammation (although the non-specificity 
of carbenoxolone makes interpretation of these results challenging). However, studies 
investigating the effects of 11β-HSD1-specific modulation in inflammatory disorders 
are still lacking. In human studies, GC metabolism in synovial explants taken from 
patients with rheumatoid arthritis and osteoarthritis was highly variable with some 
individuals exhibiting predominance to activate GC whereas others displayed 
increased GC inactivation ability (Hardy et al., 2008). However, the small study 
numbers make it difficult to extrapolate an association between GC modulation 
capacity and inflammation severity. Furthermore, this study suggested increased 
systemic 11β-HSD1 activation (through urinary metabolite analysis), although the 
lack of synovial explants from healthy controls cannot exclude the possibility that this 
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is due to 11β-HSD1 upregulation in other tissues. Although increased local GC 
activation is a hallmark of resolution of inflammation (Chapman et al., 2006), it 
appears to be ineffective during persistent inflammation. Interestingly, a recent study 
conducted in murine TNF-α activated primary preadipocytes from ob/ob or diet-
induced obese mice and 3T3-L1 preadipocytes demonstrated that 11β-HSD1 
overexpression increased iNOS, IL-6 and MCP-1 expression and stimulated NF-κB 
and MAPK signalling pathways (reversible with carbenoxolone and a selective 11β-
HSD1 inhibitor) resulting in potentiation of inflammation - in complete contradiction 
to its traditional anti-inflammatory properties (Ishii-Yonemoto et al., 2010). Whether 
a similar mechanism occurs in persistent inflammatory disorders remains to be 
investigated. 
5.1.5.3 Potential benefits of 11β-HSD1 inhibitors in skin 
Finally, local GC regeneration inhibitors may also have applications in skin disease. 
Diminished rates of wound healing are a common clinical finding in diabetic subjects, 
leading to debilitating complications particularly in the lower extremities. In one 
study, diabetic rats displayed classic symptoms of decreased wound healing ability 
including reductions in fibroplasia, neovascularisation, inflammatory cell numbers, 
skin mound tensile strength, PVA sponge hydroxyproline content, and the levels of 
mRNA transcripts for type I and III collagen. These symptoms were reversed by 
insulin therapy and, interestingly, by surgical amelioration of GC signalling through 
adrenalectomy or pharmacological inhibition following treatment with the GR 
antagonist RU486 (Bitar et al., 1999). Interestingly, GC treatment induces cleavage of 
PARP (demonstrating increased activity during diabetic neuropathy) during GC-
mediated apoptotic cell death (Robertson et al., 1997) suggesting decreased sensitivity 
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to GC-mediated regulation of PARP could be involved in the aetiology of diabetic 
neuropathy although this remains to be investigated. 
Furthermore, the inhibitory effect of GC on angiogenesis was reversed with RU486 in 
subcutaneously implanted polyurethane sponges, healing surgical wounds and in the 
myocardium of mice (Small et al., 2005).  
Moreover, 11β-HSD1 knockout mice showed enhanced angiogenesis in vitro and in 
vivo within sponges, wounds, and infarcted myocardium (Small et al., 2005), 
suggesting that amelioration of locally produced GC may improve healing of 
ischaemic or injured tissue through stimulation of angiogenesis. 
5.2 Aims 
Alterations in availability of GC in the extracellular milieu of skin are known to 
adversely affect several aspects of normal tissue homeostasis such as the inhibition of 
wound healing. Our previous data suggests that levels of 11β-HSD1 mRNA and 11β-
HSD oxoreductase activity increase as a function of donor age in primary cultures of 
HDF and whole biopsy skin tissue explants, leading to an possible increase in the 
local availability of active GC. Furthermore, this effect was also shown to be apparent 
in donor-matched PE compared to PP samples in both young and old subjects, 
suggesting that increased local GC production may be a common mediator of changes 
in skin integrity and function in both ageing and photo-ageing. Moreover, wound 
healing is also known to be reduced in ageing skin, although the underlying 
mechanisms remain unclear. 
Whilst the GC regulation of several target genes in skin has been previously 
investigated, particularly in response to supraphysiological concentrations of potent, 
synthetic GC, the potential for this to occur at pre-receptor level with physiological 
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concentrations of endogenous GC has not. Our studies therefore aimed to 
determine whether modulation of 11β-HSD1 activity with the use of specific 
inhibitors could regulate the expression of GC target genes at a pre-receptor 
level. 
As we demonstrated levels of 11β-HSD1 activity to increase with chronological and 
extrinsic ageing in human skin tissue explants, we aimed to examine possible 
associations between 11β-HSD oxoreductase activity in these samples and 
expression of GC target genes that may partly explain the age-related alterations in 
skin integrity and function. 
Finally, while studies have reported GC-mediated changes in the expression of genes 
such as collagen, MMPs and TIMPs, the regulation of other important genes involved 
in collagen biosynthesis and structural organization (see Section 5.1.2) - a feature of 
skin that is known to be greatly affected during ageing - has not been addressed. 
Furthermore, the effect of GC on many genes involved in the maintenance and 
regulation of skin tissue homeostasis (see Section 5.1.3) also remains to be 
investigated. Our studies therefore aimed to identify novel GC target genes 
involved in these processes through which alteration in pre-receptor modulation 
of local GC availability may affect skin architecture and function during ageing. 
5.3 Materials and Methods 
5.3.1 Sample preparation and culture 
Human skin tissue biopsies and HDF were prepared according to section 2.1. HDF 
were treated with cortisol according to section 3.3.1.2. For pre-receptor regulation of 
target gene expression, HDF and skin tissue biopsies were incubated with 100nM 
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cortisone for 72h with/without 1μM the 11β-HSD1-specific inhibitor LJ2 (PF-877423, 
Pfizer, New York, USA). 
5.3.2 Real-time PCR gene expression 
RNA extraction, reverse transcription and qPCR were conducted according to section 
2.3, using the primers and probes described in section 3.3.2 and the following 
(Applied Biosystems, California, USA): 
Human: COL1A1 (Hs00164004_m1), COL3A1 (Hs00943809_m1), MMP1 
(Hs00899658_m1), TIMP1 (Hs00171558_m1) and IGFBP5 (Hs00181213_m1) 
5.3.3 Fluidigm BioMark targeted gene expression array 
5.3.3.1 Principle 
The BioMark system (Fluidigm, California, USA) uses a cDNA sample and gene 
expression assay starting volume of 5μl (loaded on opposing sides of the chip), and 
distributes these in nanoliter volumes across individual reaction chambers on a central 
Integrated Fluidic Circuit (IFC) such that each sample can be assayed for each gene. 
Up to 96 samples and standard TaqMan gene expression assays (Applied Biosystems, 
California, USA) can be loaded, enabling up to 9216 qPCR reactions per run. 
Due to the micro-volumes involved, specific target amplification is required to detect 
target gene expression. 
5.3.3.2 Methods 
RNA extraction and reverse transcription were conducted according to sections 2.3.1, 
2.3.2 and 2.3.3. 
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Specific target amplification: conducted in 5μl volumes consisting of 2.5μl TaqMan 
PreAmp Master Mix (2X, Applied Biosystems, California, USA), 1.25μl pooled 
TaqMan gene expression assay (1μl each assay and 4μl 1X TE buffer, 0.2X final 
assay concentration) and 1.25μl cDNA (replaced with 1X TE for negative control). 
Following brief vortexing and centrifugation, reactions occurred as follows: 95ºC for 
10min, followed by 14 cycles of 95ºC for 15sec and 60ºC for 4min. Samples were 
subsequently diluted 1:5 with 20μl 1X TE buffer. Following preamplification, 1μl of 
each sample was pooled and serially diluted in 1X TE buffer (1:10, 1:100, 1:1000 and 
1:10000) for the standard curve. 
Sample Mix: Samples (in triplicate) and standards (in duplicate) were prepared for 
loading onto the chip in 8μl volumes, in a 96-well plate, by combining 4μl TaqMan 
Universal PCR Master Mix (2X), 0.4μl GE Sample Loading Reagent (20X, Fluidigm, 
California, USA) and 3.6μl preamplified cDNA/standard. Plates were vortexed, 
centrifuged and stored at 5ºC until required. 
Assay Mix: Gene expression assays were prepared in 8μl volumes (or scaled up for 
multiple chips) in a 96-well plate by combining 4μl TaqMan Gene Expression Assay 
(20X) and 4μl Assay Loading Reagent (2X, Fluidigm, California, USA), giving final 
concentrations of 9μM and 2μM for the primers and probe for each assay respectively. 
Plate was vortexed, centrifuged and stored at 5ºC until required. 
Prior to loading, chips were primed using the IFC controller according to 
manufacturer’s protocol (Fluidigm, California, USA) in order to close the interface 
valves and prevent premature mixing of samples and assays. Chips were then loaded 
(within 60min of priming) with 5μl Sample Mix and 5μl Assay Mix (leaving 3μl 
excess each), taking care not to introduce air bubbles into the inlets and loaded using 
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the IFC controller. Loaded chips were run on a BioMark qPCR reader according to 
manufacturer’s protocol (Fluidigm, California, USA). 
Following standard curve verification, ΔCt values were determined for each sample 
by normalizing to the geometric mean of 4 housekeeping genes (RPL13, TBP, B2M 
and PPIA) and the average of triplicates ΔCts calculated. 
5.3.3.3 Gene expression assays 
The following 96 human gene expression assays were used (Applied Biosystems, 
California, USA): 
Collagen biosynthesis and processing: COL1A1 (Hs00164004_m1), COL3A1 
(Hs00943809_m1), PEPD (Hs00944654_m1), LEPRE1 (Hs00223565_m1), PLOD1 
(Hs00609368_m1), PLOD2 (Hs00168688_m1), PLOD3 (Hs00153670_m1), 
LEPREL1 (Hs00216998_m1), LEPREL2 (Hs00204607_m1), P4HA1 
(Hs00914594_m1), P4HA2 (Hs00990001_m1), P4HA3 (Hs00420085_m1), P4HB 
(hs00168586_m1), SERPINH1 (Hs00241844_m1), LOX (Hs00184700_m1), LOXL1 
(Hs00935937_m1), LOXL2 (Hs00158757_m1), LOXL3 (Hs01046945_m1), LOXL4 
(Hs00260059_m1), ADAMTS2 (Hs00247973_m1), BMP1 (Hs00986789_m1), DCN 
(Hs00754870_s1), MMP1 (Hs00899658_m1), MMP2 (Hs01548727_m1), MMP3 
(Hs00968305_m1), MMP8 (Hs01029057_m1), MMP10 (Hs00233987_m1), MMP12 
(Hs00899662_m1), MMP13 (Hs00233992_m1), TIMP1 (Hs00171558_m1), TIMP2 
(Hs00234278_m1), TIMP3 (Hs00165949_m1), TIMP4 (Hs00162090_m1) 
Structural components: HAS1 (Hs00987418_m1), HAS2 (Hs00193435_m1), HAS3 
(Hs00193436_m1), HYAL1 (Hs00201046_m1), HYAL2 (Hs00186841_m1), HYAL3 
(Hs00185910_m1), HYAL4 (Hs00202177_m1), HYALP1 (Hs00395402_m1), 
SPAM1 (Hs00162139_m1), FBN1 (Hs00171191_m1), FBN2 (Hs00266592_m1), 
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ELN (Hs00355783_m1), HSD17B7 (Hs00996127_m1), VIM (Hs00185584_m1), 
MYH11 (Hs00224610_m1) 
Stress response: NR3C1 (Hs00353740_m1), HSD11B1 (Hs01547870_m1), 
HSD11B2 (Hs00388669_m1), H6PD (Hs00188728_m1), GSTM1 (Hs01683722_gH), 
GSTT1 (Hs00184475_m1), HSF1 (Hs00232134_m1), HSPB1 (Hs03044127_g1), 
SOD1 (Hs00533490_m1), SOD2 (Hs00167309_m1), SOD3 (Hs00162090_m1), 
HMOX1 (Hs01110250_m1), SIRT1 (Hs01009006_m1), NFE2L2 (Hs00232352_m1) 
AP-1 signalling: FOSB (Hs00171851_m1), FOSL1 (Hs04187685_m1), FOSL2 
(Hs00232013_m1), DUSP1 (Hs00610256_g1), MAPK8 (Hs00177083_m1), MAPK9 
(Hs00177102_m1), MAPK11 (Hs00177101_m1) 
Cell cycle control and growth factors: CDKN2A (Hs00923894_m1), TP53 
(Hs01034249_m1), FGF7 (Hs00384281_m1), TGFB1 (Hs00998133_m1) 
Other signalling: IGF1 (Hs01547656_m1), IGF1R (Hs00609566_m1), IGFBP1 
(Hs00426285_m1), IGFBP2 (Hs01040719_m1), IGFBP3 (Hs00181211_m1), 
IGFBP4 (Hs00181767_m1), IGFBP5 (Hs01052296_m1), IGFBP5 
(Hs00181231_m1), IGFBP6 (Hs00942697_m1), IGFBP7 (Hs00266026_m1), PPARA 
(Hs00231882_m1), PPARG (Hs00234592_m1), PPARGC1A (Hs01016724_m1), AR 
(Hs00171172_m1), ESR1 (Hs00174860_m1), ESR2 (Hs00230957_m1), PGR 
(Hs00172183_m1), CXCL1 (Hs00236937_m1) 
Housekeepers: RPL13 (Hs00744303_s1), ACTB (Hs99999903_m1), TBP 
(Hs00427621_m1), B2M (Hs00984230_m1), PPIA (Hs04194521_s1) 
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5.4 Results 
5.4.1 GC regulation of target genes in HDF 
Our earlier studies demonstrated the autoregulatory positive-feedback induction of 
11β-HSD1 mRNA expression and 11β-HSD oxoreductase activity in HDF following 
GC treatment leading to increased generation and potential accumulation of cortisol in 
the cellular microenvironment (Chapter 3). Subsequently, we aimed to confirm the 
GC-mediated regulation of several known target genes; COL1A1, COL3A1, MMP1, 
TIMP1 and IGFBP5, that play key roles in the structure and/or functional properties 
of skin. Results indicated a decrease in COL1A1, COL3A1, MMP1 and IGFBP5 with 
no significant effect in TIMP1 mRNA expression (Figure 5-4). 
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S.D 0.7 1.0 2.0 1.4 1.3 
F 8.9 8.8 13.0 8.2 14.2 
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Figure 5-4 GC-regulated target gene expression in HDF. Following 100nM cortisol treatment and 
normalizing for 18S rRNA, mRNA gene expression of collagen 1 (COL1A1, n=8), collagen 3 
(COL3A1, n=6), MMP1 (n=6) and insulin-like growth factor binding protein 5 (IGFBP5, n=6) were 
downregulated whilst TIMP1 (n=6) was unaffected. Significance * = p<0.05, ** = p<0.01 and *** = 
p<0.001 
Furthermore, COL1A1 mRNA expression was inhibited even at 1nM cortisol 
concentrations, an order of magnitude lower than those required to induce 11β-HSD1 
expression (Figure 5-5). 
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ΔCt Control 1nM 10nM 100nM 
COL1A1 8.0 8.3 8.4 8.7 
S.D 0.9 0.8 0.9 1.1 
HSD11B1 24.0 23.8 22.1 21.3 
S.D 2.8 2.8 3.2 3.2 
Figure 5-5 GC dose-response effect on target gene expression. Following normalizing for 18S 
rRNA, mRNA gene expression of collagen 1 (COL1A1) and 11β-HSD1 (HSD11B1) was shown to be 
regulated in a dose-dependant manner in HDF (n=9). Treatment with 10 and 100nM cortisol 
downregulated COL1A1 expression and upregulated HSD11B1. Furthermore, 1nM cortisol was also 
able to regulate COL1A1 but not HSD11B1. Significance * = p<0.05, ** = p<0.01 and *** = p<0.001 
These results confirm the GC-mediated regulation of known GC target genes and 
indicate that differences in sensitivity to local GC concentrations may exist between 
different genes and, as suggested by the large variation in response for the same gene, 
also between different donors. 
5.4.2 11β-HSD1-specific regulation of GC target genes in HDF 
Next, we examined the possibility that these GC target genes could be regulated by 
GC at a pre-receptor level. Experiments were conducted in representative HDF from 
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one donor that displayed detectable 11β-HSD oxoreductase activity levels at baseline 
(539 ± 331 fmol cortisol/mg cells/h, n=4). Although there was considerable variation 
in 11β-HSD oxoreductase activity between experimental replicates, the resulting 
concentrations of cortisol generated following 72h incubation with 100nM cortisone 
were within the range required to regulate target gene expression (19.4 ± 11.9nM, 
n=4).  
Indeed, cortisone was shown to downregulate MMP1 and IGFBP5 to a similar degree 
as 100nM cortisol in these cells, and importantly, this regulation was prevented by co-
incubation with the 11β-HSD1-specific inhibitor LJ2 (Figure 5-6). However, 
cortisone failed to replicate the cortisol-induced downregulation of COL3A1, whilst 
COL1A1 and TIMP1 did not respond to cortisol treatment in these cells (Figure 5-6), 
again possibly reflecting the variation in response to GC between different donors. 
0
0.5
1
1.5
2
2.5
3
Cortisol Cortisone Cortisone +LJ2
F
o
ld
-c
h
a
n
g
e
 (
m
R
N
A
) 
re
la
ti
v
e
 
to
 u
n
tr
e
a
te
d
 c
o
n
tr
o
l
*
***
**
COL1A1 COL3A1 MMP1 TIMP1 IGFBP5
*
F
o
ld
-c
h
a
n
g
e
 (
m
R
N
A
) 
re
la
ti
v
e
 
to
 u
n
tr
e
a
te
d
 c
o
n
tr
o
l
 
ΔCt COL1A1 COL3A1 MMP1 TIMP1 IGFBP5 
C 7.7 8.2 12.3 9.5 13.8 
S.D 0.7 0.3 0.3 0.4 1.1 
F 8.3 9.2 14.5 9.9 19.3 
S.D 0.6 0.1 1.9 0.6 0.9 
E 7.6 8.3 13.8 9.3 18.0 
S.D 0.8 0.4 1.2 0.7 1.9 
E+LJ2 8.1 7.8 11.9 9.1 13.9 
S.D 0.2 0.8 0.4 0.7 0.6 
Figure 5-6 11β-HSD1-specific regulation of GC target gene expression. Following 72h incubation 
with 100nM cortisone and normalizing for 18S rRNA (n=3), MMP1 and IGFBP5 mRNA expression 
was downregulated to a similar extent to that seen following 100nM cortisol treatment. No regulation 
was observed following co-incubation of cortisone with the 11β-HSD1-specific inhibitor LJ2. 
Significance * = p<0.05 and ** = p<0.01 
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5.4.3 Novel GC target genes in HDF 
As our results demonstrated that previously known GC target genes (e.g. MMP1) are 
capable of regulation through modulation of 11β-HSD oxoreductase activity, 
subsequent studies used a targeted gene expression array approach to investigate the 
GC regulation of other potential GC targets involved in maintenance of dermal 
integrity and homeostasis in HDF. The selected candidates included proteins involved 
in collagen maturation (e.g. endopeptidases, decorin), collagen structural organization 
(e.g. prolidase, prolyl 3- and 4-hydroxylases, lysyl oxidases and hydroxylases), 
collagen degradation (e.g. MMPs and TIMPs), other structural components (e.g. 
fibrillin, elastin, hyaluronic acid synthases), stress response components (e.g. 
superoxide dismutases, heat shock proteins) and dermal signalling molecules (e.g. 
TGF-β, KGF/FGF7, MAPKs). Furthermore, a set of known GC-regulated genes were 
included as internal controls (e.g. 11β-HSD1, MMP1, COL1A). 
Following treatment with 100nM cortisol, the mRNA expression of 24 genes was 
downregulated. The majority of these were genes involved in collagen biosynthesis, 
maturation and organization - including 5/5 lysyl oxidases which catalyze collagen 
cross-link formation, 4/7 prolyl hydroxylases involved in stabilization of newly 
formed procollagen triple helices and 2/3 lysyl hydroxylases responsible for the 
formation of hydroxylysine residues required for effective collagen crosslinking 
(Figure 5-7). Furthermore, expression of the collagen chaperone hsp47 (SERPINH1) 
was also downregulated by GC treatment. The internal controls reported a decrease in 
GR-α (NR3C1), COL1A1, MMP1 and IGFBP5 expression as expected from our 
earlier studies. In addition, mRNA expression of a further 15 genes was upregulated 
by GC treatment (Figure 5-8).  
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ΔCt VIM IGFBP3 LOX TIMP3 COL1A1 P4HB LOXL2 LOXL1 SERPINH1 IGFBP5 HAS2 FGF7 
C -6.7 -6.5 -5.2 -3.4 -2.8 -2.4 -1.8 -1.5 -1.4 -1.0 -1.0 -0.9 
S.D 0.2 0.6 0.3 0.6 0.5 0.3 1.1 0.6 0.6 2.5 0.9 0.7 
F -6.0 -5.6 -4.7 -2.1 -2.0 -2.1 -1.0 -0.6 -1.1 0.4 1.1 -0.2 
S.D 0.6 0.4 0.4 0.9 1.0 0.2 0.9 0.8 0.6 2.6 0.9 0.7 
 
P4HA2 PLOD1 NR3C1 MAPK9 LOXL4 PLOD2 LEPREL2 LOXL3 LEPREL1 IGF1 IGFBP1 MMP1 
-0.7 -0.3 0.0 1.0 1.3 1.5 2.6 4.5 4.6 7.6 10.2 12.6 
0.4 0.3 0.1 0.3 0.5 1.1 0.3 0.9 0.9 2.2 1.1 1.7 
-0.1 0.0 1.0 1.4 2.1 2.5 3.1 5.3 6.6 8.8 12.0 14.1 
0.3 0.3 0.6 0.3 0.4 0.4 0.4 0.8 0.9 2.0 1.3 0.9 
Figure 5-7 Genes downregulated by GC treatment of HDF. Following 100nM cortisol treatment (F) 
and normalizing for housekeeper gene expression, 24 genes were found to be downregulated in HDF 
(n=6) relative to untreated controls (C). These included a large proportion of collagen biosynthesis 
regulators and remodelling enzymes (orange bars). Genes listed in order of increasing baseline 
expression as detailed in the table. Significance * = p<0.05, ** = p<0.01 
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ΔCt HSPB1 DUSP1 ELN SOD2 IGF1R DCN IGFBP2 
C -2.6 -1.6 -0.5 -0.2 -0.1 0.0 1.3 
S,D 0.5 0.4 0.9 1.0 0.3 0.7 1.5 
F -3.3 -2.5 -1.5 -1.7 -0.3 -1.2 0.1 
S.D 0.5 0.7 0.8 1.0 0.3 0.5 0.9 
 
HSD11B1 FBN2 AR TIMP4 PPARGC1 HAS1 FOSB MMP8 
5.2 5.3 6.2 8.1 10.2 12.3 13.0 15.5 
1.1 0.9 1.0 0.6 1.0 2.1 0.9 1.9 
3.9 3.8 5.3 6.3 8.6 10.4 11.1 14.0 
0.3 0.6 1.4 0.6 1.6 2.1 1.8 1.7 
Figure 5-8 Genes upregulated by GC treatment of HDF. Following 100nM cortisol treatment (F) 
and normalizing for housekeeper gene expression, 15 genes were found to be upregulated in HDF 
(n=6) relative to untreated controls (C). Genes listed in order of increasing baseline expression as 
detailed in the table. Significance * = p<0.05, ** = p<0.01 
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The function of these genes was more variable, ranging from stress response 
resistance (e.g. HSPB1, DUSP1, SOD2) to signalling modulators (AR, PPARGC1, 
FOSB) and collagen remodelling enzymes (DCN, TIMP4, MMP8). Surprisingly, 
expression of elastin (ELN), fibrillin (FBN2) and the hyaluronic acid synthesis 
enzyme HAS2 was also upregulated - suggesting that these structural proteins may 
not be as susceptible to GC-induced atrophy as the collagens. Again, as shown in our 
previous studies expression of 11β-HSD1 (HSD11B1) was upregulated by GC 
treatment and served as a positively regulated internal control for the arrays. 
5.4.4 11β-HSD1-specific regulation of GC target genes in human skin 
ex vivo 
Our results have shown that 11β-HSD oxoreductase activity increases with ageing and 
photo-ageing in human skin and that GC are capable of modulating a range of target 
genes, including at a pre-receptor level in HDF. Subsequently, we investigated the 
possibility that increased 11β-HSD oxoreductase activity in human skin may have a 
direct effect on GC target genes through 11β-HSD1 and that this may contribute to the 
pathological consequences of skin ageing and photo-ageing. 
Using the same targeted gene expression array employed for the in vitro studies 
described above, we examined the relationship between 11β-HSD oxoreductase 
activity and expression of GC target genes in tissue-matched 100nM cortisone-treated 
human skin biopsies. Our results revealed a correlation between enzyme activity and 
target gene expression in several genes including the lysyl oxidase LEPREL1 which 
was found to decrease with increasing enzyme activity (n=16, r
2
=0.36, p<0.05, Figure 
5-9). 
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Figure 5-9 11β-HSD oxoreductase activity associates with gene expression in cortisone-treated 
human skin biopsies. Following 100nM cortisone treatment and normalizing for housekeeper gene 
expression, mRNA expression of LEPREL1, MMP10 and MMP12 (involved in collagen processing 
and remodelling) and MAPK8, FOSB and FOSL1 (involve in AP-1 signalling) was found to decrease 
with increasing 11β-HSD oxoreductase activity in human skin biopsies (n=16) 
The expression of collagen remodelling MMP10 and MMP12 (n=16, r
2
=0.26, p<0.05 
and r
2
=0.40, p<0.01 respectively, Figure 5-9), AP-1 complex regulatory proteins 
MAPK8, FOSB and FOSL1 (n=16, r
2
=0.31, p<0.05, r
2
=0.32, p<0.05 and r
2
=0.43, 
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p<0.01 respectively, Figure 5-9) and stress resistance genes DUSP1, HMOX1, SIRT1 
and NFE2L2 (n=16, r
2
=0.30, p<0.05, r
2
=0.30, p<0.05, r
2
=0.41, p<0.01 and r
2
=0.48, 
p<0.01 data not shown) displayed a similar association between increased enzyme 
activity and decreased mRNA expression. Conversely, mRNA expression of the 
antioxidant enzyme SOD3, oestrogen receptor ESR1 and the GC inactivating enzyme 
HSD11B2 (n=16, r
2
=0.25, p<0.05, r
2
=0.41, p<0.01 and r
2
=0.34, p<0.05 respectively) 
was found to increase with increasing 11β-HSD oxoreductase activity (data not 
shown). 
5.5 Discussion 
The ability of GC to downregulate collagen mRNA expression is widely accepted as a 
fundamental component of the resultant detrimental consequences in skin following 
increased GC exposure of therapeutic origin (Slavin et al., 1994, Oikarinen et al., 
1998, Oishi et al., 2002, Nuutinen et al., 2003, Jacques et al., 2010). Furthermore, the 
endogenous GC cortisol has also been shown to decrease type 1 pro-collagen 
expression in HDF following physiological (Oikarinen et al., 1983) and 
supraphysiological (Hamalainen et al., 1985) treatment, reaching a maximal 50% 
reduction in expression attributable to decreased mRNA stability rather than reduced 
transcription.  
Consistent with these studies, we observed a dose-dependant decrease in type-1 
procollagen-α1 (COL1A1) mRNA expression, reaching ~40% downregulation 
following treatment with physiological concentrations of cortisol (100nM) in HDF. 
Our results also demonstrated a similar reduction in type 3 procollagen-α1 (COL3A1), 
supported by previous findings reporting a decrease in the propeptide of type-3 
collagen following in vivo topical or systemic GC therapy (Oikarinen et al., 1992, 
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Autio et al., 1994). Interestingly, Oishi et al. reported a greater reduction in collagen 
type-3 compared to type-1 (Oishi et al., 2002) and although we observed a similar 
trend towards a greater reduction in COL3A1 mRNA expression following GC 
treatment this was not statistically significant. 
Likewise, the reduction in the interstitial type-1, -2 and -3 collagenase (MMP1) 
expression by GC treatment has been previously identified in skin explants (Koob et 
al., 1980, Oishi et al., 2002) and dermal fibroblasts (Bauer et al., 1985). The 
mechanism for this repression has been elucidated to be strongly dependant on AP-1 
inactivation (Jonat et al., 1990, Karin and Chang, 2001), as AP-1 serves as a potent 
enhancer for collagenase expression. Our data are in support of these findings, as 
MMP1 mRNA expression was also downregulated by GC treatment in HDF. 
However, we found TIMP1 expression not to be regulated by GC treatment, in 
contrast to rodent in vivo (Oishi et al., 2002) and human dermal fibroblast studies 
(Slavin et al., 1994) which reported a decrease in expression. Alternatively, 
unpublished observations by Madlener et al. suggest that TIMP1 expression is only 
weakly regulated in dexamethasone-treated mouse models of wound healing 
(Madlener et al., 1998). These conflicting data may be attributable to differences in 
experimental model employed, GC potency and/or concentration used, but in our in 
vitro system physiological concentrations of endogenous cortisol do not significantly 
affect TIMP1 mRNA expression in HDF. 
Although GC are known to adversely affect collagen expression, the most substantial 
reductions in expression are often seen following potent topical synthetic GC 
application. Additionally, Bernstein et al. reported that although striking alterations in 
papillary dermis architecture between donor-matched PE compared to PP skin existed 
with deformed collagen fibres of varying diameters and increased elastin deposits in 
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the former (Figure 5-10), collagen gene expression remained essentially unchanged 
(Bernstein et al., 1996). This study also demonstrated that collagen protein expression 
(type-1 and type-3) is decreased in PE skin, suggesting that post-translational events, 
rather than changes in transcription, are responsible for the collagen phenotype of PE 
skin. 
 
Figure 5-10 Structural differences between PP and PE human skin. Donor-matched PP (buttock, E) 
and PE (neck, F) skin samples stained for collagen (red) and elastin (green) fibres reveal a highly 
organized structure in PP skin, with a dense band of collagen below the DEJ (*) absent from PE skin. 
The latter also contains increased deposits of elastin, although the complete lack of structure is seen. 
Scale bar 10μM. Reproduced from Bernstein et al., 1996. 
Our results also demonstrated insulin-like binding protein 5 (IGFBP5) to be regulated 
by cortisol in HDF, with >80% reduction in mRNA expression following 
physiological GC treatment, as previously demonstrated for the synthetic GC 
dexamethasone (Conover et al., 1995). Initially associated with conditions of 
excessive fibrosis such as idiopathic pulmonary fibrosis (Pilewski et al., 2005), 
IGFBP5 has been shown to induce collagen and fibronectin production and promote 
fibroblast to myofibroblast differentiation in murine skin (Yasuoka et al., 2006). 
Interestingly, increased IGFBP5 expression has been linked to HDF replicative 
senescence (Yoon et al., 2004) and our observations regarding the negative regulation 
of this gene by GC (combined with the age-related increase in GC activating 
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capability of skin) could represent a compensatory mechanism to prevent senescence-
associated fibrotic disease (Garcia et al., 2007). Additionally, IGFBP5-induced 
senescence in human umbilical endothelial cells was dependant on induction of the 
tumour suppressor p53 (Kim et al., 2007). More recently, increased IGFBP5 
expression was reported in keloid-derived HDF, which are also largely resistant to GC 
(Russell et al., 2010). 
Our earlier studies demonstrated an increased capacity for HDF from older 
individuals and from donor-matched PE compared to PP sites to generate the active 
GC cortisol through increased 11β-HSD1 mRNA expression and activity. Here, we 
investigated whether this increase is capable of specific modulation of target gene 
expression, and therefore potentially contributing to an altered GC-induced regulatory 
profile in old and PE fibroblasts. Indeed, the negative regulation of MMP1 and 
IGFBP5 by cortisol was reproduced to a comparable degree with cortisone, and 
prevented by co-incubation of cortisone with the 11β-HSD1-specific inhibitor LJ2. 
The lack of TIMP1 regulation by cortisol was also consistent with a lack of 11β-
HSD1-specific regulation.  
However, although cortisol was shown to downregulate COL1A1 and COL3A1 in a 
range of HDF strains, only COL3A1 was significantly downregulated by cortisol in 
the strain used in our inhibitor studies - although this is more likely as a result of the 
low experimental replicates rather than due to a lack of GC responsiveness. 
Furthermore, neither COL1A1 nor COL3A1 was regulated by cortisone. This may be 
attributable to a reduced sensitivity of collagen mRNA expression to the levels of 
active GC generated through 11β-HSD1 which, although predicted to be high enough 
to elicit a response in a range of fibroblast strains (COL1A1 was significantly 
downregulated by 1nM cortisol), may not be sufficient in the strain used for our 
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inhibitor studies. Dose-response experiments for MMP1 and IGFBP5 would aid in 
clarifying this issue. Nevertheless, our results provide the first evidence for 11β-
HSD1-specific regulation of GC target genes in HDF and a possible mechanism 
through which the age-related increases in GC activation capability of fibroblasts may 
impact on their ability to maintain effective homeostasis. 
As the structural organization of collagen is known to be grossly altered in skin during 
ageing and photo-ageing, arguably more so than the production of collagen itself, we 
developed a targeted mRNA expression array to investigate whether any of the 
modulators of normal collagen biosynthesis and remodelling are regulated by GC in 
HDF. Our results revealed a striking effect on many elements of the collagen 
biosynthesis pathway following treatment with physiological concentrations of 
cortisol (Figure 5-11). In addition to downregulation of previously identified collagen 
targets (COL1A1, MMP1), cortisol treatment reduced expression of 4 prolyl 
hydroxylases (LEPREL1, LEPREL2, P4HA2 and P4HB), 2 lysyl hydroxylases 
(PLOD1 and PLOD2), a collagen chaperone (SERPINH1) and all 5 lysyl oxidases 
(LOX, LOXL1, LOXL2, LOXL3 and LOXL4). 
The regulation of prolyl hydroxylase by GC in skin was previously limited to studies 
in rats demonstrating a decrease in activity (Cutroneo and Counts, 1975, Benson and 
Luvalle, 1981). Recently, Vranka et al. characterized the phenotype of the prolyl 3-
hydroxylase 1 (LEPRE1) null mouse which, in addition to bone and tendon 
abnormalities displayed differences in skin architecture including a less densely 
packed dermis with fewer collagen fibrils in the skin of newborn knockout mice and 
skin thinning in the knockout adult containing clumped areas of collagen fibrils with 
some gaps and spaces in between collagen fibrils absent in the WT controls.  
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Figure 5-11 GC treatment affects multiple elements of the collagen biosynthesis pathway in HDF. In 
addition to the widely accepted downregulation of collagen transcription e.g. COL1A1 and COL3A1 
and collagen degrading enzymes e.g. MMP1, MMP9 (black crosses), our studies identified novel GC 
targets in collagen biosynthesis involving a reduction in post-translation hydroxylation enzymes 
LEPREL1, LEPREL2, P4HA2, P4HB, PLOD1 and PLOD2, the collagen chaperone hsp47 
(SERPINH1) and all lysyl oxidase enzymes LOX, LOXL1, LOXL2, LOXL3 and LOXL4 responsible 
for inter- and intra-fibril cross-link formation (red crosses). Modified from Chen and Raghunath, 2009 
These findings are echoed by mutations in LEPRE1 in humans which cause a 
recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta 
(Cabral et al., 2007), with patients also exhibiting overmodification of type I 
procollagen chains in dermal fibroblast cultures from affected individuals (Willaert et 
al., 2009). Prolyl 4-hydroxylase downregulation by GC in HDF is another novel 
finding. This enzyme is also critical in the correct folding of newly synthesized 
collagen propeptides, which are retained in the ER in the case of vitamin C deficiency 
- as vitamin C is an essential co-factor for the enzyme (Walmsley et al., 1999). 
Likewise, lysyl hydroxylase regulation by GC in HDF has not previously been 
reported. However, a deficiency in the activity of this enzyme (PLOD1) is known to 
cause Ehlers Danlos syndrome type VI characterized by neonatal kyphoscoliosis, 
generalized joint laxity, skin fragility, and severe muscle hypotonia at birth (Yeowell 
and Walker, 2000). Alternatively, mutations in PLOD2 cause Bruck syndrome (van 
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der Slot et al., 2003), which particularly affects bone collagen cross-linking (Bank et 
al., 1999), although PLOD2 overexpression has also been linked to skin fibrosis (van 
der Slot et al., 2003). More recently, a mutation in the third lysyl hydroxylase 
isozyme has been described (Salo et al., 2008) which features thin skin and blistering 
components of disease manifestation. 
GC-induced downregulation of SERPINH1 has been reported for primary human lung 
fibroblasts (Goulet et al., 2007) and we provide additional evidence that this is also 
the case for HDF. Hsp47 monitors the integrity of the triple helix of type I 
procollagen at the ER/cis-Golgi boundary and, when absent, the rate of transit from 
the ER to the Golgi is increased and helical structure is compromised as seen in 
patients deficient in SERPINH1 who present with an additional severe variant of 
osteogenesis imperfecta, although lacking a skin phenotype (Christiansen et al., 
2010). 
Our results indicated a decrease in all lysyl oxidase isozyme mRNA expression 
following GC treatment in agreement with previous rodent studies reporting a 
decrease in enzyme activity after local GC administration (Benson and Luvalle, 
1981), although a more recent study failed to record any effect on mRNA expression 
in human skin following in vivo treatment with the potent synthetic GC 
betamethasone-17-valerate (Oikarinen et al., 1998). Decreased lysyl oxidase activity 
has been identified as a cause of another Ehlers Danlos syndrome variant - type IX 
and with the clinically distinct Menkes syndrome both involving skin laxity and 
hyperextensibility (Kiuvaniemi et al., 1985). 
Collectively, the identification of these regulators of collagen biosynthesis as novel 
GC targets in HDF raises the possibility that altered local GC availability could 
contribute to several aspect of altered collagen structural organization in ageing skin. 
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Our results demonstrate that hyaluronan synthase 2 (HAS2) exhibited the strongest 
inhibition in expression following GC treatment of HDF. Although previous groups 
have demonstrated the ability of dexamethasone to inhibit this enzyme in HDF 
(Zhang et al., 2000) and in vivo human skin (Gebhardt et al., 2010), providing a 
mechanism through which GC inhibit hyaluronic acid production, our data provide 
additional evidence that physiological concentrations of endogenous GC have the 
same effect. Moreover, IGF-1 has been identified as a positive regulator for HAS-2 
(Kuroda et al., 2001) and our studies demonstrated negative regulation of this growth 
factor by cortisol, potentially identifying part of the mechanism through which GC 
inhibit HAS2 expression.  
The cytoskeletal microfilament vimentin was also downregulated by cortisol in our in 
vitro studies. Previous reports into the GC-mediated regulation of this highly 
expressed structural protein are lacking, however a global knockout mouse model 
failed to detect any morphological differences in the absence of vimentin compared to 
WT control animals, including skin (Colucciguyon et al., 1994) and remarkably even 
during induction of skin remodelling following wounding. Furthermore, a recent 
study revealed a stiffening in HDF derived from older donors characterized by a shift 
from monomeric G-actin to polymerized, filamentous F-actin, but no significant 
changes in the vimentin content (Schulze et al., 2010), suggesting that the modest 
decrease in vimentin following GC treatment we observed is unlikely to contribute to 
any phenotypic modification in skin structural properties during ageing. However, 
further detailed analyses reported significant defects in wound healing (Eckes et al., 
2000) and endothelial cell stability (Nieminen et al., 2006). Vimentin glycation has 
also been implicated recently in the skin ageing process (Kueper et al., 2007), and the 
role GC play (if any) in this modification also remains to be elucidated. 
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Although GC-mediated IGF-1 regulation in HDF is previously unreported, a reduction 
in IGF-1 signalling in senescent fibroblasts in vitro and geriatric dermis has been 
suggested to contribute to an inappropriate UVB response by epidermal keratinocytes 
that may lead to an increased risk of ageing-related non-melanoma skin cancer (Lewis 
et al., 2010). In addition to IGF-1, we found other element of the IGF-1/IGF-1R 
signalling axis to be negatively regulated by cortisol in HDF, namely IGFBP-3 and 
IGFBP-1. These results are in support of previous findings reporting dexamethasone-
induced downregulation of IGFBP-3 in human fibroblasts (Conover et al., 1995). 
IGFBP-3 is similar to IGFBP-5 in its pro-fibrotic functions (Pilewski et al., 2005) 
although IGF-independent functions in processes including retinoid X receptor alpha-
mediated apoptosis of cancer cells have been reported (Lee and Cohen, 2002). 
In addition to the potential interference in IGF signalling, KGF mRNA expression 
was also decreased by GC treatment - previously unreported in human experimental 
models. Although this may be involved in normal regulation of tissue remodelling 
shifting away from the early signalling required for re-epithelialisation, increased 
local GC prior to wounding may be detrimental to initiation of the healing process 
(Ishimoto and Ishibashi, 2002, Mercado et al., 2002). Additionally, we demonstrated 
downregulation of the AP-1 regulatory kinase MAPK9 (which phosphorylates c-Jun) 
following GC treatment in HDF, suggesting that this signalling pathway is also 
affected by GC treatment in skin - although previously not investigated. As c-Jun/AP-
1 signalling is implicated in the early stages of wound healing (Angel et al., 2001), 
preceding the anti-inflammatory GC response, GC-induced repression of c-Jun may 
be involved in the normal progression of tissue repair. As c-Jun/AP-1 signalling is 
known to positively regulate KGF secretion by mesenchymal cells, the 
downregulation of c-Jun by cortisol we observed may be responsible, in part, for the 
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concomitant decrease in KGF. Moreover, AP-1 activation is strongly implicated in 
MMP activation - potentially explaining the decrease in MMP1 observed in our in 
vitro studies. Interestingly, the GC-induced suppression of c-Jun phosphorylation and 
concomitant reduction in AP-1 activity was absent in the skin biopsies from 
corticosteroid-resistant asthmatics (Sousa et al., 1999). 
Our studies also identified several genes upregulated by cortisol in HDF. In contrast 
to the strikingly negative regulation of collagen biosynthesis, the mRNA expression 
of other structural components including elastin, decorin and fibrillin-2 was increased 
by GC treatment. Human elastin promoter activity activation by GC has been 
demonstrated in the skin of transgenic mice and in primary dermal fibroblasts isolated 
from these animals (Ledo et al., 1994). However, our results oppose previous reports 
demonstrating decreased elastin expression by dexamethasone in HDF (Kahari, 1994, 
Russell et al., 1995), a discrepancy potentially due to cells being obtained from 
different anatomical sources. Fibrillin is known to associate with elastin, and our 
results demonstrate an increase in fibrillin-2 expression, although GC-mediated 
fibrillin regulation was previously unknown. Our results support previous findings 
describing an increase in decorin mRNA expression following dexamethasone 
treatment (Kahari et al., 1995). In contrast to HAS-2, we found HAS-1 mRNA 
expression to increase following cortisol treatment, although as this isozyme is less 
active and expressed at much lower levels than HAS-2 (Itano et al., 1999, Zhang et 
al., 2000) it is unlikely to be able to compensate for the decrease in HAS-2 
expression. Regulators of collagen remodelling MMP8 and TIMP4 were also 
positively regulated by cortisol treatment in our study. Although traditionally 
perceived as a neutrophil-specific derived collagenase, MMP8 production by HDF has 
also been reported (Reuben et al., 2001). The levels of expression we detected were 
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relatively low; however, the previously unreported GC-induced increase in expression 
may contribute to increased collagen-I and -III degradation. TIMP4 is a potent 
inhibitor of MMP2 (Bigg et al., 2001) - a type IV collagenase associated with primary 
skin melanoma (Vaisanen et al., 1998). Our results reveal a previously unreported ~4-
fold increase in TIMP4 mRNA expression following cortisol treatment, suggesting 
that GC may exhibit anti-tumorigenic properties by limiting MMP2 activity in HDF. 
In contrast to the inhibitory effects on c-Jun (via MAPK9 downregulation), the AP-1 
component FosB was upregulated by cortisol treatment in HDF. However, whilst an 
active AP-1 complex can form from Jun homodimers, Fos proteins can only form 
active transcription AP-1 complexes as heterodimers with Jun proteins and thus the 
GC-induced increase in FosB is unlikely to result in increased AP-1 signalling 
although alterations in target gene expression resulting from increased AP-1 
heterodimer availability cannot be excluded. Other genes involved in cell signalling 
upregulated following cortisol treatment included PPARGC1, a transcription factor 
co-activator protein - including for the GR (Knutti et al., 2000) - known to potentiate 
GC signalling (Jang et al., 2007) and the androgen receptor, shown to form 
heterodimers with the GR, possibly resulting in mutual inhibition of transcriptional 
activity and thus limiting GC signalling (Chen et al., 1997). Alternatively, androgen 
receptor signalling is thought to suppress wound healing (Lai et al., 2009) and may 
therefore act in synergy with GC signalling. This is supported by observation that 
cutaneous wounds heal more slowly in elderly males than in elderly females (Ashcroft 
and Mills, 2002) and that castrated male rats display beneficial wound healing profiles 
compared to WT controls (Gilliver et al., 2007). 
Finally, several genes involved in stress resistance were also upregulated by cortisol 
treatment in HDF. Manganese superoxide dismutase (SOD2) is an important 
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antioxidant enzyme that attenuates oxidative free radicals in the mitochondria by 
catalyzing the formation of hydrogen peroxide from superoxide radicals. Although the 
GC-mediated regulation of SOD2 mRNA expression in HDF has not been 
investigated to date, recent studies strongly implicate this antioxidant enzyme in the 
ageing process with fibroblast-specific null mice exhibiting several phenotypic traits 
associated with premature ageing (Treiber et al., 2011). Furthermore, the ability of 
SOD2 to reduce mitochondrial oxidative stress by de-activating superoxide suggests 
this enzyme also possesses tumour-suppressing functions (van Remmen et al., 2003, 
Trimmer et al., 2011). Intriguingly, recent proteomic studies implicate SOD2 
overexpression in fibroblast senescence and skin ageing (Ferchiu et al., 2011) - 
suggesting, as is often the case in biological systems, that regulatory molecules 
function optimally within a defined range of expression. The stress-induced hsp27 
(HSPB1) has been implicated in wound healing (Laplante et al., 1998) and more 
specifically, fibroblast-mediated wound contraction (Hirano et al., 2002). Although 
the regulation by GC in HDF has not previously been examined, our observation that 
GC treatment induces a modest increase in mRNA expression suggests that GC may 
also be involved in modulating these processes through HSPB1. We also observed an 
increase in mRNA expression of the dual specificity phosphatase (DUSP1) which 
dephosphorylates (and inactivates) the MAP kinases ERK2 and p38 (Abraham and 
Clark, 2006). Amongst other regulatory functions, ERK2 and p38 are upstream 
activators of c-Fos and c-Jun transcription respectively, in addition to phosphorylating 
(and activating) assembled AP-1 complexes, suggesting DUSP-1 is a central GC 
target involved in decreased AP-1 signalling in HDF (Figure 5-12). 
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Figure 5-12 GC treatment affects multiple elements of the AP-1 signalling pathway in HDF. Our 
studies identified novel GC targets in AP-1 signalling involving a reduction in the MAP kinase JNK-2 
(MAPK-9) and an decrease in the MAPKs ERK-2 and p38 by upregulating their inactivating 
phosphatase DUSP-1. These kinases are also involved in phosphorylation (and activation) of AP-1 
complexes once formed suggesting their inactivation by GC (red crosses) are likely to decrease the 
expression of AP-1 target genes. Modified from Eferl and Wagner, 2003 
Although GC are known to inhibit MAPK expression (Clark and Lasa, 2003) and 
DUSP-1 potentiation by GC has been described for a variety of tissues and cell types 
including HeLa cells (Lasa et al., 2002), mast cells (Jeong et al., 2003), adipocytes 
(Bazuine et al., 2004), osteoblasts (Engelbrecht et al., 2003), breast and lung 
epithelial cells (Wu et al., 2005, Hermoso et al., 2004), T-lymphocytes (Li et al., 
2006), rheumatoid synovial fibroblasts (Toh et al., 2004) and myeloid cells (Abraham 
et al., 2006), our results demonstrate that this is also true for HDF. Having identified 
several new GC target genes in HDF that may interfere not only with fibroblast 
function, but affect whole skin tissue biology by disrupting mesenchymal-epidermal 
cross-talk, we investigated whether any of the implicated pathways were also affected 
in human skin biopsies ex vivo as a function of 11β-HSD oxoreductase activity. 
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Remarkably, we identified several genes that displayed a significant negative 
correlation with 11β-HSD oxoreductase levels including LEPREL1 - supporting our 
earlier observations in HDF.  
mRNA expression of other genes involved in collagen remodelling found to be 
downregulated as a function of enzyme activity included the proteoglycan- and 
fibronectin-degrading stromelysin-2 (MMP10) and the elastase MMP12 which were 
also downregulated by cortisol treatment in our in vitro studies although not quite 
reaching statistical significance. In contrast to our (previously unreported) 
observations in human skin and HDF, MMP10 expression was increased by GC 
treatment in a mouse model of wound healing (Madlener et al., 1996, Galluci et al., 
2001) although high expression in human skin has been associated with certain skin 
cancers (Kerkela et al., 2001, Fernandez-Figueras et al., 2007, Boyd et al., 2009), 
further endorsing the potentially anti-tumorigenic properties of GC. Alternatively, 
MMP10 also plays an important role in wound healing (Krampert et al., 2004) 
identifying stromelysin-2 as another target through which GC impede this vital 
function of skin. Similarly, MMP12 activity is also important in the wound healing 
process but, in contrast to MMP10, has also been reported to be downregulated by GC 
treatment in murine excisional skin wounds (Madlener et al., 1996). Additionally, our 
results provide the first evidence that this may also the case in human skin and dermal 
fibroblasts. Although traditionally expressed in macrophages, MMP12 has also been 
implicated in carcinogenesis, with increased expression in transformed keratinocytes 
in cutaneous squamous cell carcinoma (Kerkela et al., 2000). 
In support of our in vitro studies, elements of the AP-1 signalling pathway are also 
negatively correlated with 11β-HSD oxoreductase levels in human skin biopsies, 
specifically, the MAP kinase JNK1 (MAPK8) and the AP-1 heterodimer components 
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Fra-1 (FOSL1) and FosB which have not previously been described as GC targets in 
skin. Moreover, these elements were not regulated in HDF, or in the case of FosB, 
differentially regulated compared to the whole skin correlates - suggesting that GC 
may exert different effects on differing compartments of skin, or that mesenchymal-
epidermal communication must be enabled to permit the regulation of certain GC 
targets. Indeed, keratinocytes express JNK-1 and -3 but not JNK-2 (Adachi et al., 
2003), while enhanced FOSL1 expression has recently been linked to psoriasis - a 
skin disorder primarily caused by keratinocyte hyperproliferation (Sobolev et al., 
2011). 
DUSP-1 expression was also found to be negatively associated with 11β-HSD 
oxoreductase activity, although this is in contrast with the positive regulation by GC 
observed in our HDF cultures. In addition, expression of the stress resistance genes 
for hsp32 (HMOX1), SIRT1 and the transcription activator NFE2L2 were negatively 
associated with 11β-HSD oxoreductase activity in human skin biopsies. In skin, 
HMOX1 has been shown to be involved in the adaptive response to UVA-induced 
oxidative stress in HDF (Vile et al., 1994), with our studies suggesting GC may 
interfere with this response rendering skin enriched in local GC concentrations more 
vulnerable to the damaging effects of photo-exposure. The histone deacetylase SIRT1 
has been shown to inhibit GR binding to GREs in target genes (Amat et al., 2007); 
therefore the 11β-HSD oxoreductase activity-associated decrease in SIRT1 mRNA 
expression may serve as a mechanism to potentiate GC regulation of target genes. 
Moreover, in keratinocytes, SIRT1 exerts anti-proliferative effects, antagonising IL-
22 induced effects associated with psoriasis, with decreased SIRT1 expression in 
psoriatic lesions (Sestito et al., 2011) - in this respect increased GC availability may 
promote epidermal fibrosis, consistent with increased risk of psoriasis in the elderly. 
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Although traditionally anti-inflammatory, the GC-related decrease in SIRT1 
expression may promote inflammation as SIRT1 has recently been reported to possess 
anti-inflammatory properties (Barroso et al., 2011). Collectively, evidence for the role 
of SIRT1 as an anti skin-ageing enzyme (Lee et al., 2010) is exciting in the context of 
a negative association with 11β-HSD oxoreductase activity and an increase in this 
activity with ageing and photo-ageing in skin as we have demonstrated. Finally, we 
observed a negative correlation with increasing 11β-HSD oxoreductase activity for 
the oxidative stress response gene inducer NFE2L2, also recently established to be 
involved in skin wound healing processes (Braun et al., 2002), skin morphogenesis 
and cancer (Beyer et al., 2007). 
Collectively, our functional studies demonstrate for the first time (to our knowledge) 
that GC target genes in skin can be regulated directly through modulation of 11β-
HSD1 activity. We demonstrate previously unreported GC target genes including 
those involved in collagen biosythesis and remodelling, AP-1 signalling pathway and 
stress resistance, and moreover that these genes are regulated by physiological 
concentrations of the endogenous GC cortisol in HDF, raising the possibility that 
these genes too can be modulated in an 11β-HSD1-specific manner. Finally, we 
provide preliminary evidence of an association between 11β-HSD oxoreductase 
activity levels in ex vivo human skin biopsies and the expression of novel GC target 
genes, raising the possibility that the age-related increase in GC activating potential 
we described earlier may be responsible for the modulation of key regulators of skin 
function and homeostasis - particularly in the response to stress. Results of 11β-
HSD1-specific inhibitor studies in ex vivo human skin biopsies are eagerly awaited to 
confirm the age-related 11β-HSD1-specific regulation of novel GC target genes in 
skin. 
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CHAPTER 6  11β-HSD1-NULL MOUSE DERMAL PHENOTYPE 
6.1 Introduction 
6.1.1 The 11β-HSD1 knockout mouse 
First described over a decade ago by Kotelevtsev et al., the 11β-HSD1-null mouse 
was found to resist hyperglycaemia provoked by obesity or stress despite 
compensatory, increased adrenal corticosterone production (Kotelevtsev et al., 1997), 
suggesting that intracellular regeneration of corticosterone in the tissues from inert 
circulating 11-DHC contributes more to effective intracellular corticosterone 
concentrations than plasma corticosterone itself. This study raised the notion of 11-
DHC and cortisone as pro-hormones, with plasma levels not subjected to wide diurnal 
fluctuations (Walker et al., 1992) or sequestration by corticosteroid binding globulin 
(Gayrard et al., 1996), and which may possess higher tissue specificity because they 
can act only on tissues expressing 11β-HSD1. Moreover, 11β-HSD1-null mice have a 
more favourable lipid and lipoprotein profile with improved insulin sensitivity, 
glucose tolerance and a potentially atheroprotective phenotype compared to their WT 
counterparts (Morton et al., 2001). 11β-HSD1-null mice are also resistant to diet-
induced visceral obesity (Morton et al., 2004, Wamil et al., 2011). 
Intriguingly, age-related improvements in cognitive function have also been reported 
in 11β-HSD1-null mice (Yau et al., 2001, 2011), regardless of elevated circulating 
GC levels, providing initial evidence for reversal of tissue dysfunction in aged 
animals by limiting local GC reactivation. Recently, supporting studies have provided 
evidence that 11β-HSD1 mRNA expression is indeed increased in the ageing mouse 
brain (Holmes et al., 2010). Conversely, age-related bone loss occurred at a similar 
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rate in both 11β-HSD1-null and WT mice (Justesen et al., 2004), although a similar 
increase is bone cells (osteoblasts) from aged humans has been reported (Cooper et 
al., 2002). More recently, increased GC concentration in the brain has been linked to 
alcohol consumption in rodents (Little et al., 2008), proposing a novel mechanism for 
the alcohol-induced adverse effects on brain functions (such as memory loss). 
Although direct effects of alcohol intake on 11β-HSD1 levels in the brain have not 
been investigated, the proposed mechanism is supported by other studies 
demonstrating increased hepatic 11β-HSD1 expression and activity in patients with 
alcoholic liver disease (Ahmed et al., 2008). 
Furthermore, knockout mice do not appear to display any overt adverse effects in the 
functional capacities of adult tissues examined thus far including vasculature (Hadoke 
et al., 2001), bone (Justesen et al., 2004) and skeletal muscle (Semjonous et al., 
2011). Indeed knockout animals display enhanced angiogenesis in healing surgical 
wounds and following myocardial infarction (Small et al., 2005, McSweeney et al., 
2009, 2010), offering a previously uncharacterized therapeutic approach to improve 
healing of ischaemic or injured tissue. 
However, lack of 11β-HSD1 enzyme activity appears detrimental in murine foetal 
tissue development exemplified by defects in lung maturation (Hundertmark et al., 
2002), may impede the rapid clearance of apoptotic cells during resolution of 
inflammation in adult mice (Gilmour et al., 2006, Chapman et al., 2006) and increases 
susceptibility to endotoxaemia - with increased weight loss and serum pro-
inflammatory cytokine (e.g. TNF-α, IL-6) levels - following LPS challenge (Zhang 
and Daynes, 2007). Although it appears that the majority of phenotypic consequences 
following global 11β-HSD1 inactivation are positive, a more detailed analysis is 
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required to examine potentially adverse effects particularly relating to reduced anti-
inflammatory responses subsequent to initiation of an immune response. 
6.2 Aims 
Our studies have demonstrated an increase in the GC activating capacity of human 
and murine skin from older individuals as a result of increased 11β-HSD1 mRNA 
expression and oxoreductase activity. Furthermore, in HDF and human skin biopsies 
ex vivo we provide evidence that GC target genes (including several not previously 
identified in skin) are regulated in an 11β-HSD1-specific manner, supporting our 
hypothesis that increased expression of 11β-HSD1 in older individuals may play a 
significant role in the deterioration of skin structure and function. 
Although we found several biological pathways to be regulated by GC in our 
functional studies, genes involved in collagen biosynthesis, processing and 
remodelling were identified as a cluster that may be particularly susceptible to 
negative regulation by increases in local GC concentrations. To investigate this 
further in vivo, we aimed to examine histological differences between young and 
old mouse skin in WT and 11β-HSD1-null mice, with particular attention to 
collagen expression, organization and integrity. 
6.3 Materials and methods 
6.3.1 Sample preparation and culture 
11β-HSD1-null mice were generated in-house as previously reported (Semjonous et 
al., 2011). Mouse skin tissue explants stored in 10% NBF according to section 2.2.1.2 
were paraffin embedded and sectioned by Dr Nicola Carpenter (Unilever Discover, 
Bedford, UK). 
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6.3.2 Histology 
Analysis of young and aged WT and 11β-HSD1-null mouse skin sections (n=4) 
stained with Mayer’s haematoxylin and Eosin was assisted by the late Professor 
William Parish (Unilever Discover, Bedford, UK). Slides were examined for 
epidermal and dermal integrity, collagen fibre density and assembly, dermal cell 
density and overall appearance. Dermal cell count was also determined numerically 
by counting the nuclei in a 40X magnified field of view (n=4). 
6.3.3 Collagen analysis 
Slides were stained for collagen using a Masson Trichrome kit according to 
manufacturer’s guidelines. Collagen stain intensity and epidermal thickness was 
determined using the Nuance system according to section 4.3.4.3. 
6.3.4 Real-time PCR gene expression 
RNA extraction, reverse transcription and qPCR were conducted according to section 
2.3, using the primers and probes described in sections 3.3.2 and the following 
(Applied Biosystems, California, USA): 
Mouse: COL1A1 (Mm00801666_g1) and IGFBP5 (Mm00516037_m1) 
6.4 Results 
6.4.1 Aged 11β-HSD1-null mouse skin is more comparable to that of 
young WT mice 
Histological analysis between young and aged WT mice revealed striking differences 
in dermal integrity (Figure 6-1). 
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YOUNG WT AGED WT 
Figure 6-1 Changes in mouse skin histology with age (WT). Comparison of young WT (n=4) and 
old WT (n=4) skin sections revealed a grossly altered dermal organization of collagen in the aged 
individuals with a loss of structure and tissue integrity (arrows). Scale bar = 50μm 
In the latter, the collagen network appeared “loose” with noticeable atrophy and a 
“sponge-like” appearance, characterized by large, vacant inter-fibril spaces. In some 
areas of aged tissue the collagen meshwork appeared “shredded” with little / no 
structural integrity or organization. The epidermis also appeared thinner and mostly 
one cell deep in older individuals, although these differences were much more subtle 
compared to the gross abnormalities in the dermis. 
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Strikingly, these age-related changes in dermal integrity were indistinguishable 
between young and aged 11β-HSD1-null mice, which displayed a similar histological 
skin profile (Figure 6-2), suggesting that the adverse structural modifications present 
in older skin may indeed be as a consequence of increased local GC generation via 
11β-HSD1.  
AT
 
YOUNG 11β-HSD1-null AGED 11β-HSD1-null 
Figure 6-2 Changes in mouse skin histology with age (11β-HSD1-null). In striking contrast to the 
WT animals, comparison of young 11β-HSD1-null (n=4) and old 11β-HSD1-null (n=4) skin sections 
revealed similarities in dermal organization of collagen with comparable structure and tissue integrity. 
AT, adipose tissue. Scale bar = 50μm 
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Compared to aged WT skin, aged 11β-HSD1-null sections exhibited improved dermal 
integrity, with collagen fibres adopting a more densely-packed, orderly organization. 
Independent blinded analysis by Professor William Parish (Unilever Discover, 
Bedford, UK) identified the aged knockout sections as having better integrity than the 
WT counterparts on all occasions (n=4). Moreover, an aged knockout section was 
identified as having the best overall structure, whilst an aged WT section was selected 
as exhibiting the worst atrophy (Figure 6-3). 
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Figure 6-3 Improved skin histology in aged 11β-HSD1-null mice. Striking improvement in dermal 
structural organization in aged knockout (B) compared to aged WT (A) mice that revert to a similar 
integrity as observed in young animals. AT, adipose tissue. Scale bar = 50μm 
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Histology studies also revealed fewer dermal cells in aged WT (n=4) mice compared 
to young WT (n=3) and young knockout (n=4) animals (42±12 vs. 71±19 and 89±16, 
p<0.05 and p<0.01 respectively). Interestingly, dermal cell numbers were not 
statistically different between young WT and aged knockout (n=4) mice (Figure 6-4), 
but the latter remained lower than young knockout animals (59±17 vs. 89±16, p<0.05) 
suggesting that local GC generation decreases dermal cell proliferation independently 
of age. 
 
Figure 6-4 Dermal cell count according to mouse age and genotype. Dermal cell numbers in the 
papillary dermis were reduced in aged WT (n=4) mice compared to young WT (n=3) and knockout 
(n=4) animals (42±12 vs. 71±19 and 89±16 respectively). However, aged knockout (n=4) mice 
displayed reduced cell numbers only compared to young knockout animals (59±17 vs. 89±16). 
Significance * = p<0.05, ** = p<0.01 
6.4.2 Collagen density is improved in 11β-HSD1-null mice 
Although our histological analysis provided evidence for altered dermal organization, 
collagen density was more difficult to interpret from these studies. We therefore 
repeated the analysis using Masson Trichrome staining to detect changes in collagen 
content based on the intensity of staining. Using this approach, our results indicated 
that collagen density is also increased in both young (Figure 6-5) and aged (Figure 
6-6) knockout mice compared to WT counterparts.  
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YOUNG WT YOUNG 11β-HSD1-null 
Figure 6-5 Masson trichrome staining in young WT and knockout mice. Collagen staining was more 
intense in 11β-HSD1-null mice compared to WT counterparts (n=4). Scale bar = 50μm 
Semi-quantitative analysis of the staining supported these observations, with 
increased intensity of collagen staining detected in aged knockout compared to WT 
mice (A.U, 0.15±0.05 vs. 0.07±0.02, p<0.05, n=4, Figure 6-7). 
A similar trend towards increased collagen staining intensity was also observed for 
young knockout compared to young WT mice, although this did not reach statistical 
significance (0.15±0.05 vs. 0.09±0.02, p=0.07, n=4, Figure 6-7). Surprisingly, 
collagen staining intensity did not differ between young and aged mice, suggesting 
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that the balance between collagen synthesis and degradation is not affected by age in 
mice or by the increased local GC generation in older animals. 
 
OLD WT OLD 11β-HSD1-null 
Figure 6-6 Masson trichrome staining in aged WT and knockout mice. Similarly to young mice, 
collagen staining was more intense in aged 11β-HSD1-null mice (n=4) compared to WT counterparts. 
Scale bar = 50μm 
6.4.3 Epidermal thickness 
Epidermal thickness (ET) was also analyzed and found to be similar between young 
and aged mice both WT (μm, 12.5±1.7 vs. 11.4±3.6, n=4) and knockout (11.7±1.1 vs. 
13.8±4.0, n=4) and was also comparable between age-matched WT and knockout 
animals (data not shown). However, ET was more variable in the older age groups 
(both genotypes) suggesting an age- and/or genotype-specific effect may be detectable 
by increasing the power of the study. 
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Figure 6-7 Collagen staining intensity according to mouse age and genotype. Collagen intensity was 
enhanced in aged knockout compared to aged WT mice (A.U, 0.15±0.05 vs. 0.07±0.02 n=4). A similar 
trend was observed for young knockout compared to young WT mice, although this did not reach 
statistical significance (0.15±0.05 vs. 0.09±0.02, n=4). Significance * = p<0.05 
6.4.4 qPCR expression studies 
As expected, 11β-HSD1 mRNA expression was negligible in both young (n=3) and 
aged (n=3) knockout mice (ΔCt±S.D, 18.3±0.4 vs. 22.6±2.1, p<0.05 and 17.5±1.3 vs. 
23.3±2.2, p<0.01 respectively) compared to young (n=3) and aged (n=4) WT controls 
(Figure 6-8). 
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Figure 6-8 11β-HSD1 (HSD11B1) mRNA fold-change relative to age-matched WT control. 
HSD11B1 mRNA expression was decreased in both young and aged knockout mice (n=3) compared to 
young (n=3) and aged (n=4) WT controls. Significance * = p<0.05 and ** = p<0.01 
However, no significant changes in GR-α, H6PD, COL1A1 or IGFBP5 mRNA levels 
between young WT (n=3), young knockout (n=3), aged WT (n=4) and aged knockout 
(n=4) mouse skin tissue samples were detected (data not shown). 
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6.5 Discussion 
Our preliminary studies investigating the morphological phenotype of 11β-HSD1-null 
mice revealed a striking improvement in age-related dermal atrophy. The 
manifestation of intrinsically aged murine skin has been reported, although high costs 
associated with long-term animal housing has contributed to far fewer studies 
compared to research into extrinsic ageing. A recent study evaluating changes in the 
structural properties of type 1 collagen derived from aged mice reported decreased 
fibril formation rates, diameter and density with increased malleability and 
contractility (Damodarasamy et al., 2010). These reports correlate with in vivo 
findings of increased dermal atrophy in rodent (Liang et al., 2010) and human (Varani 
et al., 2006) skin with chronological ageing. Our results are in agreement with these 
studies, describing a “loosely” packed, disorganized collagen network in aged 
compared to young WT mice. Remarkably, these morphological features 
characteristic of aged skin were absent in the 11β-HSD1-null mice, which displayed a 
dermal phenotype more comparable to that of young counterparts, supporting our 
hypothesis that increased local GC activating capacity in skin during ageing and 
photo-ageing may be directly involved in the structural and functional changes 
implicated in these processes. 
Additionally to potential enhancement of tensile properties of skin from aged 11β-
HSD1-null mice directly attributable to improvements in dermal integrity, benefits 
regarding the function of dermal fibroblasts in maintaining effective homoeostasis 
could also be investigated. Indeed, several studies have demonstrated the ability of the 
ECM microenvironment (provided by mechanical properties of young relative to aged 
collagen) to influence dermal fibroblast synthesis of molecules that regulate cell/ECM 
attachment, repair and turnover (Balas and Davidson, 2001, Varani et al., 2006, 
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Damodarasamy et al., 2010). Moreover, a “looser” ECM has been linked to improved 
tumour growth and angiogenesis in older subjects (Sprenger et al., 2008).  
Although it is still debatable whether age-related collagen breakdown results from an 
increase in MMP activity, decreases in MMP inhibition by TIMPs, or changes in 
associated proteins that modulate collagen stability (Hornebeck, 2003, Fisher et al., 
2008), there is a general consensus that collagen expression and density decreases in 
skin (and other tissues) as a function of ageing (Boyer et al., 1991, Sayama et al., 
2010). Moreover, GC are known to have the same effect as previously described. Our 
hypothesis that the increased 11β-HSD1 expression and activity with age in skin may 
contribute directly to the observed decrease in dermal collagen content is also 
supported by our initial in vivo studies demonstrating a significant increase in 
collagen staining in 11β-HSD1-null mice. This was true for aged - and displayed a 
similar trend for - young mice, suggesting that GC are involved in negative regulation 
of collagen content independently of age, and that inhibition of local GC activation 
may increase collagen production in young subjects additionally to combating the 
age-related collagen decline. 
We also observed an age-related decrease in the dermal cell content in WT mice, 
whist aged knockout animals displayed a comparable number of cells to young WT 
mice. Decreased dermal fibroblast numbers in vivo have been reported for aged skin 
(Gunin et al., 2011), with decreased proliferative potential in cells obtained from aged 
individuals in culture (Bruce and Deamond, 1991). The same effect also occurs as a 
result of GC treatment in vitro (Wach et al., 1998). Our results provide initial 
evidence supporting a link between decreased cellularity as a direct effect of local GC 
generation during ageing. Similarly to the results observed for collagen density, it 
appears that dermal cellularity may also be boosted in young knockout mice. 
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Although this was not statistically significant directly, young knockout mice exhibited 
increased cell numbers compared to aged knockouts which themselves did not differ 
from the young WT animals, suggesting the increase in age-matched young knockout 
may be resolved by improving study power. As dermal fibroblasts are the primary cell 
type responsible for collagen synthesis, the increase in collagen density in knockout 
mice may be as a result of increased fibroblast proliferation. However, analysis of 
COL1A1 mRNA expression was not significantly altered in these mice suggesting 
increased collagen synthesis may not be responsible for the increased collagen density 
observed. Furthermore, mRNA expression of IGFBP5, recently demonstrated to 
induce type 1 collagen expression in human fibroblasts (Lecca et al., 2011), was also 
unaffected by age or genotype in our mouse model. Alternatively, collagen density 
may be increased as a result of increased MMP and/or decreased TIMP expression or 
activity, resulting in inhibition of collagen degradation and we plan to investigate this 
further in our future studies. 
These studies raise the possibility that in addition to improved dermal structural 
organization, collagen and cellular content, aged 11β-HSD1-null mice may display 
other advantageous skin characteristics ranging from improved wound healing to 
cancer resistance, adding to the previously documented metabolic benefits. The 
implication of these improvements within the context of preventing the development 
of an ageing skin phenotype warrants highly anticipated further research into the 
dermal phenotype of 11β-HSD1-null mice and the development of selective 11β-
HSD1 inhibitors to combat ageing and age-related disease. 
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CHAPTER 7  FINAL CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Conclusions 
The similarities between changes that occur structurally and functionally in ageing 
skin and those observed following GC therapy and in patients with elevated levels of 
endogenous GC (e.g. Cushing’s syndrome) prompted the studies presented in this 
thesis. We hypothesized that an increase in the expression and activity of the GC-
activating enzyme 11β-HSD1 in older skin may be involved in mediating some of the 
adverse changes that occur as a function of age, with the possibility that reducing 11β-
HSD1 activity in aged skin may have beneficial outcomes on skin physiology and 
could reverse the clinical and biological consequences of skin ageing. 
Whilst a limited number of studies have provided some evidence for the presence of 
11β-HSDs in human skin, the methods were variable and a detailed assessment was 
lacking. Studies examining activity were primarily in isolated sweat glands (Kenouch 
et al., 1994, Bocchi et al., 2004) and although one study examined activity in whole 
abdominal skin, the samples were homogenized and under the influence of an 
artificial co-factor regeneration system (Hennebert et al., 2007) making it difficult to 
establish if the reported results were an accurate reflection of the physiological 
activity levels. Protein expression was previously reported for 11β-HSD2 in eccrine 
sweat glands (Smith et al., 1996, Hirasawa et al., 1997) and vasculature (Smith et al., 
1996) whist one study reported 11β-HSD1 protein expression in epidermal stratum 
spinosum, with debatable expression also reported for the dermis and hair follicles 
(Hennebert et al., 2007). Moreover, mRNA expression had only been reported for 
11β-HSD2 in breast skin using semi-quantitative Northern blot analysis (Brown et al., 
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1996). Surprisingly, comparative studies in other species including mice had also not 
been reported for 11β-HSDs in skin. 
The data presented in Chapter 3 confirmed the presence of mRNA expression and 
protein and enzyme activity for both 11β-HSD1 and 11β-HSD2 in whole human skin 
tissue explants in support of our hypothesis that skin is capable of regulating local 
active GC availability at a cellular level. Our findings that dehydrogenase (11β-
HSD2) activity exceeded oxoreductase (11β-HSD1) activity were consistent with the 
mRNA expression which was greater for 11β-HSD2 than 11β-HSD1. 
Immunohistochemical studies detected protein expression in the skin structures 
previously reported (described above), with previously unreported expression also 
detected in dermal fibroblasts, sebaceous glands and microvasculature. For the first 
time, the data presented here describes a comparable tissue distribution for 11β-HSD1 
in dorsal mouse skin, supporting our observations in human skin, with protein 
expression detected in epidermal keratinocytes, dermal fibroblasts, hair follicles, 
sebaceous glands, microvasculature, subcutaneous adipose tissue (below biopsy depth 
in human skin) and the panniculus carnosus (absent in human skin). Interestingly, in 
contrast to human skin, 11β-HSD2 activity was absent in mouse skin, consistent with 
negligible 11β-HSD2 mRNA and protein expression, whilst 11β-HSD1 mRNA 
expression and activity were readily detectable. This difference may be due, in part, to 
differences between human and mouse skin architecture with an absence of 11β-
HSD2-rich eccrine sweat glands in the latter (Johns et al., 1995). Nevertheless, the 
novel finding that 11β-HSD1 is expressed in mouse skin in a comparable manner to 
human skin endorsed the ability to investigate the effects of modulating GC 
availability at a pre-receptor level on skin physiology in vivo. 
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Our observations confirmed that HDF are capable of rapidly amplifying local GC 
concentrations by increasing 11β-HSD1 activity in response to GC treatment in an 
autocrine positive-feedback manner further enhanced by the presence of TNF-α. 
Similar effects have been reported by others (Hammami and Siiteri, 1991, Hardy et 
al., 2006), supporting a pivotal role for HDF in resolution of inflammation following 
disruption of skin barrier function (e.g. wounding). Indeed, in addition to their anti-
inflammatory properties (Stojadinovic et al., 2007, Vukelic et al., 2011), GC have 
been postulated to coordinate the sequence of wound healing stages by altering cell 
function (discussed in Chapter 5), for example, by inducing fibroblast contractility 
(Skold et al., 1999). Therefore, during a resting state, the ability of dermal fibroblasts 
to activate GC (i.e. through 11β-HSD1) is likely to be low, rapidly increasing in 
response to pro-inflammatory stimuli, before returning to baseline levels upon 
cessation of stimulatory signals. Our findings in HDF were largely in support of this 
notion, with low levels of expression and undetectable oxoreductase activity in 
unstimulated cells. 
However, we observed a large degree of variation in the levels of 11β-HSD1 mRNA 
expression between fibroblasts from different donors and further analysis revealed 
this correlated with donor age (Chapter 4). This was also true for cells that had been 
treated with GC, as activity was readily detectible in cells derived from older donors 
but remained negligible in those sourced from younger individuals. Subsequently, we 
investigated whether these in vitro findings were representative of the situation in 
vivo, and examined 11β-HSD oxoreductase levels in human skin tissue explants 
obtained from young and older donors. Indeed, we observed an increased capacity to 
re-activate GC in skin from older individuals, supporting our in vitro data.  
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Moreover, our studies conducted in ageing mice revealed similar results, suggesting 
that increased 11β-HSD oxoreductase activity may be a common feature of 
mammalian skin ageing. Whilst the increased 11β-HSD oxoreductase activity 
observed in human skin reflects the “net” effect of both isozymes resulting either from 
an increase in 11β-HSD1, a decrease in 11β-HSD2, or a combination of both, our 
findings in ageing mouse skin (which are devoid of 11β-HSD2 activity and 
expression) suggest that increased 11β-HSD1 activity may be the principal cause of 
our findings in human skin. Nevertheless, the increased potential to generate active 
GC in older skin may be involved in the development of age-related abnormalities in 
skin physiology (e.g. reduced structural integrity) and function (e.g. poor wound 
healing).  
This hypothesis is supported by studies reporting a role for increased 11β-HSD1 
activity in other tissues such as adipose and liver in the development of pathologies 
such as metabolic syndrome (Bujalska et al., 1997, Masuzaki et al., 2001, 2003, 
Paterson et al., 2004). 11β-HSDs are also known to be involved in the complex 
regulation of inflammation and immunity (Chapman et al., 2009, Gilmour et al., 
2006, Freeman et al., 2005), and increased 11β-HSD1 activity in ageing mouse 
lymphocytes has also been reported (Zhang et al., 2005), suggesting a mechanism that 
may be involved in the age-related decline of the immune-system. Whilst the 
prevalence of metabolic syndrome is widely accepted to increase with ageing (Eckel 
et al., 2005, Rodriguez et al., 2005), an association with elevated 11β-HSD1 activity 
was has only recently been investigated by Honma et al., reporting increased 11β-
HSD1 expression and lipid accumulation with advancing age in the senescence-
accelerated SAMP10 mouse (Honma et al., 2011), with increased expression in 
human subcutaneous adipose tissue as a function of age also reported (Andersson et 
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al., 2009). Elevated 11β-HSD1 activity has also been reported as a function of donor 
age in primary human osteoblasts and mouse bone (Cooper et al., 2002, Weinstein et 
al., 2010), postulated to contribute to age-related increase in osteoporosis and 
increased fracture risk. Moreover, ageing mouse brain tissue has also been reported to 
display increased 11β-HSD1 activity, affecting cognition and contributing to the 
decline in brain function in older mice (Holmes et al., 2010, Sooy et al., 2010). 
Collectively, there is now a growing body of evidence that increased activity of the 
ubiquitously expressed GC-activating 11β-HSD1 isozyme is a common mediator for 
the ageing process in a variety of tissues (e.g. adipose, liver, bone, brain, and immune 
cells) with findings presented in this thesis suggesting this is also the case for skin. 
The anatomical distribution of skin also enabled us to examine the effect of extrinsic 
ageing (photo-ageing) on the expression of 11β-HSD1 with the benefit of complete 
exclusion of inter-individual confounding factors. Indeed, our result revealed 
increased 11β-HSD1 mRNA expression in HDF derived from PE (lower outer arm) 
compared to donor-matched PP (inner upper arm) skin independently of donor age, 
again corroborated by our ex vivo findings of increased “net” 11β-HSD oxoreductase 
activity in PE compared to donor-matched PP human skin biopsies from both young 
and older individuals. These results provide the fist evidence that extrinsic ageing in 
skin, which superimposes on (and accelerates) the chronological ageing process, may 
also be mediated, in part, through increased/prolonged GC exposure as a consequence 
of increased 11β-HSD1 activity (Chapter 4). Interestingly, 11β-HSD1 expression was 
upregulated in human pharyngeal mucosa by another factor contributing to extrinsic 
ageing: tobacco smoke, and moreover, was decreased in tumour tissue compared to 
unaffected mucosa (Gronau et al., 2002). This study provides intriguing evidence that 
11β-HSD1 may be upregulated in response to stress as a protective mechanism 
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against malignancy, offering a plausible reason for the increased activity reported for 
ageing tissues and our observations for intrinsically and extrinsically aged skin. 
However, the lack of reports for increased tumour incidence in any of the aged 11β-
HSD1-null mouse studies conducted to date suggests that this is not the case; although 
the possibility that anti-tumorigenic pathways upregulated during ageing may also be 
driving 11β-HSD1 expression cannot be excluded. 
In order to determine the potential functional consequences of increased 11β-HSD 
oxoreductase activity during ageing, we evaluated the previously unreported pre-
receptor regulation of GC target genes in skin (Chapter 5). We demonstrated that the 
cortisol-regulated genes MMP1 and IGFBP-5 can also be regulated by cortisone 
through 11β-HSD1 in HDF - and this was preventable by co-incubation with the 11β-
HSD1-specific inhibitor LJ2. These results reveal a pivotal role for 11β-HSD1 in skin 
and suggest that in the presence of substrate, changes in activity levels of this enzyme 
are capable of modulating target gene expression. Therefore, the increased activity 
levels with advancing donor age in skin reported in this thesis are likely to have a 
functional effect on local tissue architecture and function. 
Our functional studies in HDF also revealed novel GC target genes though which pre-
receptor regulation may exert its effects. These included the negative regulation of 
several key enzymes in the collagen biosynthesis pathway (e.g. prolyl and lysyl 
hydroxylases and lysyl oxidases). Defects in collagen structural organization have 
been reported in ageing skin (Bernstein et al., 1996) and it is of interest to speculate 
that this may be attributable, in part, to increased local GC signalling resulting from 
increased pre-receptor activation of cortisol in elderly individuals. Similarly, the 
impairment in wound healing reported for aged skin (Ashcroft et al., 1995) may be 
due to previously unreported GC-mediated impairments in AP-1 signalling presented 
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in this thesis, which may also be exacerbated in older skin as a result of elevated local 
11β-HSD1 activity. Moreover, in ex vivo human skin tissue biopsies, the expression 
of several genes involved in the collagen biosynthesis and AP-1 signalling pathways 
correlated with sample-matched 11β-HSD oxoreductase activity when treated with 
cortisone. Although these correlations may be coincidental rather than as a direct 
result of elevated 11β-HSD1 activity, inhibitor studies now underway should 
determine whether the increased pre-receptor GC metabolism in ageing skin may 
indeed alter the regulation of a wide range of genes involved in maintenance of 
dermal homeostasis and function. 
11β-HSD1 activity and expression also increased in murine skin as a function of age, 
and our functional studies in human HDF and tissue explants suggested an adverse 
impact of increased local GC activation potential on skin biology. Therefore, the final 
part of this thesis investigated whether global inactivation in the ageing mouse would 
induce benefits regarding skin structure. Preliminary studies revealed a remarkable 
reversal in age-induced dermal atrophy, loss of collagen and depletion of dermal cell 
numbers in the 11β-HSD1-null mouse compared to WT counterparts. These data are 
in support of our functional studies which identified the collagen biosynthesis 
pathway as a primary target of GC regulation in human HDF. Most importantly, these 
results provide unequivocal evidence for a causative role of increased 11β-HSD1 
activity in the skin ageing process and suggest that prevention or blockade of this 
increase with the use of specific 11β-HSD1 inhibitors may minimise the adverse 
clinical outcomes whilst promoting improved structural and functional properties of 
ageing skin. 
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7.2 Future in vitro studies 
The in vitro studies presented here were focused largely on primary cultures of HDF, 
due to their ease of maintenance and pivotal role in regulating ECM structure and 
integrity in the dermal layer of skin. However, our initial characterization studies 
examining the localization of 11β-HSDs in skin confirmed that these enzymes are also 
expressed in epidermal keratinocytes. Studies investigating potential age-related 
changes in keratinocyte 11β-HSD levels will assist in determining the cellular origin 
of the observed increase in 11β-HSD oxoreductase activity in human skin biopsies. 
Further immunohistochemistry analyses in skin sections from young and aged donors 
would also be beneficial in clarifying this issue. Moreover, as the biological functions 
of the discrete cellular components of skin are largely determined by a highly 
coordinated inter-cellular cross-talk (e.g. the complex epidermal-mesenchymal 
feedback regulation involved in wound healing), studies utilizing recently developed 
full-thickness in vitro skin equivalents may provide a more physiologically-relevant 
experimental setting. For example, this system could be used to examine the effects of 
modulating dermal fibroblast levels of 11β-HSD1 activity, either by using primary 
cells derived from aged or young donors or by artificially inducing overexpression or 
inhibition of activity in young and aged donor-derived fibroblasts respectively to 
study the effects on dermal structural architecture, dermal fibroblast-epidermal 
keratinocyte interactions and regulation of wound healing. These studies would 
provide a more detailed examination of the effects of modulating 11β-HSD1 activity 
in a more physiologically-relevant human cell based system to complement the 11β-
HSD1-null mouse studies in the absence of the ability to modulate 11β-HSD1 levels 
in humans in vivo. 
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Although the cause underlying the increase in 11β-HSD1 activity in older skin is 
currently unknown, our in vitro findings have provided a starting point for further 
research into this area. One possible underlying mechanism could be that the altered 
extracellular milieu in aged skin resulting from changes in hormone levels such as 
IGF-1 which decreases with advancing age and negatively regulates 11β-HSD1 
expression (discussed in Chapter 4 and Section 1.6.3) or TNF-α which increase with 
ageing (Rabe et al., 2006) and has been demonstrated in this thesis (Chapter 3) and by 
others (Cooper et al., 2001) to positively regulate 11β-HSD1. However, our studies in 
HDF demonstrate increased 11β-HSD1 expression and activity in cells derived from 
older donors which persists in the absence of the native in vivo extracellular 
environment suggesting that other mechanisms are responsible for the chronic 
upregulation of 11β-HSD1 in cells derived from older donors. Moreover, dermal 
fibroblasts obtained from Cushing’s syndrome patients display a comparable or even 
gain-of-function phenotype in relation to gender and age-matched normal control cells 
(Pratsinis et al., 2001, Zervolea et al., 2005, Kletsas et al., 2007) suggesting that the 
dermal atrophy in these patients is as a consequence of the hypercortisolaemic cellular 
environment in vivo and is reversible upon restoration of normal conditions.  
An alternative theory may be that 11β-HSD1 expression increases as a consequence 
of increased cellular stress during replicative senescence postulated to contribute to 
the ageing process (Cristofalo et al., 2004). Evaluating the expression profile of 11β-
HSD1 during serial passageing and correlating this with markers of cellular 
senescence (e.g. beta-galactosidase) in culture and in skin tissue sections obtained 
from young and older donors may aid in elucidating the underlying mechanisms. 
Furthermore, this system could be manipulated by treatments which accelerate 
cellular senescence such as PI3-kinase inhibitors (Tresini et al., 1998) or hydrogen 
 222 
peroxide (Frippiat et al., 2000) with the hypothesis that these treatments would also 
induce 11β-HSD1 expression. 
Similarly, this mechanism could explain the increased 11β-HSD1 expression in PE 
skin derived HDF compared to donor-matched PP cells, as the former may exhibit 
premature replicative senescence resulting from accelerated extrinsic ageing in vivo. 
Whilst replicative senescence may explain the in vitro increase in 11β-HSD1 
expression, it is likely that an altered extracellular environment is also involved in the 
upregulation of 11β-HSD oxoreductase activity reported in human skin ex vivo. 
Therefore, studies investigating the regulation of 11β-HSD1 by factors involved in 
intrinsic (e.g. GH/IGF-1) and extrinsic (e.g. UV radiation) ageing may also be of 
value. 
Finally, the in vitro functional studies identifying novel GC target genes in HDF could 
be extended to determine whether they are also regulated at a pre-receptor level 
(similarly to MMP1 and IGFBP-5). Moreover, these studies could also include 
investigation into GC and pre-receptor mediated changes in expression at the protein 
level (e.g. Western blot and ELISA analysis) and evaluating GC-induced changes in 
enzyme activity where possible (e.g. MMP zymography assays). As GC-mediated 
changes in the expression of several genes involved in phosphorylation-dependant 
signal transduction were also identified, studies into the post-translational 
phosphorylation status of these enzymes may also be of interest. 
7.3 Future in vivo studies 
Certainly, further studies regarding the phenotype of the 11β-HSD1-null mouse are 
likely to be one of the most promising avenues of research to pursue based on the 
exciting preliminary data presented in this thesis. Although initial mRNA expression 
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data for GR-α, H6PD, COL1A1 or IGFBP5 were found not to differ by age or 
genotype, subsequent data obtained from the ex vivo human biopsy studies examining 
correlations in gene expression with 11β-HSD oxoreductase activity also failed to 
detect any associations for these genes, suggesting their expression may be relatively 
stable during skin ageing. Future mRNA and protein expression studies in the 11β-
HSD1-null mouse should therefore focus on genes found to correlate with 11β-HSD 
oxoreductase activity (e.g. MMP10, MMP12 etc.) and/or genes modulated by the 11β-
HSD1-specific inhibitor LJ2 identified from ongoing ex vivo human biopsy studies. 
Currently, a conditional skin-specific 11β-HSD1-knockout mouse model is lacking. 
Although careful consideration will be required regarding the specific cellular target 
for this model (e.g. dermal fibroblast, epidermal keratinocyte or double knockout), the 
generation of these mice may aid in elucidating whether the beneficial dermal 
phenotype described in the aged global 11β-HSD1-null mouse is due to prevention of 
local or systemic GC activation capacity. Moreover, inducible conditional 11β-HSD1-
knockout models could be used ameliorate GC activation capacity at different stages 
of life to determine whether the adverse dermal outcomes associated with increased 
11β-HSD1 activity in older mice is reversible by knocking out enzyme activity in 
aged animals or just preventable by knocking out enzyme activity prior to the onset of 
the age-related increase. Alternatively, these hypotheses could be investigated by the 
systemic or topical administration of an 11β-HSD1-specific inhibitor, having the 
additional benefit of enabling dose-response studies to be conducted. 
Such future studies also require assessing the ability of skin from mice lacking 11β-
HSD1 (global-, conditional- or inhibitor-mediated) to respond when challenged, for 
example, during wounding, irritation (e.g. chemical, UV) and pathogenic insult to 
determine whether removal of GC activating ability in skin has an adverse effect on 
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the normal functions of skin. These investigations could indicate that whilst the age-
related increase in local GC activating capacity may be involved in reduced healing 
rates in elderly animals, complete ablation of 11β-HSD1 may be equally detrimental, 
and only a partial inhibition of activity in older animals to match levels in younger 
mice may be required for optimal results regarding skin physiology and function. 
Finally, if the murine in vivo studies prove successful, clinical trials with topical 
inhibitors could be conducted in humans which may lead to a reduction or reversal of 
the skin ageing process with improvements in the integrity, functional properties and 
appearance of this vital organ. 
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